WO1998024429A1

WO1998024429A1 - Synthetic techniques and intermediates for polyhydroxy, dienyllactones and mimics thereof

Info

Publication number: WO1998024429A1
Application number: PCT/US1997/021798
Authority: WO
Inventors: Amos B. Smith, Iii; Yuping Qiu; Michael Kaufman; Hirokaza Arimoto; David R. Jones; Kaoru Kobayashi
Original assignee: University of Pennsylvania Penn
Current assignee: University of Pennsylvania Penn
Priority date: 1996-12-03
Filing date: 1997-12-01
Publication date: 1998-06-11
Anticipated expiration: 1999-06-03
Also published as: JP2001515466A; EP0969829A1; CA2273881A1; US6031133A; JP2008273977A; US5789605A; JP2009102379A; EP0969829A4

Abstract

Synthetic methods for lactone-containing compounds such as the discodermolides are provided, as are compounds which mimic the chemical and/or biological activity thereof, and methods and intermediates useful in their preparation.

Description

SYNTHETIC TECHNIQUES AND INTERMEDIATES FOR POLYHYDROXY, DIENYL LACTONES AND MIMICS THEREOF

GOVERNMENT SUPPORT

Certain of the inventors were supported by National Institutes of Health Grant GM-29028.

FIELD OF THE INVENTION

This invention relates to lactone-containing compounds such as diεcodermolide, to compounds which mimic the chemical and/or biological activity thereof, and to methods and intermediates useful in their preparation.

BACKGROUND OF THE INVENTION

In 1990, Gunasekera and co-workers at the Harbor

Branch Oceanographic Institute reported the isolation of

(+) -discodermolide (1), an architecturally novel metabolite of the marine sponge Discodermia dissoluta (0.002% w/w) . ( See,

Gunasekera, et al . , J. Org. Chem. 1990, 55, 4912. Correction:

J. Org. Chem . 1991, 56, 1346) .

Initial studies revealed that (+) -discodermolide suppresses both the two-way mixed- lymphocyte reaction and the concanavalin A- induced mitogenesis of murine splenocytes in vitro with no associated cytotoxicit . Moreover, (+)-l suppresses the in vivo graft-vs . -host splenomegaly response induced by injection of parental splenocytes into FI recipient mice, with potency intermediate between those of cyclosporin A and FK506. (Longley, et al . , Transplantation 1991, 52 , 650; Longley, et al . , Transplantation 1991, 52, 656; Longley, et al . Ann . N. Y. Acad. Sci . 1993, 696, 94). These findings stimulated the recent discovery that (+)-l arrests cell development at the M phase by binding and stabilizing mitotic spindle microtubules; thus discodermolide resembles taxol in its mode of action, but the microtubule binding affinity of 1 is much higher, (ter Haar, et al . , Biochemistry 1996, 35 , 243; Hung, et al . , Che i . Sc Biol . 1996, 3 , 287). These and other results suggest that (+) -discodermolide holds considerable promise as an anticancer agent. The scarcity of natural material however has precluded a complete evaluation of its biological profile.

The absolute configuration of discodermolide remained undefined until Schreiber et al . synthesized both antipodes of

1. (Nerenberg, et al . J. Am . Chem . Soc . 1993, 115, 12621; Hung, et al., Chem . & Biol . 1994, 1, 67). Interestingly, the unnatural (-) antipode also displays significant immunosuppressant activity. There is, therefore, a need for improved synthetic methods for the preparation of polyhydroxy, dienyl lactones such as the discodermolides, as well as a need for compounds having similar chemical and/or biological activity.

OBJECTS OF THE INVENTION

It is one object of the present invention to provide polyhydroxy, dienyl lactones and mimics thereof.

It is a further object to provide processes for the preparation of such compounds and their mimics .

It is another object of this invention to provide intermediates useful in such processes.

SUMMARY OF THE INVENTION

These and other objects are satisfied by the present invention, which, in one aspect, provides synthetic methods for the discodermolides and other polyhydroxylactones . In preferred embodiments, such methods involve contacting a phosphonium salt of formula I :

with base and an alkylthiol of formula II :

II to form a diene of formula III

III wherein: R_x , R₂ , R₃ , R₆, R₇ , R₈ , R_xl , R₁₂ and R₁₃ are, independently, C^-C^ alkyl; X is a halogen;

Z, Z_ι; and Z₂ are, independently, 0, S or NR' ; R₄, R₉, R₁₄, and R₁₅ are, independently, acid labile hydroxyl protecting groups; R₅ is C₆-C₁₄ aryl; Y is 0, S or NR' _;

R' and R₁₆ are, independently, hydrogen or C^-C₈ alkyl ; and R₁₈ is C₆ - C₁₄ aryl .

In another aspect, the methods of the invention involve producing an al ene of formula IV.

IV This can be accomplished by contacting an organometallic reagent of formula Va :

Va with a vinyl halide of formula Via:

Via wherein M is Li, Cu, Mg, or Zn and R₁₀ is an acid stable hydroxyl protecting group and all other variables are as defined above. Alternatively, a vinyl halide of formula V :

Vb

can be contacted with an organometallic compound of formula VIb:

VIb

In yet another aspect, the methods of the invention involve lactones having formula VII.

VII by contacting a diene of formula Villa:

Villa with an organometallic compound having formula Va wherein R₂₄ is hydrogen and R₂₅ is hydrogen or an acid stable hydroxyl protecting group. Alternatively, an organometallic compound having formula Vlllb can be contacted with a vinyl halide having formula Vb .

VIIlb The methods of the invention also involve producing dienes having formula Villa by contacting phosphonium salts having formula IX:

IX with base and alkylthiol compounds having formula II.

The present invention also provides synthetic intermediates which are useful in the preparation of polyhydroxylactones, including the compounds having formulas I -IX and X:

X wherein:

R₁₉, R₂₀, R₂₁ and R₂₂ are, independently, C^C^ alkyl; and

R₂₃ is C₇-C₁₅ aralkyl .

The present invention also provides compounds which mimic the chemical and/or biological activity of the discodermolides In preferred embodiments, such compounds have formula XI :

XI

where

R₃₀ is substituted or unsubstituted C^C^ alkyl or a moiety formula XII or XIII:

where A is C₁-C₂₀ alkyl, -CH₂NH(T) or a moiety of formula XIV:

XIV wherein T is peptide having 1 to about 10 amino acids,-

R₃₂, R₄₀, R₄₂, R₄₃, R_4S, R₄₇, and R₄₈ are, independently, hydrogen or

alkyl;

R₄₁ is a side chain of an amino acid; and W₂ are, independently, -0R₄₉ or -NHP_1;-

Ε>₁ is hydrogen or an amine protecting group;

R₃₃ and R₃₆ are, independently, hydrogen, C_x-C₁₀ alkyl, -OR₅₀, =0 or together form -CH₂-CH₂-;

R₃₄ and R_3S are, independently, hydrogen or together form -C(H) =C(H) -C(H) =C(H) - ;

R₃₉ is -0R₅₁ or -CH₂-R₅₁;

R₃₁ and R₄₄ are, independently, C^C^ alkyl;

Q₁ and Q₂ are, independently, hydrogen, -0R_Q, -NHR₅₂, -0C(=0)NH₂ or together form -0-C (0) -NH- ; R_Q is hydrogen or a hydroxyl protecting group;

R₅₁ is substituted or unsubstituted C₆-C₁₄ aryl, tetrahydropyranyl , furanosyl, pyranosyl ( e . g . , tetramethylfucosyl, tetramethylmannosyl, tetramethylgaractosyl and tetramethylglucosyl) , C₃-C₁₀ lactonyl or 2-pyranonyl; R₄₅ is Ci-Cg alkenyl,

alkyl, C₆-C₁₄ aryl, C₂-C₁₀ heterocycloalkyl, C₃-C₁₀ cycloalkyl, or C₇-C₁₅ aralkyl ; and

R₄₉, R₅₀, and R_S2 are, independently, hydrogen or

alkyl .

The present invention also provides methods for inhibiting mammalian cell proliferation by contacting mammalian cells with a compound according to the invention or by administering a compound according to the invention (or a pharmaceutical composition comprising such a compound) to a mammal suffering from undesired cell proliferation. Also provided are methods for inhibiting rejection of a transplanted organ in a mammal comprising administering a compound or composition according to the invention to a mammalian organ recipient . BRIEF DESCRIPTION OF THE DRAWINGS

The numerous objects and advantages of the present invention may be better understood by those skilled in the art by reference to the accompanying figures, in which: Figure 1 shows a retrosynthetic analysis for (-)- discodermolide 1.

Figure 2 shows a synthetic scheme for compound 5.

Figure 3 shows a synthetic scheme for fragment A.

Figure 4 shows a synthetic scheme for compound 22. Figure 5 shows a synthetic scheme for compound 39.

Figure 6 shows a synthetic scheme for compounds 15 and 25.

Figure 7 shows a synthetic scheme for compound 34.

Figure 8 shows a synthetic scheme for fragment C. Figure 9 shows a synthetic scheme for fragment B.

Figure 10 shows a synthetic scheme for compound 39.

Figure 11 shows a synthetic scheme for compound 40.

Figure 12 shows a synthetic scheme for compound 49.

Figure 13 shows a synthetic scheme for compounds 53 and 46.

Figure 14 shows a synthetic scheme for compound 56. Figure 15 shows a synthetic scheme for compound 1. Figure 16 shows a synthetic scheme for compound 104. Figure 17 shows a synthetic scheme for compound 107. Figure 18 shows a synthetic scheme for compound 206.

Figure 19 shows a synthetic scheme for compound 212. Figure 20 shows a synthetic scheme for compound 217. Figure 21 shows a synthetic scheme for compound 305. Figure 22 shows a synthetic scheme for compound 309. Figure 23 shows a synthetic scheme for compound 401.

Figure 24 shows a synthetic scheme for compound 501. Figure 25 shows a synthetic scheme for compound 601. Figure 26 shows a synthetic scheme for compound 701 (R = alkyl) . Figure 27 shows a synthetic scheme for compound 808.

Figure 28 shows a synthetic scheme for compound 801. Figure 29 shows a synthetic scheme for compound 901. Figure 30 shows a synthetic scheme for compound 1003.

Figure 31 shows a synthetic scheme for compound 1104

(Ar = 2, 4 -dimethyl-3 -methoxyphenyl (a), 2-methyl-5- methoxyphenyl (b) , 2 , 4 -dimethyl-5 -methoxyphenyl (c), 2,4- dimethylphenyl (d) , and 4-methylphenyl (e) ) .

Figure 32 shows a synthetic scheme for compound 1111. Figures 33-36 show representative compounds of the invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS It has been found in accordance with the present invention that the synthesis of polyhydroxy, dienyl lactones such as the discodermolides can be achieved by highly convergent and stereocontrolled synthetic procedures .

As shown in Figure 1 for the (-) -discodermolide antipode, our analysis revealed a repeating triad of contiguous stereocenters, separated by Z-olefinic linkages at C(8,9) and C(13,14). Disconnections at C(8,9), C(14,15) and C(21,22) generated fragments A, B and C, each deriving in turn from a common precursor (5) containing the recurring stereochemical triad.

As shown in Figure 2 , precursor 5 was prepared by a synthetic procedure whereby hydroxy ester (-)-6 was protected as the p-methoxybenzyl (PMB) ether by treatment with the Bundle trichloroimidate reagent 7 under acidic conditions. Reduction with LiAlH₄ provided the alcohol (-)-8 after distillation. Swern oxidation, Evans aldol condensation, and Weinreb amide formation completed the construction of common precursor (+)-5. This concise five-step synthesis could be routinely carried out on a 50-g scale in 59% overall yield. In view of the polypropionate structure of the A fragment, we performed a second asymmetric aldol reaction, as shown in Figure 3. Initial formation of the p-methoxybenzylidene acetal (-)-ll from common precursor (+)-5

(78% yield) was designed to allow selective deprotection of C(21) and C(19) hydroxyls for introduction of the terminal diene and carbamate moieties. Following reduction of amide (-)-ll to the aldehyde (80% yield), (aldol reaction with oxazolidinone (+)-9 (80% yield) provided alcohol (+)-13 which incorporated the five stereocenters of subunit A. The structure of (+) -13 was confirmed by single-crystal X-ray analysis. Protection of the secondary alcohol as the TBS ether and removal of the chiral auxiliary (LiBH₄, EtOH, THF) afforded primary alcohol (-)-15 (81% yield, two steps), which could be efficiently converted either to tosylate (-)-16 or iodide (-)-A. As outlined in Figure 1, our strategy required a Z vinylic halide B for coupling with fragment A. Beginning again with the common precursor (+)-5, TBS protection (Figure 4) followed by reduction of the einreb amide [DIBAL (2 equiv) , THF, -78 ^*C] (Kim, et al . , Tetrahedron Lett . 1989, 30 , 6697)¹⁶ afforded aldehyde (+)-18 in 88% yield for the two steps. We adopted a stepwise approach to introduction of the vinyl halide, whereby (+)-18 was converted to the Z α-bromo unsaturated ester (-)-19 (Ph₃PCBrC0₂Et , PhH, reflux; 75% yield after chromatography) . Reduction to allylic alcohol (-)-20 followed by mesylation and displacement with LiBHEt₃ then furnished Z vinyl bromide (-)-22 in 77% overall yield from 19.

Our preferred synthetic strategy involves selective removal of a primary PMB ether in the presence of a PMP acetal in the AB coupling product ((-)-39, Figure 5) . A 1:1 mixture of PMB ether (-)-22 and PMP acetal (-)-15 was exposed to DDQ (1.1 equiv) in CH₂C1₂/H₂0 (Figure 6). The acetal (-)-15 largely remained intact while the debenzylated alcohol (-)-25 was formed in 83% yield.

As shown in Figure 7, we again utilized the TBS ether (+) -17 for the preparation of C from common precursor (+)-5. Oxidative cleavage of the PMB group (DDQ, CH₂C1₂, H₂0) provided alcohol 26 in variable (60-86%) yields, accompanied by the corresponding lactone. Debenzylation with Pearlman's catalyst afforded (+)-26 in 92% yield. Exposure of the alcohol to S0₃.pyr furnished aldehyde (+) -27 (98% yield), which in turn was converted to dithiane (+) -28 (79%) . In the latter step, our modification of the Evans protocol for dithiane generation [ (TMSSCH₂) ₂CH₂, ZnCl₂, Et₂0] minimized elimination of the TBS ether to form the α, β-unsaturated amide. Following reduction to aldehyde (+) -29 with DIBAL (91% yield), dimethyl acetal formation gave ( +) -30 (99%) . The coupling of dithiane 30 with R- (-) -glycidyl benzyl ether _(-)-31] then afforded alcohol

(-)-32 in 79% yield. Unmasking of the ketone moiety

[ (CF₃C0₂)₂IPh, 80%] and Evans stereocontrolled reduction (97%) provided the anti diol (-)-34, which embodied all of the stereocenters in fragment C. Acid-catalyzed cyclization of (-)-34 (TsOH, room temperature) provided methoxy pyran 35 in 87% yield as a 1:2 mixture of and β anomers (Figure 8) . Debenzylation (H₂, Pd/C) of 36 afforded alcohol 37 quantitatively. Exposure to EtSH and MgBr₂ in Et₂0 then gave a separable 6 : 1 mixture of β ethyl hemithioacetal ( +) -38 and its . anomer in 83% yield. Swern oxidation of (+) -38 furnished the final fragment (+) -C in 86% yield.

Synthesis of the desired B segment (-)-B preferably was achieved by direct olefination of aldehyde (+) -18 (41%, 6:1 Z/E) (Figure 9) , followed by chromatographic removal of the undesired E cross coupling product. Reaction of (-)-B with the organozinc derivative of (-)-A (Figure 10) was achieved by premixing iodide A with dried solid ZnCl₂ (ether, -78 'C) before addition of t-BuLi. It is believed that three equivalents of t-BuLi are required for complete consumption of (-)-A, probably because the first equivalent reacts with ZnCl₂. This modification increased the yield to 66% after flash chromatography .

Conversion of the Z trisubstituted olefin (-)-39 to the phosphonium iodide (-)-49 began with selective removal of the PMB group, as in our model study (DDQ, CH₂C1₂, H₂0) , furnishing (-)-40 in 87% yield (Figure 11) . As shown in Figure 12, alcohol (-)-40 furnished the requisite iodide 42 almost exclusively, as indicated by NMR examination of the crude material. The very sensitive iodide was used without purification. Thorough mixing of iodide 42 with i-Pr₂NEt (3 equiv) followed by exposure to excess PPh₃ (15 equiv) without solvent at 80 'C generated (-)-49 in 37% yield for the two steps. The major by-product was characterized as (-)-50 (35% yield) . The unsaturated model alcohol (+)-44 similarly afforded the Wittig salt (+)-46 in low yield (Figure 13), whereas the saturated derivative (+) -51 gave phosphonium iodide (+) -53 almost quantitatively.

As shown in Figure 14, assembly of the discodermolide backbone entailed Wittig coupling of aldehyde C with the ylide derived from AB phosphonium salt (-)-49 to install the C(8,9) Z alkene in (-)-54 (>49:1 Z/E, 76% yield). DIBAL reduction

(88% yield) followed by oxidation of the resultant primary alcohol (-)-55 then produced aldehyde (-)-56 (96%). The terminal Z diene (-)-57 was elaborated via the Yamamoto protocol in 70% yield with excellent selectivity (16:1 Z/E) . After flash chromatography, hydrolysis of the hemithio acetal and mild DMSO/Ac₂0 oxidation provided lactone (-)-58 in 82% yield for the two steps. Removal of the PMB group (DDQ, CH₂C1₂, H₂0, 95% yield) and carbamate formation (Cl₃CONCO, CH₂C1₂, neutral A1₂0_3/ 83%) afforded tris (TBS ether) (-)-60. Final deprotection with 48% HF/CH₃CN (1:9) furnished (-) -discodermolide, identical with an authentic sample (Figure 15) .

Preferred processes according to the invention involve contacting a phosphonium salt of formula I with base and an alkylthiol of formula II:

II to form a diene of formula III:

III wherein: R_x , R₂ , R₃ , R₆ , R₇ , R₈ , R_X1 , R₁₂ and R₁₃ are , independently, C^C^ alkyl; X is a halogen,-

Z, Z_1# and Z₂ are, independently, 0, S or NR' ; R₄, R₉, R₁₄, and R _1S are, independently, acid labile hydroxyl protecting groups; R_s is C₆-C₁₄ aryl; Y is 0, S or NR' ;

R' and R₁₆ are, independently, hydrogen or C^C_g alkyl; and R₁₈ is Cg-C₁₄ aryl. Such procedures preferably are run in solvents such as tetrahydrofuran at -78 °C - 0 °C. Suitable bases for such procedures include sodium hexamethyldisilazide, potassium hexamethyldisilazide , and n-butyllithium with hexamethylphosphoramide .

Alkyl groups according to the invention include but are not limited to straight chain and branched chain hydrocarbons such as methyl, ethyl, propyl, pentyl, isopropyl, 2 -butyl, isobutyl, 2-methylbutyl, and isopentyl moieties having 1 to about 10 carbon atoms, preferably 1 to about 6 carbon atoms. Cycloalkyl groups are cyclic hydrocarbons having 3 to about 10 carbon atoms such as cyclopentyl and cyclohexyl groups. Heterocycloalkyl groups are cycloalkyl groups which include at least one heteroatom (i . e . , an atom which is not carbon, such as 0, S, or N) in their cyclic backbone. Alkenyl groups according to the invention are straight chain or branched chain hydrocarbons that include one or more carbon- carbon double bonds . Preferred alkenyl groups are those having 2 to about 10 carbon atoms. Alkyl, cycloalkyl, heterocycloalkyl, and alkenyl groups according to the invention optionally can be unsubtituted or can bear one or more substituents such as, for example, halogen hydroxyl, amine, and epoxy groups .

Aryl groups according to the invention are aromatic and heteroaromatic groups having 6 to about 14 carbon atoms, preferably from 6 to about 10 carbon atoms, including, for example, naphthyl, phenyl, indolyl, and xylyl groups and substituted derivatives thereof, particularly those substituted with amino, nitro, hydroxy, methyl, methoxy, thiomethyl, trifluoro ethyl, mercaptyl, and carboxy groups. Alkaryl groups are groups that contain alkyl and aryl portions and are covalently bound to other groups through the alkyl portion, as in a benzyl group .

Protecting groups are known per se as chemical functional groups that can be selectively appended to and removed from functionality, such as hydroxyl and amine groups, present in a chemical compound to render such functionality inert to certain chemical reaction conditions to which the compound is exposed. See, e . g. , Greene and Wuts, Protective Groups in Organic Synthesis, 2d edition, John Wiley & Sons, New York, 1991. Numerous hyroxyl protecting groups are known in the art, including the acid- labile t-butyldimethylsilyl, diethylisopropylsilyl, and triethylsilyl groups and the acid- stable aralkyl ( e . g. , benzyl), triisopropylsilyl, and t- butyldiphenylsilyl groups. Useful amine protecting groups include the allyloxycarbonyl (Alloc) , benzyloxycarbonyl (CBz) , chlorobenzyloxycarbonyl , t-butyloxycarbonyl (Boc), fluorenylmethoxycarbonyl (Fmoc) , isonicotinyloxycarbonyl (i-Noc) groups.

The methods of the invention involve also are directed to the synthesis of alkenes of formula IV:

IV by contacting organometallic reagents of formula Va :

Va with vinyl halides of formula Via:

Via wherein M is Li, Cu, Mg, or Zn, and R₁₀ is an acid stable hydroxyl protecting group. Alternatively, a vinyl halide of formula V :

Vb is contacted with an organometallic compound of formula VIb

VIb

Such reactions preferably are performed in the presence of a palladium-containing catalyst such as Pd(PPh₃)₄, Pd(Cl₂) (PPh₃)₂, Pd(Cl₂) (dppf)₂.

In yet another aspect, the synthetic methods of the invention are directed to the preparation of lactones having formula VII:

by contacting a diene of formula Villa:

villa with an organometallic compound having formula Va wherein R₂₄ is hydrogen and R_2S is hydrogen or an acid stable hydroxyl protecting group. Alternatively, an organometallic compound having formula Vlllb is contacted with a vinyl halide having formula Vb .

VI I lb

The reaction of compounds having formulas V and VIII preferably is performed in ether in the presence of a palladium- or nickel-containing catalyst.

The methods of the invention also involve producing dienes having formula Villa by contacting phosphonium salts having formula IX:

with a base such as sodium hexamethyl disilazide and an alkylthiol compound having formula II. Such procedures preferably are run in solvents such as tetrahydrofuran at -78 °C - 0 °C. Suitable bases for such procedures include sodium hexamethyldisilazide, potassium hexamethyldisilazide, and n- butyllithium with hexamethylphosphoramide .

Although preferred synthetic methods are those directed to (+) -discodermolide and compounds having like stereochemistry, those skilled in the art will recognize that the methods disclosed herein can be readily adapted to the synthesis of antipodal compounds such as, for example, (-)- discodermolide, and vice versa . All such synthetic methods are within the scope of the present invention.

The present invention provides compounds which mimic the chemical and/or biological activity of the discodermolides. In preferred embodiments, such compounds have formula XI:

XI where

R, is substituted or unsubstituted C_x-C₁₀ alkyl or a moiety formula XII or XIII:

where A is Ci-Cj_o alkyl, ^■CH₂NH(T) or a moiety of formula XIV:

XIV wherein

T is peptide having 1 to about 10 amino acids;

R₃₂, R₄₀, R₄₂, R₄₃, R_4S, R₄₇, and R₄₈ are, independently, hydrogen or C_x-C₆ alkyl;

R₄₁ is a side chain of an amino acid; W_x and W₂ are, independently, -0R₄₉ or -NHP_X;

P_X is hydrogen or an amine protecting group;

R₃₃ and R₃₆ are, independently, hydrogen, C_j-C^ alkyl, -OR₅₀, =0 or together form -CH₂-CH₂-;

R₃₄ and R₃₅ are, independently, hydrogen or together form -C(H)=C(H) -C(H)=C(H) -;

R₃₉ is -0R₅₁ or -CH₂-R₅₁;

R₃₁ and R₄₄ are, independently, C^C^ alkyl;

Q_X and Q₂ are, independently, hydrogen, -OR_Q, -NHR₅₂, -0C(=0)NH₂ or together form -0-C(0)-NH-; R_Q is hydrogen or a hydroxyl protecting group;

R₅₁ is substituted or unsubstituted C₆-C₁₄ aryl, tetrahydropyranyl, furanosyl, pyranosyl, C₃-C₁₀ lactonyl or 2- pyranonyl ;

R_4S is Ci-Cg alkenyl, C_x-C₆ alkyl, C₃-C₁₄ aryl, C₂-C₁₀ heterocycloalkyl, C₃-C₁₀ cycloalkyl, or C₇-C₁₅ aralkyl; and R_4g, R₅₀, and R_S2 are, independently, hydrogen or C_X-C₆ alkyl

Some preferred compounds having formula XI are shown in Figures 33-36.

The term amino acid as used herein is intended to include all naturally-occurring and synthetic amino acids known in the art. In general, amino acids have structure H₂N-CH(R_C)- C(0)OH where R_c is the amino acid side chain. Representative, naturally-occurring side chains are shown in Table 1.

TABLE 1

CH, CH₃ - CH₂ ~ S ~ CH₂ - CH₂ ~

HO-CH, HO-CH₂-CH₂-

C₆H_S-CH₂- CH₃-CH₂(0H) -

HO- C₆H₅- CH, H0₂C-CH₂-NH₂C(0) -CH₂

-CH₂-CH₂-

CH₂-CH₂- CH₃-CH₂-CH(CH₃) - HS-CH₂-

H0₂C-CH(NH₂] ^■ CH₂ ^■" S ~ S ~ (-H₂ ^■ H₂N-CH₂- CH, ^■ CH₂ — H₂ - H₃ - CH₂ ~

CH-, - S ~ CH- - CH

Hydrophobic amino acid side chains are preferred, including the CH,-_; C₆H₅-CH₂-, CH₃-CH₂-, CH₃-S-CH₂-CH₂ (CH -CH-, (CH₃)₂-CH-

CH, CH₃-CH₂-CH(CH₃) and CH₃-CH,-CH_?-CH₂ side chains.

Peptides according to the invention are linear, branched, or cyclic chemical structures containing at least 2 covalently bound amino acids .

Certain compounds of the invention contain amino groups and, therefore, are capable of forming salts with various inorganic and organic acids. Such salts are also within the scope of this invention. Representative salts include acetate, adipate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, ca phorsulfonate, ethanesulfonate, fumarate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, methanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nitrate, oxalate, pamoate, persulfate, picrate, pivalate, propionate, succinate, sulfate, tartrate, tosylate, and undecanoate. The salts can be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is later removed in vacuo or by freeze drying. The salts also can be formed by exchanging the anions of an existing salt for another anion on a suitable ion exchange resin.

The compounds of the invention can be admixed with carriers, excipients, and/or diluents to form novel compositions. Such compositions can be used in prophylactic, diagnostic, and/or therapeutic techniques. By administering an effective amount of such a composition, prophylactic or therapeutic responses can be produced in a human or some other type mammal. It will be appreciated that the production of prophylactic or therapeutic responses includes the initiation or enhancement of desirable responses, as well as the mitigation, cessation, or suppression of undesirable responses.

The compositions of the invention are expected to find use, for example, in the inhibition of undesired cell proliferation

(e.g., cancer) and in the inhibition of rejection in organ transplantation procedures. (See, e . g. , Longley, et al . , Transplantation 1991, 52 , 650 and 656) . Compositions of the invention can be prepared by any of the methods well known in the pharmaceutical art, for example, as described in Remington ' s Pharmaceutical Sciences (Mack Pub. Co., Easton, PA, 1980). The compositions can include a compound of the invention as an active ingredient in admixture with an organic or inorganic carrier or excipient suitable, for example, for oral administration. Other suitable modes of administration will be apparent to those skilled in the art. The compound of the invention can be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, solutions, suppositories, suspensions, and any other form suitable for use. The carriers which can be used are water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form, and in addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used. The compound of the invention is included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or condition of diseases.

For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch and preferably corn, potato or tapioca starch, alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in appropriately soluble ( e . g. , gelatin) capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, glycerin and various like combinations thereof.

For parenteral administration, suspensions containing a compound of the invention in, for example, aqueous propylene glycol can be employed. The suspensions should be suitably buffered (preferably pH>8) if necessary and the liquid diluent first rendered isotonic. The aqueous suspensions are suitable for intravenous injection purposes. The preparation of such suspensions under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art. Additionally, it is possible to administer the compounds of the invention topically and this may preferably be done by way of creams, jellies, gels, pastes, ointments and the like, in accordance with standard pharmaceutical practice.

The compounds of the invention can be employed as the sole active agent in a pharmaceutical composition or can be used in combination with other active ingredients, e . g. , other agents useful in diseases or disorders.

The amount of active ingredient that is to be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. The specific dose level for any particular patient will depend on a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effects provided that such higher dose levels are first divided into several small doses for administration throughout the day. The concentrations of the active ingredient in therapeutic compositions will vary depending upon a number of factors, including the dosage of the drug to be administered, the chemical characteristics ( e . g. , hydrophobicity) of the active ingredient, and the route of administration. Typical dose ranges are from about 285 μg/kg of body weight per day in three divided doses; a preferred dose range is from about 42 μg/kg to about 171 μg/kg of body weight per day. The preferred dosage to be administered is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, and formulation of the compound excipient, and its route of administration, as well as other factors, including bioavailability, which is in turn influenced by several factors well known to those skilled in the art.

Additional objects, advantages, and novel features of this invention will become apparent to those skilled in the art upon examination of the following examples thereof, which are not intended to be limiting. All reactions were carried out in oven-dried or flame-dried glassware under an argon atmosphere, unless otherwise noted. All solvents were reagent grade. Diethyl ether and tetrahydrofuran (THF) were freshly distilled from sodium/benzophenone under argon before use. Dichloromethane, benzene and diisopropyl amine were freshly distilled from calcium hydride before use. Triethylamine and diisopropylethylamine were distilled from calcium hydride and stored over potassium hydroxide. Hexamethylphosphoramide was freshly distilled from calcium hydride. Anhydrous pyridine, dimethylformamide and dimethyl sulfoxide were purchased from

Aldrich and used without purification. n-Butyllithium and t-butyllithium were purchased from Aldrich and standardized by titration with diphenylacetic acid.

Unless stated otherwise all reactions were magnetically stirred and monitored by thin layer chromatography using 0.25 mm E. Merck pre-coated silica gel plates. Flash column chromatography was performed with the indicated solvents using silica gel-60 (particle size 0.040-0.062 mm) supplied by E. Merck. Yields refer to chromatographically and spectroscopically pure compounds, unless otherwise stated.

All melting points were determined on a Bristoline heated- stage microscope or a Thomas -Hoover apparatus and are corrected. The IR and NMR were obtained for CHC1₃ and CDC1₃ solutions respectively unless otherwise noted. Infrared spectra were recorded with a Perkin-Elmer Model 283B spectrometer using polystyrene as an external standard. Proton NMR spectra were recorded on a Bruker AM-500 spectrometer. Carbon-13 NMR spectra were recorded on a Bruker AM-500 or AM-250 spectrometer. Chemical shifts are reported relative to internal tetramethylsilane (d 0.00) for proton and chloroform δ 77.0) or benzene (δ 128.0) for carbon-13. Optical rotations were obtained with a Perkin-Elmer model 241 polarimeter in the solvent indicated. High-resolution mass spectra were obtained at the University of Pennsylvania Mass Spectrometry Service Center on either a VG micromass 70/70H high resolution double- focusing electron impact/chemical ionization spectrometer or a VG ZAB-E spectrometer. Microanalyses were performed by Robertson Laboratories, Madison, New Jersey. Single-crystal X-ray diffraction structure determination were performed at the University of Pennsylvania using an Enraf Nonius CAD-4 automated diffractometer . High performance liquid chromatography (HPLC) was performed using a Ranin component analytical/semi-prep system.

EXAMPLE 1 Alcohol (-)-8. p-Methoxybenzyl alcohol (200 g, 1.45 mol) was added to a suspension of NaH (60% in mineral oil; 5.82 g, 0.146 mol) in anhydrous ether (450 mL) over 1 h at room temperature. The mixture was stirred for 1 h and cooled to 0 °C. Trichloroacetonitrile (158 mL, 1.58 mol) was then introduced over 80 min. After 1.5 h the solution was concentrated with the water bath temperature maintained below 40 'C. The residue was treated with a mixture of pentane (1.5 L) and MeOH (5.6 mL) , stirred at room temperature for 30 min, and filtered through a short Celite column. Concentration gave the trichloroimidate (394.3 g) as a red oil which was used without further purification. A solution of (R) -(-) -Roche ester (124.7 g, 1.06 mol) in CH₂Cl₂/cyclohexane (1:2, 1.5 L) was cooled to 0 ° C and treated with trichloroimidate (364.3 g) and PPTS (13.3 g, 52.9 mmol) . After 3 h, the mixture was warmed to room temperature, stirred for 40 h, and concentrated. Filtration through a short silica column (20% ethyl acetate/hexane) afforded the ester (303.5 g) as a slight yellow oil.

The ester (303.5 g) was divided into three portions for the next reaction. In each preparation, solution of crude ester (112.8 g) in anhydrous THF (1.0 L) was cooled to 0 °C and LiAlH₄ (1.0 M in THF, 560 mL, 0.560 mol) was added over 1 h. The mixture was warmed gradually to room temperature and stirred for 24 h. After dilution with ether (1.0 L) the mixture was cooled to 0 °C and quenched carefully with saturated aqueous Rochelle'ε salt (20 mL) . The resultant mixture was then transferred to a 4-L flask, diluted with ether

(1.0 L) , and treated with additional Rochelle's solution (ca.

300 mL) with shaking untill a solid precipitated. The solution was filtered, concentrated, and the residue (including the aqueous layer) was diluted with ether (700 mL) , dried over Na₂S0₄, filtered and concentrated. The crude products of the three reactions were combined and distilled under vacuum, furnishing (-)-8 (142.7 g, 74% yield for two steps) as a colorlesε oil: [a] ²³ _D -16.9° (c 1.28, CHC1₃) ; IR (CHC1₃) 3510 (m) , 3015 (ε) , 2965 (s) , 2940 (s), 2920 (s), 2870 (ε), 2840 (m) , 1618 (s) , 1590 (m) , 1517 (s), 1470 (s), 1445 (m) , 1423 (m) , 1365 (m) , 1305 (s) , 1250 (s), 1178 (s), 1092 (s), 1037 (s), 826 (m) , 814 (m) , 718 (w) , 710 (w) cm^'1; ^XH NMR (500 MHZ, CDC1₃) d 7.23 (d, J = 8.6 Hz , 2 H) , 6.86 (d, J = 8.6 Hz, 2 H) , 4.43 (ABq, _M = 11.7 Hz, Δδ_M = 13.2 Hz, 2 H) , 3.78 (s, 3 H) , 3.61-3.54 (m, 2 H) , 3.53 (ddd, J = 9.1, 4.7, 0.8 Hz, 1 H) , 3.38 (dd, J = 9.1, 7.9 Hz, 1 H) , 2.60 (br s, 1 H) , 2.08-1.98 (m, 1 H) , 0.90 (d, J = 7.0 Hz, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 159.2, 130.2, 129.2, 113.8, 75.0, 73.0, 67.7, 55.2, 35.6, 13.4; high resolution mass spectrum (CI, NH₃) m/z 210.1252 [M⁺; calcd for C₁₂H₁₈0₃: 210.1256] .

Anal. Calcd for C₁₂H₁₈0₃ : C, 68.54; H, 8.63. Found: C, 68.41; H, 8.60.

EXAMPLE 2 Aldol (+)-10.

A solution of DMSO (40.0 mL, 564 mmol) in CH₂C1₂ (1.0 L) was cooled to -78 'C and oxalyl chloride (23.0 mL, 263 mmol) was added over 1 h. After an additional 15 min, a cooled (-78 "O solution of alcohol (-)-8 (38.0 g, 181 mmol) in CH₂C1₂ (50 mL) was introduced via a cannula over 15 min (20 mL rinse) and the resultant milky mixture was stirred 0.5 h further at -78 'C. i-Pr₂NEt (150 mL, 861 mmol) was then added over 15 min. The mixture was stirred for 30 min, slowly warmed to room temperature (70 min), and quenched with aqueous NaHS0₄ (1.0 M, 1.0 L) . The organic phase was concentrated, diluted with ether (500 mL) , washed with water (6 x 500 mL) , dried over MgS0₄, filtered and concentrated to give the corresponding aldehyde (38.0 g) aε a colorless oil.

A solution of oxazolidinone (+) -9 (44.3 g, 190 mmol) in CH₂C1₂ (500 mL) was cooled to 0 ^βC. n-Bu₂BOTf (1.0 M in CH₂Cl_2ι 199.0 mL, 199 mmol) waε introduced over 0.5 h, followed by addition of NEt₃ (30.2 mL, 217 mmol) over 10 min. The mixture was stirred at 0 °C for 0.5 h and cooled to -78 ' C . A precooled (-78 °C) solution of the above aldehyde in CH₂C1₂

(lOOmL) was then added via a cannula over 30 min (2 x 20mL rinse) . After 2 h at -78 'C and 2 h at 0 "C, the reaction was quenched with pH 7 phosphate buffer (200 mL) . The mixture was slowly treated with a solution of 30% H₂0₂ in MeOH (1:2, 600 mL) at 0 °C, stirred overnight at room temperature, and concentrated. The residue waε extracted with ethyl acetate (3 x 250 mL) and the combined extracts were washed with saturated aqueous NaHC0₃ and water (500 mL each) , dried over MgS0₄, filtered and concentrated. Flash chromatography (30% ethyl acetate/hexane) provided (+)-10 (70.9 g, 89% yield from 8) as a colorless oil: [a] ²³ _D +278° (c 0.49, CHC1₃) ,- IR (CHCI₃) 3470 (w, br) , 3020 ( ) , 2980 (m) , 2940 (m) , 2920 (m) 2880 (m) , 1790 (s) , 1705 (m) , 1620 (m) , 1590 (w) , 1520 (m) , 1485 (w) , 1460 (m) , 1390 (m) , 1360 (m) , 1305 (w) , 1230 (br, s) 1110 (m) , 1080 (m) , 1035 (m) , 985 (m) , 970 (m) , 820 (w) , 695 (w) cm^"1; H MR (500 MHZ, CDC1₃) d 7.33-7.30 (m, 2 H) , 7.27-7.19 (m, 5 H) , 6.85 (d, J = 8.7 Hz, 2 H) , 4.67-4.63 (m, 1 H) , 4.42 (apparent s, 2 H) , 4.14 (apparent d, J = 5.0 Hz, 2 H) , 3.93 (qd, J^" = 6.9, 3.4 Hz, 1 H) , 3.85 (ddd, J = 8 . 2 , 3.1, 3.1 Hz, 1 H), 3.78 (s, 3 H), 3.69 (d, J = 2.8 Hz, 1 H) , 3.54 (apparent t, J^" = 9.3 Hz, 1 H) , 3.54 (dd, J = 21.1, 9.2 Hz, 1 H) , 3.28 (dd, J = 13.4, 3.2 Hz, 1 H) , 2.76 (dd, J = 13.4, 9.6 Hz, 1 H) , 1.98-1.93 (m, 1 H) , 1.25 (d, J = 6.9 Hz, 3 H) , 0.94 (d, J = 7.0 Hz, 3 H) ; ¹³C NMR (125 MHZ, CDCI₃) d 176.1, 159.2, 153.0, 135.3, 129.9, 129.3, 129.2, 128.8, 127.2, 113.7, 75.3, 74.5, 73.1, 66.0, 55.5, 55.2, 40.6, 37.7, 35.9, 13.5, 9.7; high resolution mass spectrum (CI, NH₃) m/z 442.2243 [(M+H)⁺; calcd for C_2SH₃₂N0₆ : 442.2229] .

Anal. Calcd for C₂₅H₃₁N0₆: C, 68.01; H, 7.08. Found: C, 67.81; H, 7.26.

EXAMPLE 3

Common Precursor (+)-5.

A suspension of N, O-Dimethylhydroxylamine hydrochloride (46.9 g, 481 mmol) in THF (250 mL) was cooled to 0 'C and AlMe₃ (2.0 M in hexane, 240 mL, 480 mmol) was added over 30 min. The resultant εolution was warmed to room temperature, stirred for 0.5 h and then cooled to -30 °C. A solution of oxazolidinone (+)-10 (70.9 g, 161 mmol) in THF (150 mL) was introduced over 20 min via cannula (20 mL rinse) . After 3 h, the solution was poured slowly into a mixture of aqueous HCl (1.0 N, 1.2 L) and CH₂C1₂ (1.0 L) at 0 "C and the mixture was shaken vigorously for 1 h. The aqueous phase was extracted with CH₂C1₂ (2 x 500 mL) and the combined organic extracts were washed with water (3 x 1.0 L) , dried over MgS0₄, filtered and concentrated. The crude material waε taken up in ethyl acetate/hexane (1:3, 150 mL) with vigorouε εtirring to precipitate most of the chiral auxiliary. Filtration, concentration and flash chromatography (20% acetone/hexane afforded (+)-5 (46.2 g, 88% yield) as a colorless oil: [α] 23

D

+144° (c 0.41, CHC1₃) ; IR (CHC1₃) 3470 (m, br) , 3010 -(s), 2975

(s), 2945 (s), 2915 (s), 2870 (s), 2845 (m) , 1680 (s), 1590 (w) , 1515 (s) , 1465 (s) , 1425 (m) , 1390 (m) , 1365 (m) , 1310

(m) , 1250 (s) , 1180 (s), 1150 (m) , 1090 (ε) , 1040 (s), 1000

(s) , 825 (m) cm^"1; ^XH NMR (500 MHZ, CDC1₃) d 7.25 (d, J = 8.6

Hz, 2 H) , 6.86 (d, J = 8.7 Hz, 2 H) , 4.44 (ABq, J_ω = 11.6 Hz,

Δδ_rø = 17.1 Hz, 2 H) , 3.95 (d, J - 2.8 Hz, 1 H) , 3.79 (s, 3 H) , 3.70 (ddd, J = 8.2, 3.2, 3.2 Hz, 1 H) , 3.66 (s, 3 H) , 3.62 (dd,

J = 9.0, 4.0 Hz, 1 H) , 3.53 (dd, J = 9.1, 5.9 Hz, 1 H) , 3.17

(s, 3 H) , 3.04 (m, 1 H) , 1.91-1.84 (m, 1 H) , 1.17 (d, J = 7.0

Hz, 3 H) , 0.98 (d, J = 6.9 Hz , 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d

178.0, 159.0, 130.6, 129.1, 113.7, 113.6, 73.8, 72.8, 72.6, 61.3, 55.1, 36.5, 36.0, 14.2, 10.4; high resolution mass spectrum (CI, NH₃) m/z 326.1962 [(M+H) ⁺ ; calcd for C₁₇H_2βN0₅ : 326.1967] .

Anal. Calcd for C₁₇H₂₇N0₅ : C, 62.74; H, 8.36. Found: C, 62.74; H, 8.24.

EXAMPLE 4 einreb Amide (-)-ll.

A mixture of common precursor (+)-5 (337.3 mg, 1.04 mmol) , 4 A molecular sieves (344 mg) , and CH₂C1₂ (10 mL) was cooled to 0 "C and treated with DDQ (310.3 mg, 1.37 mmol). After 1.5 h, the mixture was filtered through a short Celite column (50% ethyl acetate/hexane) . The filtrate was waεhed with εaturated aqueous NaHC0₃ and water (100 mL each) , dried over MgS0₄, filtered and concentrated. Flash chromatography

(30% ethyl acetate/hexane) provided (-)-ll (255.6 mg, 76% yield) as a colorless oil: [a] ²³ _D -339" (c 0.520, CHC1₃); IR (CHC1-) 3010 (s) , 2970 (s), 2940 (m) , 2880 (m) , 2840 (m) , 1663 (s) , 1620 (s), 1592 (w) , 1520 (ε), 1466 (s) , 1447 (m) , 1425 (m) , 1393 (ε) , 1375 (s) , 1307 (m) , 1253 (s) , 1178 (ε) , 1120 (s), 1083 (s), 1035 (s), 1015 (m) , 1000 (ε), 930 (w) , 830 (m) , 700 (w) , 660 (w) , 620 (w) cm^'1; ^XH NMR (500 MHZ, CDC1₃) d 7.41 (d, J = 8.8 Hz, 2 H) , 6.87 (d, J = 8.8 Hz, 2 H) , 5.46 (ε, 1 H) , 4.04 (dd, J = 11.3, 4.7 Hz, 1 H) , 3.82 (dd, J = 9.8, 6.5 Hz, 1 H) , 3.79 (s, 3 H) , 3.71 (s, 3 H) , 3.51 (apparent t, J = n.2 Hz, 1 H) , 3.19 (s, 3 H) , 3.21-3.14 (m, 1 H) , 1.98-1.92 (m, 1 H) , 1.27 (d, J = 7.0 Hz, 3 H) , 0.75 (d, J = 6.8 Hz , 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 175.8, 159.8, 131.2, 127.2, 113.5, 100.7, 82.8, 72.8, 61.3, 55.3, 39.0, 33.8, 32.6, 13.1, 12.4; high resolution mass spectrum (CI, NH₃) m/z 323.1736 [M⁺; calcd for C₁₇H_2BN0₅: 323.1732] .

Anal. Calcd for C₁₇H_2SN0₅ : C, 63.14; H, 7.79. Found: C, 63.18; H, 7.74.

EXAMPLE 5 Aldehyde (-)-12.

A solution of amide (-)-ll (2.07 g, 6.40 mmol) in THF (70 mL) was cooled to -78 'C and LiAlH₄ (1.0 M in THF, 3.40 mL, 3.40 mmol) was added over 15 min. After 10 min at -78 °C and 10 min at 0 'C, the mixture was quenched with MeOH (1.0 mL) , and partitioned between ethyl acetate and εaturated aqueouε Rochelle's salt (100 mL each). The organic phase was washed with brine (100 mL) , dried over MgS0₄, filtered and concentrated. Flaεh chromatography (15% ethyl acetate/hexane) gave (-)-12 (1.38 g, 80% yield) as a colorless oil: [a] ²³ _D -7.8° (c 0.46, CHC1₃) ; IR (CHC1₃) 3015 (m) , 2970 (m) , 2940 (m) , 2840 (m) , 1735 (s), 1725 (s), 1615 (m) , 1590 (w) , 1520 (ε), 1460 (ε), 1390 (m) , 1370 (m) , 1305 (m) , 1250 (ε), 1170 (ε) , 1115 (ε) , 1085 (ε) , 1035 (ε) , 990 (m) , 960 (m) , 830 (m) cm^'1; ^XH NMR (500 MHZ, CDC1₃) d 9.74 (apparent ε, 1 H) , 7.32 (d, J = 8.8 Hz, 2 H) , 6.84 (d, J = 8.7 Hz, 2 H) , 5.46 (s, 1 H) , 4.13 (dd, J = 11.5, 4.8 Hz, 1 H) , 4.05 (dd, J^" = 10.4, 2.6 Hz , 1 H) , 3.77 (s, 3 H) , 3.56 (apparent t , J = 11.1 Hz, 1 H) , 2.56 (qd, J = 7.1, 2.6 Hz, 1 H) , 2.15-2.03 (m, 1 H) , 1.23 (d, J = 7.1 Hz ,

3 H) , 0.80 (d, J = 6.7 Hz, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 204.0, 159.9, 130.7, 127.2, 113.5, 100.9, 81.6, 72.8, 55.2, 47.4, 30.3, 11.9, 7.1; high resolution mass spectrum (CI, NH₃) m/z 265.1432 [(M+H) ⁺ ; calcd for C₁₅H₂₁0₄ : 265.1439] . EXAMPLE 6 Aldol (+)-13.

A εolution of oxazolidinone (+)-9 (21.6 g, 92.7 mmol) in CH₂C1₂ (200 mL) waε cooled to 0 'C and n-Bu₂B0Tf (1.0 M in CH₂C1_2/ 86.1 mL, 86.1 mmol) was added over 0.5 h, followed by addition of NEt₃ (15.7 mL, 112.5 mmol) over 10 min. The mixture was stirred at 0 ^°C for 1 h and cooled to -78 'C. A εolution of aldehyde (-)-12 (17.5 g, 66.2 mmol) in CH₂C1₂ (50 mL) waε added over 10 min. After additional 20 min at -78 °C and 1 h at 0 °C, the reaction was quenched with pH 7 phosphate buffer (100 mL) and MeOH (300 mL) , then εlowly treated with a solution of 30% H₂0₂ in MeOH (1:1, 100 mL) at 0 °C. After 1 h, saturated aqueous Na₂S₂0₃ (100 mL) was added. The mixture was concentrated and the residue was extracted with ethyl acetate (3 x 250 mL) . The combined extracts were washed with saturated aqueous Na₂S₂0₃, aqueous NaHC0₃ (10%) , brine (200 mL each) , dried over MgS0₄, filtered and concentrated. Flash chromatography (10% ethyl acetate/hexane) provided (+) -13 (26.3 g, 80% yield) as white crystals: mp 98-100 °C; [a] ²³ _D +13.5° (c 1.19, CHC1₃) _; IR (CHC1₃) 3690 (w) , 3520 (w, br) , 3020 (m) , 2980 (m) , 2940 (m) , 2880 (w) , 2850 (m) , 1790 (s), 1695 (m) , 1620 (m) , 1595 (w) , 1525 (m) , 1505 (w) , 1490 (w) , 1465 (m) , 1390 (s) , 1365 (m) , 1310 (m) , 1260-1210 (m, br) , 1175 (m) , 1120 (s) , 1085 (m) , 1040 (m) , 1020 (m) , 985 (m) , 970 (m) , 930 (w) , 830 (m) , 700 (m) cm^'1; ^λK NMR (500 MHZ, CDC1₃) d 7.35 (d, J = 8.7 Hz, 2 H) , 7.31 (d, J = 7.6 Hz, 2 H) , 7.27 (d, J = 7.2 Hz, 1 H) , 7.19 (d, J = 7.7 Hz, 2 H) , 6.84 (d, J = 8.7 Hz, 2 H) , 5.45 (ε, 1 H) , 4.67-4.62 (m, 1 H) , 4.14 (apparent d, J = 5.3 Hz, 2 H) , 4.08 (dd, J = 11.4, 4.8 Hz, 1 H) , 4.07 (apparent t, J = 4.1 Hz, 1 H) , 4.04-3.99 (m, 1 H) , 3.76 (s, 3 H) , 3.61 (dd, J = 9.9, 2.2 Hz, 1 H) , 3.51 (apparent t, J = 11.1 Hz, 1 H) , 3.33 (d, -T = 1.3 Hz, 1 H) , 3.21 (dd, -7 = 13.4, 3.4 Hz, 1 H), 2.76 (dd, J = 13.4, 9.4 Hz, 1 H) , 2.12-2.06 (m, 1 H) , 1.92-1.86 (m, 1 H) , 1.31 (d, J = 6.9 Hz, 3 H) , 1.07 (d, J = 7.0 Hz, 3 H) , 0.74 (d, J = 6.7 Hz, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 177.1, 160.0, 152.7, 135.0, 131.0, 129.4, 128.9, 127.40, 127.39, 113.6, 101.2, 85.8, 74.5, 73.0, 66.0, 55.2, 54.9, 39.8, 37.7, 35.7, 30.4, 12.8, 11.7, 7.8; high resolution masε spectrum (CI, NH₃) m/z 497.2410 [M⁺; calcd for C_2aH_3SN0₇: 497.2413] .

Anal. Calcd for C₂₈H_3SN0₇ : C, 67.58; H, 7.09. Found: C, 67.42; H, 7.02.

EXAMPLE 7

Acetal (+) -14.

A solution of alcohol (+)-13 (26.3 g, 52.9 mmol) and 2,6-lutidine (11.1 mL, 95.3 mmol) in CH₂C1₂ (150 mL) was cooled to -20 'C and TBSOTf (20.5 mL, 79.3 mmol) was added over 30 min. After additional 2 h at 0 °C, the mixture was diluted with ether (300 mL) , washed with aqueouε NaHS0₄ (1.0 M, 200 mL) , brine (200 mL) , dried over MgS0₄, filtered and concentrated. Flaεh chromatography (gradient elution, 5% -> 10% ethyl acetate/hexane) afforded (+) -14 (32.4 g, 100% yield) as a colorless oil: [α] ²³ _D +20.3° (c 1.32, CHC1₃) ; IR (CHC1 J 3025 (m) , 2970 (m) , 2940 (m) , 2864 (m) , 1788 (s), 1705 (m) , 1620 (m) , 1597 (w),1524 (m) , 1503 (w) , 1470 (m) , 1447 (w) , 1430 (w) , 1395 (s), 1358 (m) , 1307 (m) , 1255 (s) , 1135 (m) , 1120 (s), 1075 (m) , 1030 (m) , 985 (m) , 976 (m) , 930 (m) , 865 (m) , 838 (s) , 813 (m) , 790 (m) , 700 (m) cm^"1; ^XH NMR (500 MHZ, CDC1₃) d 7.38 (d, J = 8.7 Hz, 2 H) , 7.30-7.12 (m, 5 H) , 6.82 (d, J = 8.7 Hz, 2 H) , 5.44 (s, 1 H) , 4.30 (dddd, J = 13.4, 7.3, 5.1, 5.1 Hz, 1 H) , 4.11 (dd, J^" = 7.1, 4.0 Hz , 1 H) , 4.02 (dd, J = 11.2, 4.7 Hz, 1 H), 3.97 (dq, -7 = 7.0, 7.0 Hz, 1 H), 3.80 (dd, J = 8.9, 2.3 Hz, 1 H) , 3.740 (apparent t, -7 = 4.9 Hz, 1 H), 3.738 (s, 3 H) , 3.48 (apparent t, J = 11.1 Hz, 1 H) , 3.27 (apparent t, J = 8.2 Hz, 1 H) , 3.15 (dd, -7 = 13.4, 3.2 Hz, 1 H) , 2.59 (dd, -J = 13.4, 9.8 Hz, 1 H) , 2.05 (apparent qd, -7 -= 7.4, 4.2 Hz, 1 H) , 2.02-1.94 (m, 1 H) , 1.19 (d, J = 6.9 Hz , 1 H) , 1.04 (d, J^" = 7.5 Hz, 3 H) , 0.92 (s, 9 H) , 0.73 (d, J = 6.7 Hz, 3 H) , 0.05 (ε, 3 H) , 0.04 (ε, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 175.6, 159.9, 152.4, 135.5, 132.0, 129.4, 128.8, 127.8, 127.2, 113.4, 100.7, 80.7, 74.6, 73.1, 65.3, 55.3, 55.2, 41.4, 40.9, 37.4, 30.6, 26.0, 18.1, 15.0, 12.7, 11.5, -4.0, -4.6; high resolution mass spectrum (CI, NH₃) m/z 612.3340 [(M+H)\- calcd for C₃₄H₅₀NO₇Si: 612.3356] . Anal . Calcd for C₃₄H₄₉N0₇Si : C , 66 . 74 ; H , 8 . 07 . Found : C , 66 . 69 ; H , 7 . 98 .

EXAMPLE 8 Alcohol (-)-15. A solution of acetal (+) -14 (32.0 g, 52.3 mmol) in THF

(600 mL) was cooled to -30 °C and EtOH (6.14 mL, 105 mmol) was added, followed by addition of LiBH₄ (2.0 M in THF, 52.3 mL, 105 mmol) over 15 min. After additional 1 h at 0 " C and 12 h at room temperature, the mixture was diluted with ether (1.0 L) , quenched carefully with aqueous NaOH (1.0 N, 200 mL) and εtirred for 2 h at room temperature. The layers were separated and the organic phase was washed with brine (500 mL) , dried over Na₂S0₄, filtered and concentrated. Flash chromatography (20% ethyl acetate/hexane) provided (-)-15 (18.7 g, 81% yield) as a colorless oil: [α]²³ _D -36.1° (c 1.15, CHC1₃) ; IR (CHC1₃) 3630 (w) , 3480 (w, br) , 3010 (m) , 2960 (s) , 2940 (ε) , 2885 (m) , 2860 (s), 1620 (m) , 1594 (w) , 1523 (s), 1468 (s), 1445 (w) , 1430 (w) , 1395 (m) , 1365 (m) , 1307 (m) , 1255 (ε), 1175 (m) , 1165 (m),1150 (m) , 1120 (ε), 1080 (s) , 1030 (ε) , 990 (m) , 968 (m) , 910 (ε), 860 (m) , 833 (s) , 700 (m) , 645 (m) cm^"1; ^λ NMR

(500 MHZ, CDC1₃) d 7.36 (d, -7 = 8.7 Hz, 2 H), 6.85 (d, J^" = 8.8

Hz, 2 H) , 5.38 (s, 1 H) , 4.08 (dd, J = 11.2, 4.7 Hz , 1 H) , 3.84

(dd, -7 = 6.7, 1.9 Hz, 1 H) , 3.77 (s, 3 H) , 3.53 (dd, -7 = 9.9,

1.8 Hz, 1 H) , 3.55-3.52 (m, 1 H) , 3.47 (apparent t, J = 11.1 Hz, 1 H) , 3.44 (dd, J = 10.3, 6.2 Hz, 1 H) , 2.08-1.97 (m, 2 H) , 1.94 (dqd, J = 7.1, 7.1, 1.7 Hz , 1 H) , 1.76 (br s, 1 H) , 1.02 (d, J = 7.1, 3 H) , 0.88 (s, 9 H) , 0.84 (d, J = 6.9 Hz, 3 H) , 0.73 (d, J = 6.7 Hz, 3 H) , 0.03 (ε, 3 H) , 0.00 (ε, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 159.8, 131.4, 127.3, 113.5, 101.0, 82.9, 74.3, 73.3, 66.3, 55.2, 38.7, 37.8, 30.7, 26.1, 18.3, 12.2, 11.1, 10.7, -4.0, -4.2; high reεolution mass εpectrum (CI, NH₃) m/z 439.2889 [(M+H)⁺; calcd for C₂₄H₄₃0₅Si: 439.2879].

Anal. Calcd for C₂₄H₄₂0₅Si: C, 65.71; H, 9.65. Found: C, 65.51; H 9.54. EXAMPLE 9 Tosylate (-)-16.

A solution of alcohol (-)-15 (5.00 g, 11.4 mmol) in anhydrous pyridine (30 mL) was cooled to 0 °C and treated with TsCl (3.91 g, 20.5 mmol) . After 30 min at 0 'C and 5 h at room temperature, the reaction waε quenched with εaturated aqueouε NaHC0₃ (20 mL) . The mixture waε diluted with ether (200 mL) , waεhed with aqueouε NaHS0₄ (1.0 M) , aqueous NaHC0₃ (10%), brine (200 mL each) , dried over MgS0₄, filtered and concentrated. Flash chromatography (10% ethyl acetate/hexane) provided (-)-15 (6.76 g, 100% yield) as white εolid: mp 71-72 °C; [a] ²³ _D -23.2° (c 1.42, CHC1₃) ; IR (CHC1₃) 3020 (m) , 3000 (m) , 2960 (s) , 2935 (s) , 2880 (m) , 2855 (s) , 1617 (m) , 1600 (m) , 1590 (m) , 1518 (m) , 1495 (w) , 1462 (ε), 1390 (m) , 1360 (ε), 1302 (m) , 1250 (ε) , 1190 (ε) , 1178 (ε), 1120 (s) , 1098 (s) , 1085 (s) , 1070 (ε, 1032 (ε), 963 (s) , 900 (m) , 830 (s) , 810 (s) , 653 (m) ,- ^XH NMR (500 MHZ, CDC1₃) d 7.70 (d, J = 8.3 Hz, 2 H) , 7.34 (d, J = 8.7 Hz, 2 H) , 7.25 (d, J = 8.8 Hz, 2 H) , 6.86 (d, J = 8.7 Hz , 2 H) , 5.36 (s, 3 H) , 4.07 (dd, J = 11.2, 4.7 Hz, 1 H), 3.85 (dd, -7 = 7.3, 2.7 Hz, 1 H) , 3.79 (s, 3 H) , 3.71 (dd, J = 7.1, 1.7 Hz, 1 H) , 3.48 (dd, -7= 9.9, 1.4 Hz, 1 H) , 3.45 (apparent t, -7 = 11.1 Hz, 1 H) , 2.40 (8, 3 H) , 2.15 (dqd, -7 = 13.9, 7.0, 1.7 Hz, 1 H) , 2.05-1.96 (m, 1 H) , 1.83 (dqd, -7 = 7.1, 7.1, 1.6 Hz, 1 H), 0.94 (d, J = 7.1 Hz, 3 H) , 0.82 (ε, 9 H) , 0.81 (d, J^" = 7.7 Hz, 3 H) , 0.69 (d, -7 = 6.7 Hz, 3 H) , -0.04 (ε, 3 H) , -0.11 (s, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 159.8, 144.6, 133.2, 131.3, 129.7, 127.9, 127.3, 113.5, 100.9, 82.0, 73.7, 73.2, 73.0, 55.2, 38.4, 35.5, 30.6, 26.0, 21.6, 18.3, 12.2, 10.6, 10.3, -3.9, -4.3; high resolution maεε spectrum (FAB, NBA) m/z 593.2955 [(M+H)⁺; calcd for C₃₁H₄₉0₇SSi : 593.2968] .

EXAMPLE 10 Fragment ( - ) -A.

From Tosylate (-)-16: A εolution of Toεylate (-)-16

(6.76 g, 11.4 mmol) in anhydrouε DMF (50 mL) waε treated with Nal (17.1 g, 114.0 mmol), heated at 60 °C for 1.5 h, and cooled to room temperature. The mixture waε diluted with ether (200 mL) , waεhed with water (200 mL) , saturated aqueous Na₂S₂0₃ (100 mL) , brine (200 mL) , dried over MgS0₄, filtered and concentrated. Flash chromatography (3% ethyl acetate/hexane) provided (-)-A (5.87 g, 94 % yield) aε a colorless oil. From Alcohol (-)-15: A solution of alcohol (-)-15

(4.70 g, 10.7 mmol), PPh₃ (4.21 g, 16.1 mmol) and imidazole (1.09 g, 16.1 mmol) in benzene/ether (1:2, 75 mL) was treated with I₂ ( 4.08 g, 16.1 mmol) under vigorous stirring. The mixture waε stirred 1 h then diluted with ether (200 mL) , washed with saturated Na₂S₂0₃, brine (100 mL each) , dried over MgS0₄, filtered and concentrated. Flash chromatography (2% ethyl acetate/hexane) furnished (-)-A (5.56 g, 95% yield) as a colorleεs oil: [α]²³ _D -39.3° (c 2.01, CHC1.) ,- IR (CHC1 -) 3015 (m) , 2960 (s) , 2940 (s) , 2860 (m) , 1620 (w) , 1520 (m) , 1465 (m) , 1430 (w) , 1390 (m) , 1305 (w) , 1255 (ε), 1230 (m) , 1215 (m) , 1205 (m) , 1170 (m) , 1120 (m) , 1070 (m) , 1035 ( ) , 990 (w) , 970 (w) , 930 (w) , 830 (m) cm^-1; ^XH NMR (500 MHZ, CDC1₃) d 7.39 (d, J = 8.7 Hz, 2 H) , 6.86 (d, J = 8.8 Hz, 2 H) , 5.40 (ε, 1 H) , 4.09 (dd, J = 11.2, 4.7 Hz, 1 H) , 3.85 (dd, J = 7.1, 1.9 Hz , 1 H) , 3.79 (8, 3 H) , 3.48 (dd, J = 8.2, 1.5 Hz, 1 H) , 3.47 (apparent t, -7 = 11.1 Hz, 1 H) , 3.18-3.12 (m, 2 H) , 2.11-2.00 (m, 2 H) , 1.84 (ddq, J = 7.1, 7.1, 1.6 Hz, 1 H) , 1.02 (d, J = 7.1 Hz, 3 H) , 0.98 (d, J = 6.7 Hz, 3 H) , 0.89 (ε, 9 H) , 0.72 (d, -7= 6.7 Hz, 3 H) , 0.06 (8, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 159.8, 131.4, 127.4, 113.4, 100.9, 82.4, 75.5, 73.2, 55.3, 39.6, 38.7, 30.7, 26.2, 18.4, 14.7, 14.5, 12.2, 10.7, -3.7, -3.8; high resolution maεε spectrum (CI, NH₃) m/z 548.1833 [(M) ⁺; calcd for C₂₄H₄₁I0₄Si: 548.1819].

Anal. Calcd for C₂₄H₄₁0₄ISi : C, 52.55; H, 7.53. Found: C, 52.77; H, 7.68.

EXAMPLE 11 Amide (+)-17.

A solution of common precursor (+)-5 (12.1 g, 37.2 mmol) and 2,6-lutidine (7.80 mL, 70.0 mmol) in CH₂C1₂ (90 mL) waε cooled to 0°C and tert-Butyldimethylεilyl trifluoromethanesulfonate (12.8 mL, 55.8 mmol) was added over 10 min. After 1.5 h, the mixture was diluted with Et₂0 (100 mL) , washed with aqueous NaHS0₄ (1.0 M) , brine (200 mL each), dried over . MgS0₄, filtered and concentrated. Flash chromatography (10% ethyl acetate/hexaneε) provided (+) -17 (16.4 g, 100% yield) aε a colorless oil: lot] ²³ _D +9.49° (c 1.47, CHC1₃) ; IR (CHC1₃) 3018 (s) , 2970 (s), 2945 (s), 2900 (m) , 2870 (s) , 1658 (s),1620 (m) , 1592 (w) , 1520 (s) , 1470 (s) , 1448 (m) , 1425 (m) , 1393 (m) , 1367 (m) , 1308 (m) , 1255 (s), 1213 (s), 1185 (m) , 1178 (m) , 1115 (s) , 1084 (s) , 1042 (s) , 1000 (s) , 940 (w) , 928 (w) , 871 (s) , 839 (s) , 770 (s), 726 (s), 664 (m) cm^"1; ^XH NMR (500 MHZ, CDC1₃) d 7.21 (d, J^" = 8.7 Hz, 2 H) , 6.83 (d, J = 8.7, 2 H) , 4.36 (ABq, -7_M = 11.6 Hz, Δδ_M = 17.3 Hz, 2 H) , 3.92 (dd, -7 = 8.2, 3.0 Hz, 1 H), 3.77 (s, 3 H), 3.55 (s, 3 H), 3.54 (dd, J = 9.2, 2.5 Hz, 1 H) , 3.13 (dd, -7 = 9.2, 7.8 Hz, 1 H) , 3.09 (s, 3 H) , 3.15-3.09 (m, 1 H) , 1.92-1.87 (m, 1 H) , 1.09 (d, J = 7.0 Hz, 3 H) , 0.98 (d, -7 = 7.0 Hz, 3 H) , 0.88 (ε, 9 H) , 0.04 (apparent ε, 6 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 176.8, 159.1, 130.9, 129.2, 113.7, 76.0, 72.7, 71.9, 61.1, 55.2, 39.3, 38.9, 26.1, 18.4, 15.3, 15.0, -3.87, -3.93; high reεolution mass spectrum (CI, NH₃) m/z 440.2823 [(M+H)⁺; calcd for C₂₃H₄₂NO_sSi: 440.2832] .

Anal. Calcd for C₂₃H₄₁NO_sSi: C, 62.83; H, 9.40. Found: C, 63.05; H, 9.32.

EXAMPLE 12 Aldehyde (+)-18.

A solution of amide (+)-17 (9.19 g, 20.9 mmol) in THF (350 mL) was cooled to -78 °C and DIBAL (1.0 M in hexane, 44.0 mL, 44.0 mmol) was added over 30 min. After 0.5 h at -78 °C, the reaction was quenched with MeOH (10 mL) . The mixture was diluted with ether (500 mL) , waεhed with εaturated aqueouε Rochelle's salt, brine (300 mL each), dried over MgS0₄, filtered and concentrated. Flash chromatography (10% ethyl acetate/hexane) gave (+) -18 (7.05 g, 89% yield) as a colorleεs oil: [α.] ³ _D +23.2° (c 1.49, CHC1₃) ; IR (CHC1₃) 2960 (ε), 2930 (s) , 2860 (s) , 1730 (ε), 1610 (m) , 1583 (w) , 1510 (m) , 1460 (m) , 1373 (m) , 1360 (w) , 1300 (m) , 1245 (s) , 1170 (m) , 1085 (m) , 1033 (s) , 933 (w) , 835 (s) cm^-1; ^XH NMR (500 MHZ, CDC1₃) d

9.67 (d, J = 0.9 Hz, 1 H) , 7.22 (d, -7 = 8.7 Hz, 2 H) , 6.86 (d,

-7 = 8.7 Hz, 2 H) , 4.37 (ABq, _M = 11.6 Hz, Δδ_M = 23.6 Hz, 2

H) , 4.18 (dd, J = 6.1, 3.7 Hz, 1 H) , 3.78 (s, 3 H) , 3.41 (dd, J = 9.2, 5.7 Hz, 1 H) , 3.31 (dd, -7 = 9.2, 6.0 Hz, 1 H) , 2.47

(qdd, J = 7.1, 3.7, 0.9 Hz, 1 H) , 2.03-1.95 (m, 1 H) , 1.08 (d,

J = 7.0 Hz, 3 H) , 0.94 (d, J = 7.0 Hz, 3 H) , 0.84 (s, 9 H) ,

0.04 (S, 3 H) , -0.03 (8, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 204.8,

159.2, 130.5, 129.2, 113.8, 72.7, 72.4, 71.7, 55.3, 50.0, 38.3, 25.9, 18.2, 14.3, 8.4, -4.1, -4.4; high reεolution masε εpectrum (FAB, NBA) m/z 403.2304 [(M+Na)⁺; calcd for

C₂₁H₃₆0₄SiNa: 403.2280] .

EXAMPLE 13 Bromo Ester 19. A εolution of aldehyde (+) -18 (822.1 mg, 2.16 mmol) in benzene (20 mL) was treated with Ph₃P=CBrC0₂Et (2.28 g, 5.34 mmol) , heated at reflux for 40 h and cooled to room temperature. The mixture was filtered through a short silica column (20% ethyl acetate/hexane) and concentrated. Flash chromatography (3% ethyl acetate/hexane) afforded Z- Bromo ester (-)-19 (861.4 mg, 75% yield) and E-Bromo Ester (+)-19 (101.0 mg, 8.8% yield) .

Z-Bromo Eεter (-)-19: Colorleεε oil; [α] ²³ _D -6.38° (c 1.85, CHC1₃) ; IR (CHC1₃) 2960 (s) , 2940 (s) , 2860 (s) , 1725 (s) , 1618 (m) , 1590 (w) , 1515 (s) , 1468 (m) , 1390 (m) , 1370 (m) , 1303 (m) , 1250 (ε, br) , 1176 (m) , 1090 (s) , 1037 (ε) , 1008 (m) , 950 (m) , 940 (m) , 840 (s) cm^'1; ^JH NMR (500 MHZ, C₆D_S) d 7.45 (d, J = 9.7 Hz, 1 H) , 7.26 (d, J = 8.6 Hz, 2 H) , 6.80 (d, J = 8.7 Hz, 2 H) , 4.37 (ABq, J_M = 11.6 Hz, Δδ_M = 19.3 Hz, 2 H) , 3.99, (dq, J = 10.8, 7.1 Hz, 1 H) , 3.94 (dq, J = 10.8, 7.1 Hz , 1 H) , 3.82 (apparent t, J = 5.4 Hz, 1 H) , 3.41 (dd, J = 9.1, 6.3 Hz, 1 H) , 3.31 (s, 3 H) , 3.30 (dd, J = 9.2, 6.5 Hz, 1 H) , 3.13-3.06 (m, 1 H) , 2.05 (apparent septet, J = 6.9 Hz, 1 H) , 1.013 (d, J = 7.0 Hz, 3 H) , 1.006 (d, J = 6.8 Hz, 3 H) , 0.97 (s, 9 H) , 0.92 (apparent t, J = 7.1 Hz, 3 H) , 0.06 (s, 3 H) , 0.05 (ε, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 162.5, 159.1, 149.6, 130.8, 129.0, 114.9, 113.7, 75.5, 72.6, 72.2, 62.4, 55.3, 40.2, 38.9, 26.0, 18.3, 14.2, 14.1, 13.7, -4.0, -4.2; high resolution masε εpectrum (CI, NH₃) m/z 546.2270 [ (M+NH )₄ ⁺ _; calcd for C₂₅H₄₅N0₅BrSi: 546.2251] . Anal. Calcd for C_2BH₄₁0_sBrSi_: C, 56.70; H, 7.80.

Found: C, 56.96; H, 7.86.

E-Bromo Ester ( + )-19. Colorlesε oil; [a] ²³ _D +3.2° (c 1.65, CHC1₃) ; IR (CHCI₃) 2965 (s) , 2940 (s) , 2905 (m) , 2890 (m) , 2865 (s) , 1720 (ε) , 1617 (m) , 1590 (w) , 1518 (ε) , 1468 (s) , 1375 (ε), 1350 (m) , 1305 (m) , 1250 (s, br) , 1177 (m) , 1090 (s) , 1035 (s) , 1007 (m) , 950 (m) , 840 (s) , 675 (w) cm^"1; ^XH NMR (500 MHZ, CDCI₃) d 7.23 (d, J = 8.6 Hz, 2 H) , 6.86 (d, J = 8.7 Hz, 2 H) , 6.56 (d, J = 10.6 Hz, 1 H) , 4.39 (apparent s, 2 H) , 4.24 (dq, J = 10.8, 7.1 Hz, 1 H) , 4.22 (dq, J = 10.8, 7.1 Hz , 1 H) , 3.79 (s, 3 H) , 3.61 (dd, -7 = 5.5, 5.0 Hz, 1 H) , 3.43 (dd, -7 = 9.2, 5.5 Hz, 1 H) , 3.39-3.32 (m, 1 H) , 3.24 (dd, J^" = 9.1, 7.2 Hz, 1 H) , 1.98-1.90 (m, 1 H) , 1.30 (apparent t, J = 7.1 Hz, 1 H) , 1.00 (d, -7 = 6.7 Hz, 3 H), 0.94 (d, -7 = 7.0 Hz, 3 H) , 0.89 (ε, 9 H) , 0.05 (S, 3 H) , 0.03 (s, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 162.8, 159.1, 151.9, 130.8, 129.1, 113.7, 110.2, 76.3, 72.6, 72.2, 62.1, 55.2, 38.8, 26.1, 18.3, 14.7, 14.1, 13.9, -4.06, -4.10; high reεolution mass spectrum (CI, NH₃) m/z 529.1982 [(M+H)\- calcd for C₂₅ H₄₂Br0₅Si: 529.1985] .

Anal. Calcd for C₂₅H₄₁0₅BrSi : C, 56.70; H, 7.80. Found: C, 56.83; H, 7.99.

EXAMPLE 14

Allylic Alcohol (-)-20.

A solution of ester (-)-19 (858.4 mg, 1.62 mmol) in CH₂C1₂ (16 mL) was cooled to -78 "C and DIBAL (1.0 M in hexane, 3.60 mL, 3.60 mmol) was added over 10 min. After 5 min at -78 'C and 10 min at room temperature, the reaction was quenched with MeOH (200 mL) , followed by addition of saturated aqueous Rochelle's salt dropwise with εtirring until a εolid precipitated. The solution was εeparated by decanting (3 x 30 mL rinse, ethyl acetate) and the combined organic solutionε were dried over MgS0₄, and concentrated. Flash chromatography (10% ethyl acetate/hexane) provided (-)-20 (674.5 mg, 85% yield) as a colorless oil: [α] ²³ _D -15.5° (c 2.51, CHC1₃); IR

(CHC1₃) 3600 (w) , 3420 (w, br) , 3010 (m) , 2960 (s), 2940 (ε), 2890 (m) , 2860 (ε) , 1618 (m) , 1590 (w) , 1520 (s) , 1470 ( ) , 1380 (m) , 1315 (m) , 1307 (m) , 1255 (s), 1178 (m) , 1085 (ε), 1039 (s) , 1010 (m) , 972 (m) , 940 (m) , 840 (s) , 675 (m) , 660 (m) cm^"1; ^XH NMR (500 MHZ, CDC1₃) d 7.24 (d, J = 8.7 Hz , 2 H) , 6.87

(d, J = 8.7 Hz, 2 H) , 5.88 (br d, J = 9.3 Hz , 1 H) , 4.39 (ABq, J_M = 11.6 Hz, { 5^ = 18.3 Hz, 2 H) , 4.16 (apparent d, J = 5.6 Hz, 2 H) , 3.79 (ε, 3 H) , 3.59 (apparent t, J = 5.3 Hz, 1 H) , 3.48 (dd, J = 9.2, 5.3 Hz, 1 H) , 3.23 (dd, J = 9.2, 7.7 Hz, 1 H) , 2.82-2.76 (m, 1 H) , 2.00-1.92 (m, 1 H) , 0.98 (d, J = 6.9 Hz, 3 H) , 0.97 (d, J = 6.8 Hz, 3 H) , 0.88 (s, 9 H) , 0.024 (s, 3 H) , 0.016 (S, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃ ) d 159.1, 134.1, 130.9, 129.1, 125.1, 113.7, 76.5, 72.6, 72.3, 68.4, 55.3, 39.1, 38.7, 26.1, 18.4, 14.9, 14.3, -3.9, -4.0; high resolution mass εpectrum (CI, NH₃) m/z 487.1873 [(M+H) ⁺ ; calcd for C₂₃H₄₀O₄BrSi : 487.1879] .

Anal. Calcd for C₂₃H₃₉0₄BrSi : C, 56.66; H, 8.06. Found: C, 56.72; H, 8.07.

EXAMPLE 15 Mesylate (-)-21.

A εolution of alcohol (-)-20 (6.85 g, 14.1 mmol) in CH₂C1₂ (150 mL) waε cooled to 0 'C and MεCl (2.20 mL, 28.4 mmol) waε added over 2 min. After 10 min, the reaction was quenched with aqueouε NaHS0₄ (1.0 M, 100 mL) . The organic phase waε waεhed with water (100 mL) , dried over MgS0₄, and concentrated.

Flash chromatography (10% ethyl acetate/hexane) afforded (-)-21

(7.85 g, 99% yield) as a colorless oil: [c.] ²³ _D -14.6° (c 1.40, CHC1₃) ; IR (CHC1₃) 3020 (m) , 2960 (s), 2940 (ε), 2880 (m) , 2860 (ε), 1730 (w) , 1610 (m) , 1583 (m) , 1510 (s), 1460 (m) , 1410 ( ) , 1362 (s) , 1300 (m) , 1250 (s), 1220 (s), 1175 (s) , 1080 (s) , 1032 (s) , 1002 ( ) , 960 (m) , 937 (s) , 835 (s) cm^"1; ^XH NMR (500 MHZ, CDC1₃) d 7.23 (d, J = 8.6 Hz , 2 H) , 6.86 (d, J = 8.6 Hz, 2 H) , 6.07 (d, J = 9.4 Hz, 1 H) , 4.74 (d, J= 0.4 Hz, 2 H) , 4.38 (ABq, -7^ = 11.7 Hz, Δδ_M = 25.5 Hz, 2 H) , 3.79 (s, 3 H) , 3.61 (apparent t, J = 5.2 Hz, 1 H) , 3.44 (dd, -7 = 9.2, 5.7 Hz , 1 H) , 3.22 (dd, -7 = 9.2, 7.3 Hz, 1 H) , 3.01 (s, 3 H) , 2.84-2.77 (m, 1 H) , 1.99-1.91 (m, 1 H) , 0.98 (d, J = 6.8 Hz, 3 H) , 0.96 (d, J = 7.0 Hz, 3 H) , 0.88 (s, 9 H) , 0.03 (s, 3 H) , 0.02 (s, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃ ) d 159.1, 140.9, 130.8, 129.1, 116.7, 113.8, 76.1, 74.2, 72.6, 72.1, 55.3, 39.6, 38.8, 38.5, 26.0, 18.3, 14.7, 14.3, -3.9, -4.0; high resolution mass spectrum (CI, NH₃) m/z 582.1911 [(M+NH₄)⁺ _; calcd for C₂₄H₄₅NO_sBrSSi: 582.1920] .

EXAMPLE 16

Vinyl Bromide ( - ) -22.

A solution of mesylate (-)-21 (6.43 g, 11.4 mmol) in benzene (120 mL) was treated with LiBHEt₃ (1.0 M in THF, 25.0 mL, 25.0 mmol) at room temperature. After 0.5 h, the reaction was quenched with aqueous NaOH (1.0 N, 50 mL) . The mixture was diluted with ethyl acetate (200 mL) , waεhed with brine (2 x 200 mL) , dried over MgS0₄, filtered and concentrated. Flash chromatography (5% ethyl acetate/hexane) provided (-)-22 (4.86 g, 91%) as a colorlesε oil: [α] ²³ _D -16.9° (c 1.69, CHC1₃) ,- IR (CHC1₃) 3005 (m) , 2965 (s), 2935 (s), 2860 (s) , 1660 (w) , 1610 (m) , 1585 (w) , 1510 ( ) , 1460 (m) , 1425 (w) , 1377 (m) , 1360 (m) , 1300 (m) , 1250 (s), 1180 (m) , 1170 (m) , 1075 (s), 1030 (m) , 860 (m) , 835 (s) , 805 (m) , 660 (w) cm^"1; ^XH NMR (500 MHZ, CDC1₃) d 7.24 (d, J = 8.6 Hz, 2 H) , 6.86 (d, J = 8.6 Hz, 2 H) , 5.47 (apparent dd, J = 9.0, 1.2 Hz, 1 H) , 4.39 (ABq, _M = 11.7 Hz, Δδ_M = 15.8 Hz, 2 H) , 3.79 (s, 3 H) , 3.56 (apparent t, -7 = 5.4 Hz, 1 H) , 3.50 (dd, J = 9.1, 5.1 Hz, 1 H) , 3.22 (dd, -7 = 8.8, 8.1 Hz, 1 H) , 2.74-2.67 (m, 1 H) , 2.21 (d, J = 1.1 Hz, 3 H) , 1.99-1.91 (m, 1 H) , 0.98 (d, J = 6.9 Hz, 3 H) , 0.94 (d, -7 = 6.8 Hz, 3 H) , 0.88 (s, 9 H) , 0.01 (ε, 3 H) , 0.00 (ε, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 159.1, 133.4, 131.0, 129.1, 120.6, 113.7, 76.7, 72.6, 72.5, 55.3, 39.7, 38.7, 28.8, 26.1, 18.4, 14.8, 14.4, -3.96, -4.01; high resolution mass spectrum (FAB, NBA) m/z 493.1763 [(M+Na) ⁺ ; calcd for C₂₃H₃₉0₃BrSiNa : 493.1750]. EXAMPLE 17

Vinyl Silane (-)-23.

A solution of vinyl bromide (-)-22 (83.2 mg, 0.177 mmol) in THF (2.0 mL) was cooled to -78 °C and n-BuLi (1.6 M in hexane, 260 ml, 416 mmol) was added over 10 min. After 1 h at -78 'C and 15 min at room temperature, the reaction was quenched with H₂0 (200 mL) . The mixture was concentrated and dissolved in ethyl acetate (30 mL) , washed with water (30 mL) , dried over MgS0₄, filtered and concentrated. Flash chromatography (5% ethyl acetate/hexane) provided (-)-23 (47.9 mg, 69% yield) as a colorless oil: [a] ²³ _D -61.5° (c 0.615, CHC1₃) ; IR (CHC1₃) 3680 (w) , 3470 (m, br) , 1614 ( ) , 1588 (w) , 1513 (s), 1465 (m) , 1442 (m) , 1415 (m) , 1360 (m) , 1302 (m) , 1250 (s) , 1176 (m) , 1120 (m) , 1077 (m) , 1032 (m) , 992 (m) , 830 (S) , 820 (S) , 805 (s) cm^"1; ^XH NMR (500 MHZ, CDC1₃) d 7.22 (d, J = 8.7 Hz, 2 H) , 6.85 (d, J = 8.7 Hz, 2 H) , 6.22 (dq, J = 10.5, 1.6 Hz, 1 H) , 4.42 (ABq, _M = 11.4 Hz, Δδ_M = 18.8 Hz, 2 H) , 3.78 (s, 3 H) , 3.65 (br s, 1 H) , 3.56 (dd, J = 9.1, 4.0 Hz, 1 H) , 3.44 (dd, J = 8.8, 2.9 Hz, 1 H) , 3.42 (apparent t, J = 8.8 Hz, 1 H) , 2.45 (dqd, J = 10.3, 6.6, 2.7 Hz, 1 H), 1.95-1.87 (m, 1 H) , 1.78 (d, -7 = 1.6 Hz, 3 H) , 0.91 (d, J = 6.7 Hz, 3 H) , 0.87 (s, 9 H) , 0.80 (d, J = 7.0 Hz, 3 H) , 0.09 (s, 3 H) , 0.08 (S, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 159.4, 147.7, 130.8, 129.7, 129.4, 113.9, 79.9, 76.4, 73.3, 55.3, 38.1, 36.3, 27.1, 26.6, 17.8, 13.4, 13.1, -3.4, -3.7; high resolution mass spectrum (CI, NH₃) m/z 393.2821 [(M+H)⁺; calcd for C₂₃H₄₁0₃Si : 393.2824]. Anal. Calcd for C₂₃H₄₀O₃Si: C, 70.36; H, 10.27. Found: C, 70.58; H, 10.57.

EXAMPLE 18 trans Olefin (+)-24.

A solution of vinyl bromide (-)-22 (27.8 mg, 0.0591 mmol) in ether (600 μL) was cooled to - 78 °C, and t-BuLi (1.7 M in pentane, 103 μL, 0.175 mmol) waε added over 2 min. After 10 min at -78 °C and 5 min at room temperature, the reaction was quenched with MeOH (100 mL) . The mixture was filtered through a short silica plug, and concentrated. Flash chromatography (1% ethyl acetate/hexane) provided (+)-24 (21.9 mg, 94% yield) aε a colorleεε oil; [a] ²³ _D +19.3° (c 1.10,

CHC1₃) ; IR (CHC1₃) 3000 (m) , 2960 (s), 2935 (ε), 2880 (m) , 2860

(ε), 1612 (m) , 1587 (w) , 1510 (s), 1462 (m) , 1440 (m) , 1405 (w) , 1375 (m) , 1360 (m) , 1300 (m) , 1250 (s) , 1170 (m) , 1090

(s) , 1034 (s) , 1002 (m) , 970 (m) , 934 (w) , 850 (m) , 832 (ε),

720 (m) cm^"1; ^XE NMR (500 MHZ, C₆D₆) d 7.24 (d, J = 8.7 Hz, 2 H) ,

6.80 (d, J = 8.6 Hz, 2 H) , 5.43 (ddq, J = 15.3, 7.8, 1.4 Hz, 1

H) , 5.34 (dqd, J = 15.4, 6.3, 0.7 Hz, 1 H) , 4.38 (ABq, J^ = 11.7 Hz, Δδ_M = 30.7 Hz, 2 H) , 3.58 (apparent t , J = 5.2 Hz, 1 H) , 3.57 (dd, J = 9.0, 5.1 Hz, 1 H) , 3.36 (dd, J = 9.0, 7.2 Hz, 1 H) , 3.30 (S, 3 H) , 2.39 (ddq, J = 6.8, 6.8, 6.8 Hz, 1 H) , 2.17-2.10 (m, 1 H) , 1.58 (apparent d, J = 6.1 Hz, 3 H) , 1.07 (d, J = 7.2 Hz, 3 H) , 1.05 (d, J = 6.9 Hz, 3 H) , 1.00 (s, 9 H) , 0.10 (ε, 3 H) , 0.08 (s, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 159.0, 135.6, 131.1, 129.1, 123.9, 113.7, 78.4, 72.6, 72.5, 55.3, 40.4, 37.9, 26.2, 26.1, 18.4, 18.0, 15.9, 15.1, -3.8, -4.1; high resolution mass spectrum (CI, NH₃) m/z 393.2836 [(M+H)⁺ _; calcd for C₂₃H₄₁0₃Si: 393.2824].

EXAMPLE 19

Alcohol (-)-25.

A solution of PMB ether (-)-22 (50.0 mg, 0.106 mmol) and PMB acetal (-)-15 (46.5 mg, 0.106 mmol) in CH₂C1₂ (2.0 mL) was cooled to 0 °C, then treated with H₂0 (100 mL) and DDQ (26.5 mg, 0.117 mmol) . After 30 min, the mixture was diluted with ether (60 mL) , washed with saturated aqueous NaHC0₃ (60 mL) , brine (3 X 60 mL) , dried over MgS0₄, filtered and concentrated. Flaεh chromatography (gradient elution, 5% -> 10% ethyl acetate/hexane) afforded (-)-25 (31.0 mg, 83% yield) and recovered (-)-15 (40.0 mg, 86% recovery).

(-)-25: [c.]²³ _D -13.3° (c 0.99, CHC1₃) ; IR (CHC1₃) 3640 (w) , 3520 (m) , 3000 ( ) , 2960 (s) , 2940 (s) , 2890 (m) , 2860 (s) , 1660 (w) , 1472 (m) , 1465 (m) , 1440 (m) , 1407 (m) , 1390 (m) , 1380 (m) , 1360 (m) , 1258 (ε) , 1072 (s) , 1023 (s), 1005 (ε) , 980 (m) , 937 (m) , 847 (ε) cm^"1; ^XH NMR (500 MHZ, CDC1₃) d 5.50 (apparent dd, -7 = 9.0, 1.1 Hz , 1 H) , 3.65 (dd, -J = 11.0, 4.8 Hz, 1 H) , 3.59 (dd, J = 11.0 , 5.7 Hz , 1 H) , 3.56 (apparent t, J = 5.2 Hz, 1 H) , 2.80- 2.72 ( , 1 H) , 2.25 (d, J = 1.0 Hz, 3 H) , 2.20 (br s, 1 H), 1.86-1.78 (m, 1 H) , 0.99 (d, J = 7.1 Hz, 3 H), 0.98 (d, J = 6.9 Hz, 3 H), 0.90 (s, 9 H), 0.09 (s, 3 H), 0.05 (ε, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 132.6, 121.7, 79.7, 65.6, 40.9, 38.8, 28.9, 26.1, 18.3, 15.5, 15.0, -3.9, -4.0; high reεolution maεε spectrum (CI, NH₃) m/z 351.1087 [M⁺; calcd for C₁₅H₃₁0₂BrSi: 351.1093] .

EXAMPLE 20 Alcohol (+)-26.

A solution of amide (+)-17 (323.5 mg, 0.738 mmol) in EtOH (8.0 mL) was stirred for 5 h under H₂ atmosphere in the presence of Pearlman's catalyst (20% Pd(OH)₂/C, 104.1 mg) , then filtered and concentrated. Flaεh chromatography (10 mL εilica, 20% ethyl acetate/hexane) provided (+) -26 (216.7 mg, 92% yield) as a colorleεε oil: [ ] ²³ _D +16.1° (c 2.60, CHC1₃) ; IR (CHC1₃) 3480 (m, br) , 3000 (s) , 2958 (s) , 2935 (ε) , 2880 (s) , 2860 (s) , 1635 (ε), 1460 (ε) , 1415 (m) , 1390 (s), 1360 (m) , 1285 (w) , 1255 (s) , 1174 (m) , 1148 (m) , 1093 (ε), 1070 (ε) , 1047 (ε), 1033 (ε) , 990 (ε) , 935 (m) , 905 (w) , 860 (s) , 830 (ε) cm^"1; ^XH

NMR (500 MHZ, CDC1₃) d 4.05 (dd, J = 9.1, 3.1 Hz, 1 H) , 3.69

(ε, 3 H) , 3.55-3.50 (m, 1 H) , 3.23 (ddd, J = 10.1, 10.1, 2.8

Hz, 1 H) , 3.13 (ε, 3 H) , 3.09 (br m, 1 H) , 2.81 (br m, 1 H) ,

1.91-1.83 (m, 1 H) , 1.14 (d, J = 7.0 Hz, 3 H) , 0.879 (d, J = 7.0 Hz, 3 H) , 0.879 (s, 9 H) , 0.08 (s, 3 H) , 0.06 (s, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 177.3, 75.2, 64.9, 61.5, 40.8, 38.2, 32.2, 26.0, 18.2, 15.9, 12.8, -4.1, -4.3; high resolution mass spectrum (CI, NH₃) m/z 320.2265 [(M+H)⁺; calcd for C_lsH₃₄N0₄Si: 320.2256] .

EXAMPLE 21

Aldehyde (+)-27.

A solution of alcohol (+) -26 (8.80 g, 27.5 mmol) and

NEt₃ (15.3 mL, 110 mmol) in CH₂C1₂ (50 mL) was cooled to -10 'C and treated with S0₃.pyr (13.1 g, 82.6 mmol) in DMSO (100 mL) . After 20 min at room temperature, the mixture was diluted with ether (300 mL) , washed with aqueous NaHS0₄ (1.0 M, 200 mL) , brine (4 x 200 mL) , dried over MgS0₄, filtered and concentrated. Flash chromatography (20% ethyl acetate/hexane) afforded (+) -27 (8.55 g, 98% yield) as a colorless oil: [ x] ²³ _D +51.2° (c 1.00, CHC1₃) ; IR (CHC1₃) 3010 (m) , 2960 (ε), 2940 (ε) , 2895 (m) , 2865 (m) , 1750 (m) , 1720 (s) , 1647 (s) , 1460 (s), 1420 (m) , 1390 (s) , 1360 (m) , 1255 (ε), 1180 (m) , 1105 (m) , 1077 ( ) , 1040 (s) , 995 (s), 936 (m) , 853 (s), 837 (s), 710 (m) , 657 (m) cm^"1; ^XH NMR (500 MHZ, CDC1₃) d 9.68 (d, -7 = 1.6 Hz, 1 H) , 4.22 (dd, -7= 8.9, 2.6 Hz, 1 H) , 3.68 (s, 3 H) , 3.10 (apparent s, 4 H) , 2.46 (qdd, J = 7.1, 2.6, 1.5 Hz, 1 H), 1.16 (d, -7 = 6.9 Hz, 3 H) , 1.10 (d, J= 7.0 Hz, 3 H) , 0.88 (ε, 9 H) , 0.092 (ε, 3 H) , 0.088 (ε, 3 H) ; ¹³C NMR (125 MHZ, CDC1,) d 203.2, 175.6, 75.1, 61.5, 52.1, 39.6, 32.1, 25.9, 18.2, 15.4, 10.2, -4.07, -4.11; high resolution masε spectrum (CI,NH₃) /z 318.2096 [(M+H)⁺; C₁₅H₃₂N0₄Si: 318.2100].

EXAMPLE 22 Dithiane (+)-28.

A solution of ZnCl₂ (dried at 140 °C for 1 h under vacuum, 170.5 mg, 1.25 mmol) in ether (6.0 mL) was cooled to 0

°C and (TMSSCH₂)₂CH₂ (175.0 μL, 0.628 mmol) was added. The resultant white milky εuεpension was treated with aldehyde

(+)-27 (180.0 mg, 0.567 mmol) in ether (6.0 mL) . The mixture was εtirred for 4.5 h at 0 °C and 1.5 h at room temperature, then partitioned between ethyl acetate (50 mL) and aqueouε ammonia (30 mL) . The organic phaεe waε waεhed with brine (2 x 30 mL) , dried over MgS0₄, filtered and concentrated. Flash chromatography (10% ethyl acetate/hexane) provided (+) -28 (182.9 mg, 79% yield) as a white solid: mp 55-57 °C; [a] ²³ _D +18.5° (c 1.44, CHC1₃) ; IR (CHC1₃) 3015 (m) , 2970 (s), 2945 (s) , 2910 (m) , 2870 (m) , 1665 (ε) , 1475 (m) , 1470 (m) , 1437 (m) , 1430 (m) , 1420 (m) , 1390 (m) , 1365 (m) , 1320 (w) , 1280 (m) , 1260 (m) , 1120 (m) , 1115 (m) , 1097 (m) , 1080 (m) , 1065 (m) , 1040 (m) , 1000 (m) , 940 (w) , 925 (w) , 910 (w) , 877 (m) , 838 (s) , 815 (m) , 800 (m) , 700 (w) , 675 (w) , 660 (w) cm^"1; ^XH NMR (500 MHZ, CDC1₃) d 4.33 (d, J^" = 4.2 Hz, 1 H) , 4.23 (dd, J = 7.1, 3.6 Hz, 1 H) , 3.68 (s, 3 H) , 3.15 (ε, 3 H) , 2.98 (dq, J^" = 6.8, 3.7 Hz, 1 H) , 2.90 (ddd, J = 14.1, 12.2, 2.5 Hz, 1 H) , 2.83-2.77 (m, 3 H) , 2.09-2.03 (m, 1 H) , 1.94 (ddq, J^" = 7.2,

7.2, 4.3 Hz, 1 H) , 1.88-1.76 (m, 1 H) , 1.08 (d, J = 7.2 Hz, 3 H) , 1.07 (d, J = 6.9 Hz, 3 H) , 0.90 (s, 9 H) , 0.13 (s, 3 H) ,

0.02 (s, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 176.2, 73.2, 61.0, 50.8, 44.2, 38.6, 31.3, 30.3, 26.2, 18.4, 12.9, 11.0, -4.1, -4.2; high reεolution maεs spectrum (CI^', NH₃) m/z 408.2081 t(M+H)⁺; calcd for C₁₈H₃₈N0₃S₂Si : 408.2062] . Anal. Calcd. for C_lβH₃₇N0₃S₂Si : C, 53.03; H, 9.15.

Found: C, 53.06; H, 9.31.

EXAMPLE 23 Aldehyde (+)-29.

A solution of dithiane (+) -28 (1.05 g, 2.58 mmol) in THF (40 mL) was cooled to -78 °C and DIBAL (1.0 M in hexane, 5.15 mL, 5.15 mmol) was added over 15 min. After 10 min at -78 °C, the mixture was quenched with MeOH (2.0 mL) and partitioned between ether and εaturated aqueouε Rochelle's salt (50 mL each) . The organic phase was washed with brine (30 L) , dried over MgS0₄, filtered and concentrated. Flash chromatography (10% ethyl acetate/hexane) provided (+) -29 (822 mg, 91% yield) as white solid: mp 54-55 °C; [ex] ²³ _D +50.8^° (c 1.19, CHC1₃) ; IR (CHCI₃) 2965 (ε) , 2940 (s), 2910 (s), 2865 (s) , 2720 (w) , 1730 (s) , 1475 (m) , 1467 (m) , 1428 (m) , 1418 (m) , 1390 (m) , 1365 ( ) , 1280 ( ) , 1260 (s) , 1190 (m) , 1150 (m) , 1104 (s), 1070 (m) , 1030 (s) , 1007 (m) , 953 (m) , 940 (m) , 910 (m) , 835 (s) , 810 (m) , 675 (m) cm^"1; ^XH NMR (500 MHZ, CDC1₃) d 9.70 (s, 1 H) , 4.44 (dd, J^" = 8.3, 2.2 Hz, 1 H) , 4.38 (d, J = 3.7 Hz, 1 H) , 2.93 (ddd, J = 14.1, 12.3, 2.6 Hz, 1 H) , 2.84-2.80 (m, 3 H) , 2.43 (qd, J= 7.1, 2.2 Hz, 1 H) , 2.13-2.07 (m, 1 H) , 2.02 (dqd, J = 8.2, 7.1, 3.7 Hz, 1 H) , 1.88-1.79 (m, 1 H) , 1.10 (d, J = 6.9 Hz, 3 H) , 1.05 (d, J = 7.1 Hz, 3 H) , 0.87 (s, 9 H) , 0.16 (s, 3 H) , -0.01 (s, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 204.6, 71.1, 51.0, 49.7, 43.5, 31.3, 30.3, 26.2, 26.0, 18.4, 12.9, 6.8, -3.9, -4.3; high resolution masε εpectrum (CI, NH₃) m/z 349.1678 [(M+H)⁺; calcd for C₁₆H₃₃0₂S₂Si : 349.1691]. Anal . Calcd for C₁₆H₃₂0₂S₂Si : C , 55 . 12 ; H , 9 . 25 . Found : C , 55 . 08 ; H , 9 . 28 .

EXAMPLE 24

Dimethoxy Acetal (+)-30. A εolution of aldehyde (+) -29 (792 mg, 2.27mmol) in

HC(OMe)₃/MeOH (48 mL, 1:5) was treated with TεOHΗ Q (8.6 mg, 0.045 mmol) at room temperature. After 30 min, NEt₃ (1.0 mL) was added and the mixture was concentrated. Flash chromatography (10% ethyl acetate/hexane) provided (+)-30 (886 mg, 99% yield) as a white solid: mp 58-59 °C; [ex] ²³ _D +27.1° (c 2.85, CHC1₃) ,- IR (CHC1₃) 2960 (s) , 2940 (s), 2905 (s), 2860 (m) , 2835 (m) , 1473 (m) , 1463 (m) , 1432 (m) , 1425 (m) , 1415 (m) , 1387 (m) , 1362 (m) , 1340 (w) , 1278 (m) , 1252 (s), 1190 (m) , 1158 (m) , 1104 (s) , 1070 (m) , 1050 (m) , 1030 (s) , 1005 (m) , 963 (m) , 938 (m) , 908 (m) , 873 (m) , 834 (ε) , 810 (m) cm^"1; ^λE NMR (500 MHZ, CDC1₃) d 4.41 (d, -7 = 3.1 Hz, 1 H), 4.23 (d, -7 = 8.6 Hz, 1 H) , 4.02 (dd, -7 = 8.6, 1.3 Hz, 1 H), 3.29 (ε, 3 H), 3.26 (8, 3 H) , 2.93 (ddd, J = 14.0, 12.4, 2.5 Hz, 1 H) , 2.85-2.78 (m, 3 H) , 2.11-2.05 (m, 1 H) , 1.93-1.77 (m, 3 H) , 1.00 (d, J = 7.2 Hz, 3 H) , 0.91 (8, 9 H) , 0.85 (d, J^" = 6.9 Hz, 3 H) , 0.17 (S, 3 H) , 0.09 (8, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 105.0, 71.5, 53.0, 51.5, 51.2, 43.8, 37.4, 31.3, 30.2, 26.3, 18.8, 12.9, 8.1, -3.8, -4.3; high reεolution mass spectrum (FAB, NBA) m/z 417.1934 t(M+Na)⁺; calcd for C₁₈H₃₈0₃S₂SiNa : 417.1930]. Anal. Calcd for C₁₈H₃₈0₃S₂Si : C, 54.78; H, 9.70. Found:

C, 54.80; H, 9.66.

EXAMPLE 25

Hydroxy Acetal (- ) -32.

A εolution of dithiane (+)-30 (3.60 g, 9.12 mmol) in 10% HMPA/THF (60 mL) waε cooled to -78 ^°C and treated with t-BuLi (1.7 M in pentane, 5.63 mL, 9.58 mmol) dropwiεe over 15 min. The mixture was stirred 1 h at -78 °C and 1 h at -42 'C, then recooled to -78 °C. A solution of benzyl R- ( - ) -glycidyl ether (1.65 g, 10.0 mmol) in 10% HMPA/THF (12 mL) was added via cannula. After 0.5 h, the reaction mixture was warmed to -42 °C for 0.5 h and quenched with saturated aqueouε NH₄C1 (20 mL) . The mixture was diluted with ether (200 mL) , washed with water, brine (200 L each) , dried over MgS0₄, filtered and concentrated. Flash chromatography (10% ethyl acetate/hexane) afforded (-)-32 (4.04 g, 79% yield) as a colorless oil: [ex] ²³ _D -5.9° (c 2.1, CHC1₃) ; IR (CHC1₃) 3450 (w, br) , 3020 (m) , 2960 (s) , 2940 (s) , 2910 (m) , 2860 (m) , 2840 (m) , 1605 (w) , 1500 (w) , 1475 (m) , 1468 (m) , 1458 (m) , 1440 (m) , 1430 (m) , 1393 (m) , 1387 (m) , 1365 (m) , 1280 (w) , 1255 (m) , 1233 (m) , 1203 (m) , 1167 (w) , 1153 (w) , 1110 (s), 1060 (m) , 1045 (m) , 1030 (m) , 1010 (m) , 980 (w) , 940 (m) , 910 (w) , 860 (m) , 837 (s) , 800 (m) , 695 (m) , 670 (m) , 660 (m) cm^"1; ^XH NMR (500 MHZ, CDC1₃) d 7.35-7.25 (m, 5 H) , 4.64 (dd, J = 4.0, 1.1 Hz, 1 H), 4.57 (ABq, J_rø = 12.1 Hz, Δδ_M = 17.8 Hz, 2 H) , 4.21 (d, J = 7.7 Hz, 1 H) , 4.14-4.09 (m, 1 H) , 3.48 (dd, J = 9.5, 6.0 Hz, 1 H) , 3.47 (dd, J = 9.6, 5.0 Hz, 1 H) , 3.37 (d, J = 0.7 Hz, 1 H) , 3.36 (s, 3 H) , 3.29 (s, 3 H) , 3.08 (ddd, J = 14.4, 11.4, 2.9 Hz, 1 H) , 2.95 (ddd, -7 = 14.4, 11.3, 3.1 Hz, 1 H) , 2.71-2.64 (m, 2 H) , 2.59 (dqd, -7= 6.7, 6.7, 0.9 Hz, 1 H), 2.49 (dd, -7 = 15.6, 7.9 Hz, 1 H) , 2.30 (dq, -7 = 4.0, 7.3 Hz, 1 H), 2.27 (dd, -7 = 15.6, 2.3 Hz, 1 H) , 2.04-2.00 (m, 1 H) , 1.86-1.78 (m, 1 H) , 1.18 (d, J = 7.4 Hz, 3 H) , 0.94 (d, J^" = 6.8 Hz, 3 H) , 0.90 (s, 9 H) , 0.08 (S, 3 H) , 0.07 (S, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 138.2, 128.4, 127.6, 106.9, 74.4, 73.3, 70.0, 67.9, 55.7, 53.6, 52.6, 47.2, 39.4, 38.5, 26.3, 26.1, 26.0, 25.0, 18.3, 9.8, 9.5, -3.9, -4.9; high resolution mass spectrum (FAB, NBA) m/z 581.2763 [(M+Na) ⁺ ; calcd for C₂₈H_B00₅S₂SiNa : 581.2767].

EXAMPLE 26 Ketone (+)-33. A solution of hydroxy acetal (-)-32 (3.94 g, 7.05 mmol) in H₂0/MeOH (1:9, 75 mL) was treated with (CF CQ ) JP-h

(4.55 g, 10.6 mmol) at 0 °C. After 5 min, the mixture was quenched with saturated NaHC0₃ (20 mL) and extracted with ether

(200 mL) . The organic phase was washed with brine (200 mL) , dried over MgS0₄, filtered and concentrated. Flash chromatography (20% ethyl acetate/hexane) furnished (+) -33 (2.66 g, 80% yield) as a colorless oil. [ex] ²³ _D +36° (c 0.36, CHC1₃) ; IR (CHC1₃) 3580 (w, br) , 3005 (m) , 2960 (ε), 2930 (ε), 2900 (m) , 2860 (m) , 1710 (m) , 1463 (m) , 1455 (m) , 1387 (m) , 1362 (m) , 1253 (m) , 1220 (m) , 1105 (s), 1070 (s),1053 (s), 1030 (ε), 1002 (m) , 938 (m) , 866 (m) , 830 (s) , 808 (m) , 690 (m) , 660

(m) cm^"1; ^XH NMR (500 MHZ, CDC1₃) d 7.34-7.25 (m, 5 H) , 4.54

(apparent s, 2 H) , 4.40-4.25 (m, 1 H) , 4.23 (dd, J = 7.6, 1.9 Hz, 1 H) , 4.19 (d, J = 8.0 Hz, 1 H) , 3.46 (dd, -7 = 9.7, 4.9 Hz, 1 H) , 3.43 (dd, -7= 9.7, 5.9 Hz, 1 H) , 3.27 (s, 3 H) , 3.25 (s, 3 H) , 3.01 (d, J = 3.8 Hz, 1 H) , 2.76 (dd, J = 18.0, 8.7 Hz, 1 H) , 2.74 (dq, J = 7.1, 7.1 Hz, 1 H) , 2.62 (dd, -7 = 17.9, 3.2 Hz, 1 H) , 1.83 (dqd, -7 = 8.0, 7.0, 1.9 Hz, 1 H) , 0.97 (d, -7 = 7.1 Hz, 3 H) , 0.88 (d, -7 = 6.9 Hz, 3 H) , 0.83 (ε, 9 H) , 0.06

(ε, 3 H) , -0.05 (s, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 213.0, 138.0, 128.4, 127.71, 127.68, 105.0, 73.4, 73.3, 71.8, 66.5,

52.9, 52.6, 52.3, 46.5, 37.9, 26.1, 18.4, 12.7, 8.8, -4.1,

-4.8; high resolution mass spectrum (FAB, NBA) m/z 491.2821

[(M+Na) ⁺ ; calcd for C₂₅H₄₄0₆SiNa : 491.2805].

EXAMPLE 27 Diol (-)-34.

A solution of Me₄NBH(OAc)₃ (1.80 g, 6.84 mmol) in

H0Ac/CH₃CN (1:1, 10.0 mL) was cooled to -40 °C and ketone

( +)-33 (536 mg, 1.14 mmol) in CH₃CN (5 mL) was added. After 12 h at -20 'C, the mixture was treated with saturated aqueouε Rochelle'ε εalt (20 mL) and extracted with CH₂C1₂ (3 x 50 mL) . The combined organic extractε were waεhed with saturated NaHC0₃, brine (100 mL each), dried over MgS0₄, filtered and concentrated. Flash chromatography (1:1:1, CH₂Cl₂/ether/hexane) provided (-)-34 (519 mg, 97% yield) as a colorlesε oil: [ex] ³ _D -7.78° (C 0.900, CHC1₃) ; IR (CHC1₃) 3680 (w) , 3460 (m, br) , 3015 (m) , 2960 (8), 2940 (s) , 2900 ( ) , 2865 (s) , 1470 (m) , 1460 (m),1390 (m) , 1365 (m) , 1260 (m) , 1230 (m) , 1208 (m) , 1112 (ε) , 1065 (ε), 1030 (m) , 1010 (m) , 942 (m) , 865 ( ) , 838 (m) , 698 (m) cm"¹,- ^XH NMR (500 MHZ, CDC1₃) d 7.33-7.30 (m, 4 H) , 7.29-7.25 (m, 1 H) , 4.55 (ABq, J_M = 12.0 Hz, Δδ_M = 15.7 Hz, 2 H) , 4.16-4.11 (m, 1 H) , 4.13 (d, J = 7.8 Hz, 1 H) , 4.07 (dd, J = 4.8, 1.6 Hz, 1 H) , 3.73 (br s, 1 H) , 3.68 (dddd, J = 9.3,

9.3, 2.4, 2.4 Hz, 1H) , 3.50 (dd, J = 9.6, 4.5 Hz, 1 H) , 3.42

(dd, J = 9.4, 7.0 Hz, 1 H) , 3.38 (s, 3 H) , 3.29 (s, 3 H) , 3.09

(d, J = 4.0 Hz, 1 H) , 1.90 (dqd, -7 = 7.0, 7.0, 1.5 Hz, 1 H) , 1.76 (br dd, J = 13.6, 8.5 Hz , 1 H) , 1.68 (dqd, -7 = 9.6, 6.9,

5.0 Hz, 1 H) , 1.49 (ddd, J = 14.3, 9.0, 2.9 Hz , 1 H) , 0.894 (d,

J = 7.9 Hz, 3 H) , 0.886 (s, 9 H) , 0.80 (d, J = 7.0 Hz, 3 H) ,

0.055 (s, 3 H) , 0.048 (s, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d

138.2, 128.4, 127.7, 127.6, 107.3, 74.5, 73.3, 71.0, 70.9, 67.8, 55.2, 52.1, 45.9, 37.3, 36.9, 25.9, 18.2, 11.6, 10.6,

-4.3, -4.7; high resolution mass spectrum (FAB, NBA) m/z

493.2951 [(M+Na)⁺; calcd for C₂₅H₄₆0₆SiNa: 493.2962] .

EXAMPLE 28 Alcohol (-)-35. A solution of (-)-34 (123.3 mg, 0.262 mmol) in benzene

(10 mL) was treated with Ts0HΗ₂O (2.0 mg, 0.0105 mmol) at room temperature. After 20 min, the mixture was quenched with NEt₃

(1.0 mL) and concentrated. Flash chromatography (2% ether/CH₂Cl₂) afforded 35 (100.1 mg, β/ex = 2:1, 87% yield) as a colorless oil. β Anomer (35): [a] ²³ _D -3.3° (c 2.25, CHC1₃) ; IR (CHC1₃) 3680 (w) , 3580 (w) , 3490 (w) , 3010 (m) , 2960 (s), 2930 (s), 2880 (m) , 2860 (s), 1603 (w) , 1525 (w) , 1515 (w) , 1493 (m) , 1470 (m) , 1460 (m) , 1450 (m) , 1387 (m) , 1360 (m) , 1347 (m) , 1330 (m) , 1253 (s) , 1225 (m) , 1200 (m) , 1143 (m) , 1110 (s) , 1070 (ε), 1045 (s) , 1020 (s), 1015 (m) , 1003 (m) , 985 (m) , 950 (m) , 870 (m) , 853 (m) , 833 (s) , 807 (m) , 800 (m) , 790 (m) , 690 (m) , 670 (m) , 657 (m) cm^"1; ^XE NMR (500 MHZ, CDC1₃) d 7.34-7.25 (m, 5 H) , 4.69 (d, J = 2.4 Hz, 1 H) , 4.55 (ABq, J^ = 12.0 Hz, Δδ^ = 14.6 Hz, 2 H) , 4.17-4.12 (m, 1 H) , 3.78 (ddd, J = 9.7, 9.7, 2.5 Hz, 1 H) , 3.60 (apparent t, J = 2.7 Hz, 1 H) , 3.51 (dd, -7 = 9.5, 4.1 Hz, 1 H) , 3.42 (s, 3 H) , 3.39 (dd, J^" = 9.5, 7.0 Hz, 1 H) , 2.86 (d, J = 3.8 Hz , 1 H) , 1.88 (apparent qt, J = 7.1, 2.7 Hz, 1 H) , 1.76 (ddd, -7 = 14.4, 8.9, 2.6 Hz, 1 H) , 1.72-1.65 (m, 1 H) , 1.53 (ddd, J = 14.4, 9.3, 2.9 Hz, 1 H) , 0.90 (d, -7 = 8.2 Hz, 3 H), 0.89 (ε, 9 H), 0.78 (d, -7 = 6.8 Hz, 3 H) , 0.04 (s, 3 H) , 0.02 (s, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 138.2, 128.4, 127.7, 101.2, 76.7, 74.7, 73.3, 73.0, 67.4, 56.6, 41.1, 36.0, 34.7, 25.9, 18.1, 13.7, 9.7, -4.6, -4.9; high resolution mass spectrum (FAB, NBA) m/z 461.2693 [(M+Na)⁺; calcd for C₂₄H₄₂0₅SiNa : 461.2699]. a Anomer (35): [α]²³ _D +48° (c 0.54, CHC1₃); IR (CHC1₃) 3670 (w) , 3570 (w) , 3480 (w, br) , 3005 (m) , 2960 (s) , 2930 (s) , 2880 (m) , 2855 (ε) , 1600 (w) , 1527 (w) , 1515 (w) , 1495 (w) , 1460 (m) , 1360 (m) , 1253 (ε) , 1225 (m) , 1212 (m) , 1200 (m) , 1170 (m) , 1148 (m) , 1106 (s) , 1087 (s) , 1048 (s), 1030 (s), 963 (m) , 872 (m) , 833 (s) , 788 (m) , 690 (m) cm^"1; ^XH NMR (500 MHZ, CDC1₃) d 7.34-7.24 (m, 5 H) , 4.55 (ABq, J _M = 12.1 Hz, Δδ _ω = 14.4 Hz, 2 H) , 4.30 (d, J = 2.9 Hz , 1 H) , 4.12-4.07 (m, 1 H) , 4.01 (ddd, J = 9.2, 9.2, 2.7 Hz, 1 H) , 3.51 (apparent t, J = 4.4 Hz, 1 H) , 3.50 (dd, -7 = 9.5, 4.2 Hz, 1 H) , 3.39 (dd, J^" = 9.5, 7.1 Hz, 1 H) , 3.28 (s, 3 H) , 2.86 (d, -7 = 3.2 Hz, 1 H) , 1.85 (qdd, J = 7.3 , 5.2, 2.9 Hz, 1 H), 1.76 (dqd, J = 9.3, 6.9, 4.0 Hz, 1 H) , 1.71 (ddd, J = 14.5, 9.0, 2.8 Hz, 1 H) , 1.55 (ddd, -7 = 14.4, 9.2, 2.9 Hz, 1 H), 0.96 (d, -7 = 7.3 Hz, 3 H) , 0.88 (s, 9 H), 0.81 (d, J = 6.8 Hz, 3 H) , 0.03 (s, 3 H) , -0.01 (8, 3 H) ; ¹³C NMR d 138.2, 128.4, 127.7, 101.2, 76.7, 74.7, 73.3, 73.0, 67.4, 56.7, 41.1, 36.0, 34.7, 25.9, 18.1, 13.7, 9.7, -4.6, -4.9; high reεolution mass spectrum (FAB, NBA) m/z 461.2715 [(M+Na) ⁺ ; calcd for C₂₄H₄₂0₅SiNa : 461.2699] .

EXAMPLE 29

Methyl Pyranoside 36.

A solution of 35 (281.2 mg, β/ex = 2:1, 0.642 mmol) and 2,6-lutidine (224.0 μL, 1.92 mmol) in CH₂C1₂ (6.0 mL) was cooled to 0 °C and TBSOTf (295.0 μL, 1.28 mmol) was added over 5 min. After 1 h at 0 °C, the mixture was diluted with ethyl acetate (100 mL) , washed with aqueous NaHS0₄ (1.0 M, 50 mL) , brine (100 mL) , dried over MgS0₄, filtered and concentrated. Flash chromatography (5% ethyl acetate/hexane) provided 36 (344.6 mg, β/ex = 2:1, 97% yield) as a colorless oil. anomer: [ex]² +50.0° (c 1.44, CHC1 ^ ; IR (CHC1 )

2960 (s) , 2935 (s) , 2885 (s) , 2860 (s) , 1490 (w) , 1460 (m) , 1388 (m) , 1378 (m) , 1360 (m) , 1250 (s) , 1190 (m) , 1145 (m) , 1105 (ε), 1085 (ε), 1050 (s) , 1025 (s) , 1002 (s) , 963 (m) , 934 (m) , 867 (m) , 833 (s) , 690 (m) cm^"1; ^XE NMR (500 MHZ, CDC1₃) d 7.32-7.25 (m, 5 H) , 4.51 (ABq, J_m = 12.1 Hz, Δδ_ω = 19.7 Hz, 2 H) , 4.23 (d, J = 4.8 Hz, 1 H) , 4.03 (dddd, J = 8.0, 5.3, 5.3, 2.5 Hz, 1 H) , 3.87 (ddd, J = 9.9 , 7.8, 1.8 Hz, I H), 3.53 (dd, J = 7.2, 4.8 Hz, 1 H) , 3.39 (dd, J^" = 9.8, 5.6 Hz, 1 H) , 3.37 (dd, J = 10.0, 5.2 Hz, 1 H) , 3.33 (s, 3 H) , 1.79 (dqd, J = 7.1, 7.1, 4.9 Hz, 1 H) , 1.71-1.64 ( , 2 H) , 1.53 (ddd, J = 14.4, 8.8, 1.9 Hz, 1 H) , 0.94 (d, J = 7.0 Hz, 3 H) , 0.89 (s, 9 H) , 0.865 (s, 9 H) , 0.862 (d, J = 6.9 Hz, 3 H) , 0.07 (s, 3 H) , 0.04 (S, 3 H) , 0.03 (S, 3 H) , 0.005 (s, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 138.5, 128.3, 127.6, 127.5, 103.8, 75.5, 73.2, 72.8, 69.8, 69.1, 55.7, 38.9, 38.5, 37.6, 26.0, 25.8, 18.18, 18.16, 15.1, 12.9, -3.9, -4.6, -4.7, -4.8; high resolution mass spectrum (FAB, NBA) m/z 575.3552 [(M+Na)\- calcd for C₃₀H_5SO₅Si₂Na: 575.3564]. β anomer: [a] ²³ _D +13.3° (c 1.38, CHC1.) ; IR (CHC1 } 3003 (m) , 2960 (s) , 2935 (s) , 2880 (s) , 2860 (s), 1495 (w) , 1470 (m) , 1464 (m) , 1390 (m) , 1360 (m) , 1350 (m) , 1330 (w) , 1253 (s), 1155 (ε), 1140 (s) , 1120 (s), 1090 (s), 1045 (ε), 1022 (ε), 1002 (s) , 953 (m) , 933 (m) , 850 (s) , 830 (s) , 690 (m) , 658 (m) cm^"1; 'H NMR (500 MHZ, CDC1₃) d 7.32-7.22 (m, 5 H) , 4.74 (d, J = 2.4 Hz, 1 H) , 4.50 (ABq, -J_M = 13.2 Hz, Δδ_M = 17.8 Hz, 2 H) , 4.23-4.18 (m, 1 H) , 3.74 (ddd, J = 10.6, 10.6, 1.3 Hz, 1 H) , 3.60 (apparent t, J = 2.7 Hz, 1 H) , 3.48 (s, 3 H) , 3.38 (dd, J = 9.8, 4.5 Hz, 1 H) , 3.35 (dd, J = 9.8, 5.7 Hz, 1 H) , 1.88 (qdd, J = 7.1, 2.7, 2.7 Hz, 1 H) , 1.66 (ddd, -7 = 14.0, 10.1, 1.6 Hz, 1 H) , 1.63-1.55 (m, 1 H) , 1.49 (ddd, J = 14.0, 10.8, 1.8 Hz, 1 H) , 0.91 (d, J = 7.1 Hz, 3 H) , 0.89 (s, 9 H) , 0.88 (S, 9 H) , 0.785 (d, J = 6.8 Hz, 3 H) , 0.07 (s, 3 H) , 0.045 (s, 3 H) , 0.040 (S, 3 H) , 0.02 (s, 3 H) ; ¹³C NMR (125 MHZ, CDC1 d 138.5, 128.2, 127.6, 127.4, 100.6, 76.9, 75.8, 73.2, 71.7, 67.9, 56.7, 41.1, 38.4, 35.0, 26.1, 25.8, 18.2, 18.1, 14.0, 9.7, -3.9, -4.5, -5.0; high resolution mass spectrum (FAB, NBA) m/z 575.3560 [(M+Na)⁺; calcd for C₃₀H Q₆Sj. Na:₂ 575.3564] . EXAMPLE 30

Primary Alcohol 37.

A solution of 36 (331.6 mg, 0.600 mmol) in EtOH/EtOAc

(1:8, 9 mL) was treated with Pd/C (10% wet, E101 NE/ , 51.2 mg) under H₂ atmoεphere for 3 h, then filtered and concentrated.

Flaεh chromatography (10% ethyl acetate/hexane) provided 37

(276.6 mg, β/ex = 2:1, 99% yield) as a colorless oil. β anomer: [a] ²³ _D +16.9° (c 2.52, CHC1₃) ; IR (CHC1₃) 3680 (w) , 3590 (w, br) , 3450 (w, br) , 3000 (m) , 2960 (s) , 2925 (s) , 2880 (m) , 2855 (s), 1470 ( ) , 1462 (m) , 1388 (m) , 1360 (m) , 1253 (s) , 1222 (m) , 1200 (m) , 1150 (m),1130 (m) , 1110 (s) , 1098 (m) , 1065 (s) , 1046 (s) , 1023 (s), 1002 (m) , 980 (m) , 952 (m) , 894 (m) , 865 (m) , 850 (m) , 830 (s), 663 (m) , 657 (m) cm^"1; ^XH NMR (500 MHZ, CDC1₃) d 4.73 (d, J = 2.5 Hz , 1 H) , 4.09-4.05 (m, 1 H) , 3.64 (ddd, J = 10.5, 10.5, 1.3 Hz, 1 H) , 3.60

(apparent t, J= 2.5 Hz, 1 H) , 3.62-3.59 (m, 1 H) , 3.47 (s, 3

H) , 3.47-3.42 (m, 1 H) , 1.95-1.85 (m, 2 H) , 1.82 (ddd, J =

14.3, 9.2, 1.5 Hz, 1 H) , 1.60 (dqd, J = 10.2, 6.8, 2.5 Hz, 1

H) , 1.45 (ddd, J = 14.3, 10.7, 2.6 Hz, I H), 0.895 (d, -7 = 7.5 Hz, 3 H) , 0.887 (apparent s, 18 H) , 0.785 (d, J = 6.8 Hz, 3 H) , 0.09 (s, 3 H) , 0.08 (S, 3 H) , 0.04 (s, 3 H) , 0.02 (ε, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 100.8, 76.8, 72.2, 69.5, 67.6, 56.8, 41.0, 38.2, 34.9, 25.9, 25.8, 18.1, 14.0, 9.7, -4.2, -4.6, -4.7, -5.0; high resolution mass spectrum (FAB, NBA) m/z 485.3080 [(M+Na) ⁺ ; calcd for C₂₃H_so0₅SiNa : 485.3094]. anomer: [α] ²³ _D +54.9° ( c 1.20, CHC1₃) ; IR (CHC1₃) 3670 (w) , 3590 (w) 3440 (w, br) , 3000 (m) , 2960 (s), 2925 (s) , 2880 (m) , 2855 (s) , 1463 (m) , 1390 (m) , 1360 (m) , 1255 (s) , 1225 (m) , 1192 (m) , 1168 (m) , 1143 (m) , 1102 (s) , 1083 (ε),1045 (s) , 1030 (m) , 1002 (m) , 963 (m) , 932 (m) , 862 (m) , 833 (s) cm^"1; E NMR (500 MHZ, CDC1₃) d 4.25 (d, J = 4.2 Hz, 1 H) , 3.89 (dddd, J = 6.5, 4.6, 4.6, 4.6 Hz, 1 H) , 3.80 (ddd, J = 9.1, 9.1, 2.3 Hz, 1 H) , 3.61 (br dd, J = 10.9, 3.4 Hz, 1 H) , 3.51 (dd, J = 6.5, 4.6 Hz, 1 H) , 3.52-3.48 (m, 1 H) , 3.33 (s, 3 H) , 2.15 (S, br, 1 H) , 1.81 (dqd, J = 6.9, 6.9, 4.2 Hz, 1 H) , 1.72-1.60 (m, 3 H) , 0.94 (d, -7 = 7.1 Hz, 3 H) , 0.882 (s, 9 H) , 0.879 (S, 9 H) , 0.845 (d, J = 6.8 Hz, 3 H) , 0.09 (s, 3 H) , 0.08 (S, 3 H) , 0.02 (s, 3 H) , 0.00 (s, 3 H) ; ¹³C NMR (125 MHz, CDC1₃) d 104.0, 72.7, 71.3, 70.0, 67.6, 55.7, 38.7, 38.5, 37.3, 25.8, 18.13, 18.08, 15.2, 13.1, -4.4, -4.6, -4.7; high resolution mass spectrum (FAB, NBA) m/z 485.3081 [(M+Na)⁺; calcd for C₂₃H₅₀0₅Si₂Na: 485.3094] .

EXAMPLE 31 Alcohol 38.

A solution of 37 (276.6 mg, 0.598 mmol) in Et₂0 (40 mL) was treated with EtSH (8.90 mL, 120 mmol) and MgBr₂. Et₂0 (1.54 g, 5.96 mmol) at room temperature. After 60 h, the mixture was diluted with ethyl acetate (50 mL) , washed with brine (2 x 100 mL) , dried over MgS0₄, filtered and concentrated. Flash chromatography (3% acetone/hexane) provided 38 ex (34.4 mg, 12% yield) and 38 β (211.3 mg, 71% yield) . β anomer: colorless oil; [ex] ²³ _D +16.6° (c 1.18, CHC1₃) ; IR (CHC1₃) 3595 (m) , 3400 (m, br) , 3000 (m) , 2960 (s), 2930 (ε) , 2855 (ε) , 1655 (w) , 1612 (ε) , 1588 (m) , 1510 (ε) , 1462 (s) , 1375 (m) , 1360 (m) , 1300 (m) , 1250 (s, br) , 1170 (m) , 1080 (s, br) , 1030 (ε) , 1002 (m) , 967 (m) , 835 (ε) cm^"1; "H NMR

(500 MHZ, CDCI₃) d 5.08 (d, J = 2.3 Hz, 1 H) , 4.04-4.00 (m, IH) , 3.62 (ddd, J = 10.4, 10.4, 1.0 Hz, 1 H) , 3.60 (ddd, J =

11.1, 11.1, 4.2 Hz, 1 H) , 3.56 (apparent t, J = 2.7 Hz , 1 H) , 3.43 (ddd, J = 11.7, 7.9, 4.1 Hz, 1 H) , 2.70 (dq, J = 12.7, 7.4 Hz, 1 H) , 2.67 (dq, J = 12.8, 7.5 Hz, 1 H) , 1.95 (dd, J = 7.9, 4.8 Hz, 1 H) , 1.86 (qdd, J = 7.1, 2.7, 2.7 Hz, 1 H) , 1.79 (ddd, J = 14.4, 9.0, 1.4 Hz, 1 H) , 1.66-1.59 (m, 1 H) , 1.57 (s, 3 H) , 1.45 (ddd, J = 14.4, 10.5, 2.7 Hz, 1 H) , 1.27 (apparent t , J^" = 7.4 Hz, 1 H) , 0.99 (d, J = 7.1 Hz, 3 H) , 0.90 (s, 9 H) , 0.89 (ε, 9 H) , 0.79 (d, J = 6.8 Hz, 3 H) , 0.083 (ε, 3 H) , 0.075 (s, 3 H) , 0.04 (s, 3 H) , 0.03 (ε, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 81.0, 76.2, 75.0, 69.8, 67.6, 41.9, 38.3, 34.5, 25.9, 25.8,

25.2, 18.1, 15.2, 14.4, 11.5, -4.2, -4.56, -4.63, -4.9; high resolution mass spectrum (FAB, NBA) m/z 515.3037 [(M+Na) ; calcd for C₂₄H₅₂0₄SSi₂Na: 515.3023] . ex anomer: colorless oil; [a] ²³ _D +94.5° (c 0.33, CHC1₃) ; IR (CHC1₃) 3680 (w) , 3580 (w) , 3440 (w, br) , 3010 (m) , 2960 (s), 2930 (ε), 2880 (m) , 2860 (ε), 1513 (w) , 1470 (m) , 1462 (m) , 1390 (m) , 1380 (m) , 1360 (m) , 1257 (s), 1225 (m) , 1200 (m) , 1114 (m) , 1070 (s) , 1047 (s), 1022 (m) , 1002 (m) , 957 (m) , 860 (m) , 833 (s) , 705 (ε) , 660 (m) cm^"1; ^XH NMR (500 MHZ, CDC1₃) d 4.76 (d, J^" = 3.1 Hz, 1 H) , 4.04 (ddd, J^" = 9.8, 9.8, 1.8 Hz, 1 H) , 3.84 (dddd, J = 5.0, 5.0, 5.0, 5.0 Hz, I H), 3.57 (dd, J = 11.0, 4.2 Hz, 1 H) , 3.53 (apparent t, J = 4.0 Hz , 1 H) , 3.47 ( dd, J = 11.0, 4.7 Hz, 1 H) , 2.57 (dq, J = 12.8, 7.5 Hz, 1 H) , 2.54 (dq, J = 12.8, 7.5 Hz, 1 H) , 1.97-1.91 (m, 1 H) , 1.75 (ddd, J = 14.7, 6.1 Hz, 2.0, 1 H) , 1.72-1.65 (m, 1 H) , 1.60 (ddd, J = 14.9, 10.0, 5.1 Hz, 1 H) , 1.60-1.50 (br, 1 H) , 1.23 (apparent t, J= 7.4 Hz, 3 H), 1.06 (d, J = 7.1 Hz, 3 H) , 0.92 (8, 9 H) , 0.89 (ε, 9 H) , 0.85 (d, J = 6.9 Hz, 3 H) , 0.12 (S, 3 H) , 0.08 (S, 3 H) , 0.05 (s, 3 H) , 0.02 (s, 3 H) ; ¹³C NMR (125 MHZ, CDCI₃) d 85.3, 73.8, 71.5, 69.2, 67.5, 40.6, 38.2, 36.4, 26.4, 26.1, 25.9, 18.2, 18.1, 17.5, 14.7, 13.9, -4.2, -4.4, -4.8; high reεolution mass spectrum (FAB, NBA) m/z 515.3045 [(M+Na)⁺; calcd for C₂₄H_S20₄SSi₂Na : 515.3023] .

EXAMPLE 32 Fragment (+) -C .

A solution of DMSO (100 μL, 1.42 mmol) in CH₂C1₂ (2.0 mL) waε cooled to -78 °C and oxalyl chloride (55.0 μl, 0.630 mmol) waε introduced dropwiεe. After 15 min. a cooled (-78 °C) solution of 38 ex (104.8 mg, 0.213 mmol) in CH₂C1₂ (1.0 mL) was introduced via cannula (2 x 500 μL rinse) . The resultant milky solution was stirred for 15 min at -78 °C and i-Pr₂NEt (370 μl, 2.12 mmol) was added dropwise. The reaction mixture waε εtirred for 0.5 h, εlowly warmed to room temperature (15 min), and quenched with aqueouε NaHS0₄ (1.0 M, 4.0 mL) . The organic phaεe waε diluted with ether (30 mL) , waεhed with brine (3 x 30 mL) , dried over MgS0₄, filtered and concentrated. Flash chromatography (2% ethyl acetate/hexane) furniεhed (+)-C (88.8 mg, 86% yield) as a colorlesε oil: [ex] ²³ _D +11.2° (c 1.42, CHC1₃) ; IR (CHC1₃) 2960 (ε) , 2935 (s), 2880 (s), 2860 (s), 1735 (s), 1470 (m) , 1460 (m) , 1380 (m) , 1360 (m) , 1320 (m) , 1295

(w) , 1265 (s), 1153 (m) , 1120 (m) , 1080 (m) , 1060 (s), 1043

(ε) , 1025 (ε) , 1003 (ε), 970 (m) , 950 (m) , 935 (m) , 903 (m) ,

865 (m) , 835 (s) , 800 (m) , 690 (m) cm^"1; ^λE NMR (500 MHZ, CDC1₃) d 9.56 (d, J = 0.9 Hz, 1 H) , 5.07 (d, J = 2.3 Hz, 1 H) , 4.35

(ddd, J = 7.9, 2.2, 0.6 Hz, 1 H) , 3.70 (ddd, J = 10.3, 10.3,

1.5 Hz, 1 H) , 3.57 (apparent t, -7 = 2.7 Hz, 1 H) , 2.71-2.60 (m,

2 H) , 1.86 (apparent qt, J = 7.1, 2.7 Hz, 1 H) , 1.78 (ddd, -7 =

14.1, 10.4, 7.8 Hz, 1 H) , 1.72-1.66 (m, 1 H) , 1.67 (ddd, J = 10.3, 3.9, 1.8 Hz, 1 H) , 1.25 (apparent t, J = 7.4 Hz, 3 H) ,

1.00 (d, J^" = 7.2 Hz, 3 H) , 0.90 (s, 9 H) , 0.89 (ε, 9 H) , 0.78

(d, J = 6.8 Hz, 3 H) , 0.10 (8, 3 H) , 0.04 (s, 6 H) , 0.03 (s, 3

H) ; ¹³C NMR (125 MHZ, CDC1₃) d 202.6, 81.2, 76.1, 74.9, 73.7,

41.9, 35.8, 34.4, 25.82, 25.79, 25.2, 18.2, 18.1, 15.3, 14.3, 11.5, -4.2, -4.5, -4.9, -5.2; high reεolution maεε spectrum

(CI, NH₃) m/z 491.3058 [(M+H)⁺; calcd for C₂₄H₅₁0₄SSi₂: 491.3046].

EXAMPLE 33 Fragment ( - ) -B .

From vinyl bromide (-)-22: A solution of (-)-22 (3.78 g, 8.04 mmol) in HMPA/DMF (2:1, 6 mL) was added to a mixture of Kl (4.15 g, 250 mmol), NiBr₂ (34.9 mg, 0.160 mmol), and Zn powder (23.2 mg, 0.355 mmol). The mixture waε εtirred at room temperature for 15 min then heated to 90 °C. The green color mixture turned black-brown after 5 min and dark green after 1 h. After additional 1 h at 90 °C, the mixture was cooled to room temperature, diluted with ethyl acetate (200 mL) , washed with brine (4 x 200 mL) , dried over MgS0₄, filtered and concentrated. Flash chromatography (2% ethyl acetate/hexane) provided B (3.59 g, containing 13% unreacted vinyl bromide) as a colorless oil.

From aldehyde (+)-18: A suspenεion of EtPh₃P⁺I^" (15.1 g, 36.1 mmol) in THF (200 mL) waε treated with n-BuLi (1.6 M in hexane, 23.0 mL, 36.8 mmol) at room temperature over 10 min. After an additional 10 min, the reεultant red εolution was added via cannula to a cooled (-78 °C) solution of I₂ (8.02 g, 31.6 mmol) in THF (300 mL) over 15 min. The yellow εlurry formed waε εtirred at -78 °C for 5 min and at -23 °C for 10 min. NaHMDS (1.0 M in THF, 31.0 mL, 31.0 mmol) waε added over 8 min and the mixture stirred 15 min further. A solution of aldehyde ( + ) -18 (6.96 g, 18.3 mmol) in THF (50 mL) was introduced via cannula (lOmL rinse) , and the reaction mixture was stirred at -23 °C for 10 min, warmed to room temperature, stirred for 3 h, and then quenched with MeOH (10 mL) . Following concentration and filtration through a silica column (50% ethyl acetate/hexane) , the filtrate was washed with εaturated aqueouε Na₂S₂0₃, brine (300 mL each) , dried over MgS0₄, filtered and concentrated. Flaεh chromatography (5% ethyl acetate/hexane) furniεhed B (6:1 Z/E, 3.94 g, 41% yield) aε a colorless oil.

An analytical sample of (-)-B was obtained by reversed-phase HPLC (gradient elution, 90% CH₃CN/H₂0 -> 100% CH₃CN) : [α]²³ _D -23° (c 0.30, CHC1₃) ; IR (CHC1₃) 3000 (m) , 2960 (ε) , 2930 (s) , 2880 (m) , 2855 (s) , 1610 (m) , 1588 (w) , 1510 (s) , 1463 (m) , 1453 (m) , 1428 (m) , 1405 (w) , 1390 (m) , 1377 (m) , 1360 (m) , 1303 (m) , 1250 (s) , 1180 (m) , 1172 (m) , 1080 (s, br) , 1033 (s) , 1002 (m) , 948 (m) , 935 (m) , 922 (m) , 833 (s), 803 (m) , 760 (m, br) , 720 (m) , 658 (m) cm^"1; ^τE NMR (500 MHZ, CDC1₃) d 7.25 (d, J = 8.6 Hz, 2 H) , 6.87 (d, J = 8.7 Hz, 2 H) , 5.28 (apparent dd, J = 8.9, 1.4 Hz , 1 H) , 4.41 (ABq, J_m = 7.0 Hz, Δδ_M = 10.2 Hz, 2 H) , 3.80 (s, 3 H) , 3.60 (apparent t, J = 5.3 Hz, 1 H) , 3.51 (dd, -7 = 9.1, 5.1 Hz , 1 H) , 3.23 (dd, J = 9.0, 8.0 Hz, 1 H) , 2.54-2.47 (m, 1 H) , 2.44 (d, J = 1.4 Hz, 3 H) , 2.00-1.92 (m, 1 H) , 1.00 (d, J = 6.9 Hz, 3 H) , 0.95 (d, J = 6.7 Hz, 3 H) , 0.89 (s, 9 H) , 0.02 (s, 3 H) , 0.01 (s, 3 H) _/ ¹³C NMR (125 MHZ, CDC1₃) d 159.1, 139.6, 131.0, 129.1, 113.7, 98.9, 76.5, 72.6, 72.5, 55.3, 44.5, 38.7, 33.5, 26.1, 18.4, 14.7, 14.5, -3.95, -3.99; high resolution maεε spectrum (FAB, NBA) m/z 541.1626 [(M+Na)⁺; calcd for C₂₃H₃₉0₃ISiNa : 541.1611].

EXAMPLE 34 Olefin (-)-39. ZnCl₂ (1.32 g, 9.69 mmol) was dried at 160 °C under vacuum overnight and then treated with a solution of (-)- A (5.25 g, 9.59 mmol) in dry Et₂0 (50 L) via a cannula (2 x 25 mL rinse) . The mixture was stirred at room temperature until most of the ZnCl₂ dissolved and cooled to -78 °C. t-BuLi (1.7 M in pentane, 17.0 mL) was added over 30 min, and the resultant εolution waε stirred 15 min further, warmed to room temperature, and stirred for 1 h. The solution waε added by cannula to a mixture of B (3.21 g, 6.19 mmol; 6:1 Z/E) and Pd(PPh₃)₄ (364.0 mg, 0.315 mmol) . The mixture was covered with aluminum foil, stirred overnight, and then diluted with ethyl acetate (100 mL) , washed with brine (2 x 100 mL) , dried over MgS0₄, filtered and concentrated. Flash chromatography (5% ethyl acetate/hexane) gave (-)-39 (3.32 g, 66% yield) as a white semiεolid: [ex] ²³ _D -28.6° (c 1.53, CHC1₃); IR (CHC1₃) 3010

(m) , 2970 (s) , 2940 (s), 2865 (s), 1620 (m) , 1590 (w) , 1520 (s) , 1465 (S) , 1445 (m) , 1390 (m) , 1380 (m) , 1360 ( ) , 1305

(m) , 1250 (ε), 1175 (m) , 1115 (s) , 1080 (s) , 1040 (ε), 970 (m) , 940 (w) , 860 (m) , 835 (s) cm^"1; ^XH NMR (500 MHZ, CDC1₃) d 7.36

(d, J = 8.7 Hz, 2 H) , 7.22 (d, J = 8.6 Hz, 2 H) , 6.86 (d, J =

9.0 Hz, 2 H) , 6.84 (d, J = 8.9 Hz, 2 H) , 5.37 (s, 1 H) , 5.00 (d, J = 10.2 Hz, 1 H) , 4.36 (ABq, J^ = 11.6 Hz, Δδ_M = 17.4 Hz,

2 H) , 4.08 (dd, J = 11.2, 4.7 Hz , 1 H) , 3.78 (s, 3 H) , 3.77 (s,

3 H) , 3.61 (dd, J = 7.1, 1.8 Hz , 1 H) , 3.51 (dd, -7 = 9.9, 1.7 Hz, 1 H) , 3.47 (apparent t, J = 11.0 Hz, 1 H) , 3.46 (dd, J^" = 9.1, 5.0 Hz, 1 H) , 3.38 (dd, J = 6.0, 4.8 Hz, 1 H) , 3.19 (apparent t, J = 8.8 Hz, 1 H) , 2.51 (ddq, J = 10.1, 6.5, 6.5 Hz, 1 H) , 2.32 (apparent t, -7= 12.2 Hz, 1 H) , 2.08-2.02 (m, 1 H) , 1.99-1.93 (m, 2 H) , 1.88 (dqd, -7 = 7.1, 7.1, 1.8 Hz, I H), 1.67 (br d, J = 11.1 Hz, 1 H) , 1.55 (d, J = 0.5 Hz , 3 H) , 1.01 (d, -J = 7.1 Hz, 3 H) , 0.94 (d, J = 6.9 Hz, 3 H) , 0.90 (s, 9 H) , 0.89 (d, J = 6.7 Hz, 3 H) , 0.87 (ε, 9 H) , 0.74 (d, J = 6.3 Hz , 3 H) , 0.73 (d, J = 6.4 Hz, 3 H) , 0.03 (s, 3 H) , 0.013 (s, 3 H) , 0.008 (s, 3 H) , 0.003 (ε, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 159.8, 159.0, 132.0, 131.5, 131.2, 131.1, 129.0, 127.3, 113.7, 113.5, 101.1, 83.4, 78.49, 78.46, 73.3, 72.6, 72.5, 55.3, 38.8, 38.2, 37.5, 35.6, 33.7, 30.8, 26.27, 26.25, 23.1, 18.42, 18.40, 17.0, 14.6, 12.6, 12.1, 10.9, -3.5, -3.7, -3.8, -3.9; high resolution mass spectrum ( FAB , NBA) m/z 835 . 5315 [ (M+Na ) ⁺ ; calcd f or C₄₇H₈₀O₇Si₂Na : 835 . 5341 ] .

Anal . Calcd for C₄₇H₈₀O₇Si₂ : C , 69 . 41 ; H , 9 . 91 . Found : C , 69 . 52 ; H , 10 . 10 .

EXAMPLE 35

Alcohol (-)-40.

A solution of olefin (-)-39 (2.65 g, 3.26 mmol) in CH₂C1₂ (32 mL) was cooled to 0 ^°C and treated with H₂0 (1.50 mL) and DDQ (774 mg, 3.41 mmol). After 4 h, the mixture was diluted with CH₂C1₂ (20 mL) , dried over MgS0₄, and filtered through a silica column (50% ethyl acetate/hexane) . Following concentration, the residue was disεolved in EtOH (50 mL) and treated with NaBH₄ (500 mg, exceεs) at room temperature to reduce the contaminated p-methoxybenzyl aldehyde. After 0.5 h, the mixture was quenched with εaturated aqueouε NH₄C1 (50 mL) at 0 °C then concentrated. The reεidue waε partitioned between CH₂C1₂ (200 mL) and water (100 mL) . The organic phaεe waε waεhed with water (100 mL) , dried over MgS0₄, filtered and concentrated. Flaεh chromatography (10% ethyl acetate/hexane) provided (-)-40 (2.06 g, 91% yield) aε a white εolid. mp 99-100 °C; [α]²³ _D -25.4° (c 1.35, CHC1₃); IR (CHC1₃) 3520 (w) 3010 (m) , 2960 (s) , 2940 (s), 2880 (m) , 2860 (m) , 1620 (m) 1593 (w) , 1520 (m) , 1565 (m) , 1390 (m) , 1360 (m) , 1255 (s) 1175 (m) , 1165 (m) , 1117 (m) , 1075 (s), 1037 (s), 1025 (s) 1005 (m) , 982 (m) , 965 (m) , 930 (w) , 835 (s) , 800 (m) , 705 (w) 675 (w) , 660 (w) cm^"1; ^XE NMR (500 MHZ, CDC1₃) d 7.36 (d, J = 8.7 Hz, 2 H) , 6.86 (d, J = 8.8 Hz, 2 H) , 5.37 (s, 1 H) , 5.01 (d, J = 10.1 Hz, 1 H) , 4.09 (dd, J = 11.2, 4.7 Hz, 1 H) , 3.79 (s, 3 H) , 3.65 (dd, J^" = 10.4, 4.7 Hz , 1 H) , 3.63 (dd, -7 = 7.0, 1.8 Hz, 1 H) , 3.54-3.50 (m, 1 H) , 3.51 (dd, J = 10.0, 2.0 Hz, 1 H) , 3.47 (apparent t, J = 11.2 Hz, 1 H) , 3.41 (dd, J^" = 6.6, 4.0 Hz, 1 H) , 2.59 (ddq, -7 = 13.2, 6.7, 6.7 Hz, 1 H) , 2.33 (apparent t, J = 12.2 Hz, 1 H) , 2.24 (apparent t, J = 5.5 Hz, 1 H) , 2.09-1.95 (m, 2 H) , 1.89 (dqd, J = 7.0, 7.0, 1.7 Hz, 1 H) , 1.84-1.77 (m, 1 H) , 1.72 (br d J = 11.0 Hz, 1 H) , 1.58 (d, J = 0.8 Hz, 3 H) , 1.01 (d, J = 7.1 Hz, 3 H) , 0.98 (d, J = 7.1 Hz, 3 H) , 0.94 (d, J = 6.7 Hz, 3 H) , 0.910 (s, 9 H) , 0.905 (s, 9 H) , 0.75 (d, -7 = 7.1 Hz, 3 H) , 0.74 (d, -7 = 7.1 Hz, 3 H) , 0.09 (s, 3 H) , 0.07 (8, 3 H) , 0.05 (s, 3 H) , 0.01 (s, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 159.8, 133.0, 131.5, 130.5, 127.3, 113.4, 101.0, 83.3, 81.6, 78.4, 73.3, 65.4, 55.3, 38.5, 38.2,

37.6, 37.0, 33.7, 30.8, 26.17, 26.16, 23.2, 18.4, 18.3, 17.4,

15.7, 12.6, 12.1, 10.9, -3.57, -3.61, -3.66, -3.9; high resolution mass spectrum (CI, NH₃) m/z 693.4918 [ (M+H)⁺; calcd for C₃₉H₇₃0₆Si₂: 693.4945] . Anal. Calcd for C₃₉H₇₂O_εSi₂: C, 67.58; H, 10.47.

Found: C, 67.30; H, 10.54.

EXAMPLE 36

Phosphonium Salt (-)-49.

A solution of alcohol (-)-40 (402.8 mg, 0.577 mmol) in PhH/Et₂0 (1:2, 45 mL) was treated with PPh₃ (532 mg, 2.03 mmol) and imidazole (158 mg, 2.32 mmol) . After the imidazole disεolved, I₂ (437 mg, 1.72 mmol) waε added under vigorous εtirring. The mixture was stirred 2 h and then treated with NEt₃ (2 mL) . The resultant yellow suspension waε diluted with CH₂C1₂ (50 mL) and waεhed with saturated aqueous Na₂S₂0₃ (100 mL) , saturated aqueous NaHC0₃ (100 mL) , and brine (2 x 100 mL) .

The organic phase was dried over MgS0₄, filtered and concentrated. Filtration through a εhort εilica column

(NEt₃/ethyl acetate/hexane, 2:10:90) removed triphenylphoεphine oxide, affording the impure iodide 42. Preparative TLC (500 mm silica gel plate, 4% acetone/hexane) furnished an analytical εample aε an unεtable white εolid: ^λE NMR (500 MHZ, CDC1₃) d 7.35 (d, J - 8.8 Hz, 2 H), 6.85 (d, J = 8.7 Hz, 2 H) , 5.37 (s, 1 H) , 5.02 (d, J^" = 10.2 Hz, 1 H) , 4.08 (dd, J = 11.2, 4.7 Hz, 1 H) , 3.78 (ε, 3 H) , 3.62 (dd, -7= 7.0, 1.8 Hz, 1 H) , 3.51 (dd, J = 9.9, 1.7 Hz, 1 H) , 3.47 (apparent t, J = 11.1 Hz, 1 H) , 3.37 (dd, J = 6.3, 4.3 Hz, 1 H) , 3.32 (dd, -J = 9.6, 4.5 Hz, 1 H) , 2.99 (dd, J = 9.5, 8.6 Hz, 1 H) , 2.50 (ddq, J = 10.2, 6.5, 6.5 Hz, 1 H) , 2.31 (apparent t, J = 12.2 Hz, 1 H) , 2.08-1.95 (m, 2 H) , 1.88 (dqd, J = 7.1, 7.1, 1.7 Hz, 1 H) , 1.85-1.78 (m, 1 H) , 1.74 (br d, -7 = 11.7 Hz, 1 H) , 1.57 (apparent s, 3 H) , 1.01 (apparent d, J = 7.0 Hz, 6 H) , 0.91-0.89 (m, 3 H) , 0.90 (S, 9 H) , 0.89 (s, 9 H) , 0.74 (d, J = 6.8 Hz, 3 H) , 0.73 (d, J = 6.7 Hz, 3 H) , 0.06 (s, 3 H) , 0.05 (ε, 3 H) , 0.01 (ε, 3 H) , -0.02 (s, 3 H) _; ¹³C NMR (125 MHZ, CDCl₃/l% pyridine-d₅, 20 mg εample) d 159.8, 132.9, 131.5, 130.4, 127.3, 113.5, 101.1, 83.3, 79.6, 78.5, 73.3, 55.3, 41.4, 38.3, 37.6, 36.0, 33.7,

30.8, 26.20, 26.17, 23.2, 18.4, 17.7, 17.3, 13.5, 12.6, 12.2,

10.9, -3.5, -3.6, -4.0; high reεolution maεε spectrum (FAB, NBA) m/z 803.3935 [(M+H) ⁺ ; calcd for C₃₉H₇₂0₅ISi₂ : 803.3963]. The very sensitive impure iodide (obtained by filtration through silica) was quickly mixed with i-Pr₂NEt (300 μL, 1.72 mmol) and PPh₃ (2.47 g, 9.42 mmol). The mixture was heated at 80 'C for 24 h, then cooled to room temperature and extracted with hexane (2 x 30 mL) . The residue was purified by flash chromatography (2% MeOH/CHCl₃) furnishing (-)-49 (224.9 mg, 37% yield from (-)-39) as a pale yellow foam. The hexane extract was concentrated and purified by flash chromatography

(2% ethyl acetate/hexane) affording a mixture of cyclization products (200 mg) . Further purification by normal phase HPLC (1.5% ethyl acetate/hexane) provided (-)-50 aε the major cyclization product.

Wittig reagent (-)-49: [ex] ²³ _D -25.3^° (c 1.48, CHC1₃) ,- IR (CHC1₃) 2960 (s) , 2930 (s), 2860 (m) , 1615 ( ) , 1590 (w) , 1515 (m) , 1485 (w) , 1460 (m) , 1440 (m) , 1385 (m) , 1360 (m) , 1300 (m) , 1250 (ε) , 1215 (m, br) , 1180 (m) , 1110 (ε) , 1080 (m) , 1025 (m) , 1005 (m) , 965 (m) , 945 (w) , 860 (m) , 830 (s), 732 (m) , 725 (m) , 710 (m) , 680 (m) , 653 (m) cm^"1; ^XH NMR (500 MHZ, CDC1₃; concentration dependent) d 7.82-7.76 (m, 15 H) , 7.35 (d, J = 8.8 Hz, 2 H) , 6.84 (d, J = 8.8 Hz, 2 H) , 5.35 (s, 1 H) , 5.30 (d, J = 10.5 Hz, 1 H) , 4.07 (dd, J = 11.2, 4.7 Hz, 1 H) , 3.77 (ε, 3 H) , 3.73-3.67 (m, 2 H) , 3.56 (dd, J = 7.0, 1.8 Hz, 1 H) , 3.48 (dd, J = 9.8, 1.7 Hz, 1 H) , 3.46 (apparent t, J = 11.1 Hz, 1 H) , 3.31 (ddd, J = 15.6 , 11.2, 11.2 Hz, 1 H) , 2.49 (ddq, J = 10.5, 6.4, 6.4 Hz, 1 H) , 2.25 (apparent t, -7 = 12.1 Hz, 1 H) , 2.10-1.92 (m, 3 H) , 1.85 (dqd, J = 7.1, 7.1, 1.8 Hz, 1 H) , 1.57-1.52 (m, 1 H) , 1.56 (ε, 3 H) , 0.98 (d, J = 7.1 Hz, 3 H), 0.89 (d, J = 6.6 Hz, 3 H), 0.852 (ε, 9 H) , 0.849 (s, 9 H) , 0.72-0.71 (m, 3 H) , 0.71 (d, J = 6.6 Hz, 3 H) , 0.69 (d, J = 6.9 Hz, 3 H) , 0.10 (s, 3 H) , -0.02 (s, 3 H) , -0.03 (s, 3 H) , -0.07 (s, 3 H) / ¹³C NMR (125 MHZ, CDC1₃) d 159.8, 135.2 (J_cp = 2.6 Hz) , 133.5 (J^" _CP = 10.0 Hz) , 132.9, 131.4, 130.6 (-7_CP = 12.6 Hz) , 130.3, 127.3, 118.4 (J_cp = 85.5 Hz) , 113.4, 101.0, 83.2, 80.1 (-7_CP = 14.0 Hz) , 78.3, 73.2, 55.3, 38.1, 37.4, 36.0, 33.7 (-7_CP = 4.4 Hz) , 33.6, 30.7, 26.1, 25.5 (-7_CP = 49.7 Hz) , 22.9, 18.33, 18.29, 17.2, 17.1, 12.5, 12.1, 10.9, -3.2, -3.6, -3.7, -4.0; high resolution maεε εpectrum (FAB, NBA) m/z 937.5708 [(M-I)⁺; calcd for C_S7H₈₆0₅PSi₂: 937.5751] .

Olefin (-)50: white solid; mp 80-82 °C; [a] ²³ _D -18° (c 0.48, CHC1₃) ; IR (CHC1₃) 2955 (s) , 2920 (s) , 2880 (m) , 2850 (ε) , 1640 (w) , 1613 (m) , 1588 (w) , 1517 (m) , 1460 (m) , 1387 (m) , 1360 (m) ,1300 (m) , 1250 (s) , 1178 (m) , 1170 (m) , 1160 (m) , 1115 (m) , 1080 (m) , 1023 (s) , 1000 (m) , 980 (m) , 960 (m) , 930 (w) , 887 (m) , 855 (m) , 830 (m) , 715 (m) cm^"1; ^XH NMR (500 MHZ, C₆Dg) d 7.62 (d, -7 = 8.7 Hz, 2 H) , 6.83 (d, -7 = 8.7 Hz, 2 H) , 5.46 (s, 1 H) , 5.00 (s, 1 H) , 4.95 (ε, 1 H) , 3.93 (dd, J = 11.1, 4.7 Hz, 1 H) , 3.89 (dd, J = 7.2, 1.5 Hz , 1 H) , 3.55 (dd, J = 9.9, 1.9 Hz, 1 H) , 3.51 (apparent t, -7 = 5.9 Hz, 1 H) , 3.27 (ε, 3 H) , 3.22 (apparent t, J = 11.0 Hz, 1 H) , 2.32 (dd, J = 13.6, 3.5 Hz, 1 H) , 2.27-2.20 (m, 1 H) , 2.16 (dd, J = 13.7, 9.5 Hz, 1 H) , 2.07-1.92 (m, 4 H) , 1.87-1.80 (m, 1 H) , 1.50-1.42 (m, 1 H) , 1.18 (d, J = 7.1 Hz, 3 H) , 1.10 (d, J = 6.6 Hz, 3 H) , 1.06 (d, J = 6.6 Hz, 3 H) , 1.04 (s, 9 H) , 1.02 (d, J = 7.0 Hz , 3 H) , 1.00 (s, 9 H) , 0.41 (d, J = 6.7 Hz , 3 H) , 0.13 (ε, 3 H) , 0.09 (ε, 3 H) , 0.08 (s, 3 H) , 0.06 (s, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 159.8 (q) , 150.7 (q) , 131.5 (q) , 127.3, 113.4, 108.3 (CH_j) ₍ 101.0, 83.2, 81.9, 78.1, 73.3 (CH₂) , 55.2, 49.9, 44.9, 41.4 (CHJ , 39.0 (CH₂) , 38.3, 36.6, 33.4, 30.8, 26.3, 25.9, 18.5 (q) , 18.2 (q) , 17.8, 15.5, 12.9, 12.1, 11.0, -3.4, -3.7, -4.6, -4.7; high resolution masε εpectrum (FAB, NBA) m/z 697.4642 [(M+Na)⁺; calcd for C₃₉H₇₀O₅Si₂Na: 697.4659] . EXAMPLE 37

Model Olefin (+)-43.

NaHMDS (0.6 M in PhMe, 9.46 mL, 5.68 mmol) was added over 10 min to a suspenεion of (CH₃) ₂CHP⁺Ph₃ I^" (2.52 g, 5.83 mmol) in PhMe (20 mL) at room temperature. After 15 min, the mixture waε cooled to -78 °C, and aldehyde (+)-18 (1.46 g, 3.84 mmol) in PhMe (15 mL) waε introduced via a cannula (15mL rinεe) . After 20 min at -78 °C and 30 min at room temperature, the reaction waε quenched with MeOH (1.0 mL) . The εolution waε εeparated, and the oil reεidue waε extracted with hexane (3 x 30 mL) . The combined organic εolutions were then concentrated and, and flash chromatography (2% ethyl acetate/hexane) provided ( +) -43 (1.44 g, 92% yield) as a colorless oil: [c_]²³ _D +8.07° (c 2.57, CHC1₃) ; IR (CHC1-) 2960 (s), 2925 (s), 2880 (s), 2855 (s), 1610 (m) , 1585 (m) , 1510 (s) , 1460 (s), 1375 (m) , 1360 (m) , 1300 (m) , 1245 (s) , 1172 (m) , 1085 (ε, br) , 1035 (s) , 1003 (m) , 970 (m) , 950 (m) , 935 (m) , 862 (s) , 835 (s) cm^"1,- *H NMR (500 MHZ, CDC1₃) d 7.23 (d, J = 9.0 Hz, 2 H) , 6.85 (d, J = 8.6 Hz, 2 H) , 4.92 (d-quintet, J = 9.7, 1.4 Hz, 1 H) , 4.37 (apparent s, 2 H) , 3.78 (ε, 3 H) , 3.49 (dd, J = 9.2, 4.9 Hz, 1 H) , 3.39 (dd, J = 6.3, 4.5 Hz, 1 H) , 3.19 (dd, J = 9.0, 8.4 Hz , 1 H) , 2.49 (ddq, J = 9.6, 6.7, 6.7 Hz, 1 H) , 2.00-1.92 (m, 1 H) , 1.63 (d, J = 1.2 Hz, 3 H) , 1.55 (d, -7 = 1.3 Hz, 3 H) , 0.945 (d, J = 7.0 Hz, 3 H) , 0.874 (d, J = 6.7 Hz, 3 H) , 0.873 (s, 9 H) , 0.01 (apparent s, 6 H) ; ¹³C NMR (125 MHZ, CDC1₃) 159.0, 131.1, 129.7, 129.4, 129.1, 113.7, 78.6, 72.6, 55.3, 38.5, 36.0, 26.2, 25.8, 18.4, 17.9, 17.0, 14.8, -3.88, -3.95; high reεolution maεε spectrum (CI, NH₃) m/z 407.2984 [(M+H)⁺; calcd for C₂₄H₄₃0₃Si: 407.2981].

EXAMPLE 38

Alcohol (+)-44.

A mixture of olefin (+)-43 (387.6 mg, 0.954 mmol) in

CH₂C1₂ (10 mL) was treated with Hp (500 μL) and DDQ (320 mg,

1.41 mmol) . After 30 min at room temperature, the mixture waε filtered through a εhort εilica plug (50% ethyl acetate/hexane) and concentrated. Flash chromatography (3% ethyl acetate/hexane) provided (+) -43 (273.1 mg, 99% yield) as a colorlesε oil: [ex] ²³ _D +17.5° (c 2.80, CHC1₃); IR (CHC1₃) 3620 (w) , 3500 (m, br) , 2955 (s) , 2925 (s) , 2880 (s) , 2860 (s) , 1460 (ε) , 1405 (m) , 1375 (m) , 1360 (m) , 1337 (m) , 1252 (ε) , 1070 (s) , 1050 (ε) , 1015 (s) , 1002 (s), 978 (m) , 933 (m) , 832 (s) cm^"1; ^XH NMR (500 MHZ, CDC1₃) d 4.92 (apparent d quintet, J = 9.7, 1.4 Hz, 1 H) , 3.66 (ddd, -7 = 11.0, 4.4, 4.4 Hz, I H), 3.52 (ddd, -7 = 11.0, 5.5, 5.5 Hz, 1 H) , 3.42 (dd, J = 6.8, 4.0 Hz , 1 H) , 2.57 (ddq, J = 9.6, 6.8, 6.8 Hz, I H), 2.45 (apparent t, J = 5.2 Hz, 1 H) , 1.85-1.78 (m, 1 H) , 1.65 (d, J = 1.3 Hz, 3 H) , 1.59 (d, J = 1.3 Hz, 3 H) , 0.98 (d, J = 7.1 Hz , 3 H) , 0.92 (d, J = 6.8 Hz, 3 H), 0.90 (s, 9 H), 0.08 (s, 3 H), 0.05 (s, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃ ) d 130.7, 128.5, 81.7, 65.5, 38.1, 37.4, 26.2, 25.8, 18.3, 17.9, 17.4, 15.9, -3.7, -3.9; high resolution masε spectrum (CI, NH₃) m/z 287.2418 [(M+H)\- calcd for C₁₆H₃₅0₂Si: 287.2406].

EXAMPLE 39

Wittig reagent (+)-46.

Iodine (1.08 g, 4.24 mmol) was added to a εolution of alcohol (+) -44 (810 mg, 2.83 mmol), PPh₃ (1.11 g, 4.24 mmol) and imidazole (289 mg, 4.24 mmol) in benzene/ether (1:2, 21 mL) under vigorous stirring at room temperature. After 40 min, the mixture waε diluted with ether (100 mL) , washed with saturated Na₂S₂0₃ (50 mL) , brine (100 mL) , dried over MgS0₄, filtered and concentrated. Flash chromatography (hexane) provided a mixture of 45/47/48 (1.06 g, 97% yield, 18:1:1) as a colorlesε oil; This material was then treated with J-Pr₂NEt (928 μL, 5.33 mmol) and PPh₃ (7.01 g, 26.7 mmol) then heated at 80 °C for 13 h. The mixture was extracted with hexane (3 x 100 mL) . The residue was purified by flash chromatography (2% MeOH/CHCl₃) providing Wittig reagent (+)-48 (207.1 mg, 38% yield from

(+) -46) aε a pale yellow foam. The hexane extract was concentrated and purified by flash chromatography (hexane) affording a mixture of two cyclization products (380 mg) and further purification by preparative TLC (hexane) afforded (-) -49 and (-) -50. Wittig reagent ( + )-46: [ ] ²³ _D +4.8^° (c 1.23, CHC1₃) ,- IR (CHC1₃) 2940 (S), 2860 (m) , 1588 (w) , 1482 (w) , 1468 (m) , 1460 (m) , 1440 (s) , 1380 (m) , 1360 (w) , 1310 (w) , 1253 (m) , 1230 (m) , 1210 (m) , 1110 (s), 1080 (m) , 1050 (m) , 1018 (m) , 1000 ( ) , 995 (m) , 860 (m) , 832 (s) , 800 (m) , 708 (m) , 680 (m) , 652 (m) cm^"1,- ^XE NMR (500 MHZ, CDC1₃ ,- concentration dependent) d 7.81-7.67 (m, 15 H) , 4.92 (d, J = 9.7 Hz, 1 H) , 3.50 (apparent t, J = 5.3 Hz, 1 H) , 3.38 (ddd, J = 14.9 , 14.9, 1.5 Hz, 1 H) , 3.25 (ddd, -7 = 15.6, 11.1, 11.1 Hz, 1 H) , 2.42 (ddq, -7 = 9.7, 6.6, 6.6 Hz, 1 H) , 2.10-2.00 (m, 1 H) , 1.53 (ε, 3 H) , 1.43 (ε, 3 H) , 0.83 (ε, 9 H) , 0.81 (d, J = 6.7 Hz, 3 H) , 0.75 (d, J = 6.8 Hz, 3 H) , 0.03 (s, 3 H) , -0.02 (ε, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d, 135.3 (J_cp - 2.8 Hz), 133.3 (-7_cp = 9.9 Hz), 131.0, 130.6 (J_cp = 12.4 Hz), 128.0, 118.2 (J_cp = 85.6 Hz), 80.4 (J_cp = 13.3 Hz), 36.0, 33.0 (J_cp = 4.0 Hz), 26.1, 25.6, 25.1 (-7_cp = 50.8 Hz), 18.3, 18.1, 17.9, 16.4, -3.3, -4.0; high resolution masε εpectrum (FAB, NBA) m/z 531.3221 [(M-I)⁺ _; calcd for C₃₄H₄₈OPSi: 531.3213] .

Olefin (-)-47: Colorleεs oil; [ ] ²³ _D -14° (c 0.36, CHC1₃) ,- IR (CHC1₃) 2960 (s) , 2930 .(s), 2860 (ε), 1470 (m) , 1460, 1370 (m) , 1360 (m) , 1250 (m) , 1206 (w) , 1165 (m) , 1140 (m) , 1070 (ε) , 1020 (8), 1000 (m) , 932 (w) , 908 (w) , 897 (w) , 853 (m) , 830 (ε) cm^"1; *H NMR (500 MHZ, CDC1₃) d 3.63 (d, br, J = 3.6 Hz, 1 H) , 2.50 (apparent q, J = 7.3 Hz , 1 H) , 2.28 (ddd, J = 15.5, 7.7, 0.8 Hz, 1 H) , 2.13-2.03 (m, 1 H) , 1.99-1.91 (m, 1 H) , 1.60 (apparent br ε, 3 H) , 1.57 (apparent d, J = 0.8 Hz, 1 H) , 0.94 (d, J = 6.7 Hz, 3 H) , 0.91 (d, J = 7.4 Hz , 3 H) , 0.85 (ε, 9 H) , 0.01 (apparent ε, 6 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 138.9 (q) , 122.0 (q) , 82.9, 46.1, 36.4, 35.8 (CH₂), 25.9, 21.2, 20.4, 18.3 (q) , 18.0, 14.3, -4.6, -4.8; high reεolution maεs εpectrum (CI, NH₃) m/z 269.2310 [(M+H)\- calcd for C₁₆H₃₃OSi: 269.2300] .

Olefin (-)-48: Colorless oil; [ex] ²³ _D -3.8° (c 0.24, CHC1₃) ; IR (CHC1₃) 2953 (s) , 2925 (s), 2880 (m) , 2855 (m) , 1638 (w) , 1470 (m) , 1460 (m) , 1385 (w) , 1373 (m) , 1360 (w) , 1250 (m) , 1135 (m) , 1117 (m) , 1100 (m) , 1075 (m) , 1028 (m) , 1000 (m) , 932 (w) , 865 (m) , 830 (s) cm^'1; ^XE NMR (500 MHZ, C₆D₆) d 4.84-4.83 (m, 1 H) , 4.79-4.77 (m, 1 H) , 3.46 (apparent t, J = 5.3 Hz, 1 H) , 1.94-1.88 (m, 1 H) , 1.87-1.78 (m, 2 H) , 1.73 (ddd, J = 12.4, 7.3, 7.3 Hz, 1 H) , 1.66 (apparent dd, ,7 = 1.3, 0.8 Hz, 3 H) , 1.45 (ddd, -7= 12.2, 10.3, 8.7 Hz, 1 H) , 1.00 (d, J = 6.9 Hz, 3 H) , 0.99 (s, 9 H) , 0.96 (d, J = 6.7 Hz, 3 H) , 0.06 (S, 3 H) , 0.05 (s, 3 H) ; ¹³C NMR (125 MHZ, C₆D_S) d 147.4 (q) , 110.3 (CH₂), 82.3, 53.1, 45.4, 37.5 (CH )₂, 37.3, 26.1, 19.3, 18.4 (q) , 18.0, 15.6, -4.4, -4.5; high resolution mass spectrum (CI, NH₃) m/z 269.2315 [(M+H) ⁺ ; calcd for C_ιeH₃pSi: 269.2300] .

EXAMPLE 40 Alcohol (+)-51.

A solution of olefin (+)-44 (70.9 mg, 0.28 mmol) in EtOH/EtOAc (1:8, 4.5 mL) was treated with Pd/C (10% wet, ElOl NE/W, 15.2 mg) under H₂ atmosphere for 18 h. The mixture was then filtered through a short silica pipet and concentrated. Flash chromatography (5% ethyl acetate/hexane) provided ( + ) -51 (70.8 mg, 100% yield) as a colorless oil. [x]²³ _D +28° (c 0.15, CHC1₃) ; IR (CHC1₃) 3680 (w) , 3620 (w) , 3500 (w, br) , 3010 (m) , 2960 (s) , 2935 (s) , 2900 (m) , 2885 (m) , 2860 (m) , 1522 (w) , 1510 (w) , 1470 (m) , 1426 (m) , 1420 (m) , 1412 (m) , 1387 (m) , 1370 (m) , 1255 (m) , 1205 (m) , 1070 (m) , 1030 (m) , 1013 (m) , 1002 (m) , 980 (m) , 925 (m) , 833 (ε), 720 (m) , 665 (m) , 658 (m) cm^"1; ^XE NMR (500 MHZ, CDC1₃) d 3.60-3.56 (m, 2 H) , 3.46 (dd, J = 5.5, 3.8 Hz, 1 H) , 2.46 (br s, 1 H) , 1.89-1.81 (m, 1 H) , 1.74-1.66 (m, 1 H) , 1.64-1.56 (m, 1 H) , 1.21 (ddd, J = 13.3, 8.9, 4.6 Hz, I H), 1.09 (ddd, J = 13.7 , 9.6, 5.3 Hz , 1 H) , 0.94 (d, J = 7.0 Hz, 3 H) , 0.90 (s, 9 H) , 0.88 (d, J = 6.6 Hz, 3 H) , 0.86 (d, J = 6.9 Hz, 3 H) , 0.83 (d, J = 6.6 Hz, 3 H) , 0.095 (s, 3 H) , 0.07 (s, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 81.3, 66.3, 42.5, 37.8, 35.7, 26.1, 25.4, 23.8, 21.8, 16.4, 15.1, -3.9, -4.1; high resolution mass spectrum (CI, NH₃) m/z 289.2565 [(M+H)⁺; calcd for C₁₆H₃₇0₂Si: 289.2562] . EXAMPLE 41 Iodide (+)-52.

A solution of alcohol (+)-51 (150 mg, 0.520 mmol), PPh₃ (205 mg, 0.780 mmol) and imidazole (53 mg, 0.780 mmol) in benzene/ether (1:2; 6.0 mL) was treated with iodine (198 mg, 0.780 mmol) under vigorous stirring at room temperature. After 40 min, the mixture was diluted with ether (100 mL) , washed with saturated Na₂S p ₃ (50 mL) , brine (100 mL) , dried over MgS0₄, filtered and concentrated. Flash chromatography (hexane) provided (+) -51 (195 mg, 94% yield) as a colorless Oil: [ex] ² +24.2° (c 2.21, CHC1₃) ; IR (CHC1₃) 2960 (s), 2935 (ε), 2900 (m) , 2860 (s) , 1470 (m) , 1463 (m) , 1425 (w) , 1405 (w) , 1382 (m) , 1368 (m) , 1360 (m) , 1290 (w) , 1255 (s), 1190 (m) , 1170 (m) , 1082 (s) , 1065 (m) , 1028 (m) , 1003 (m) , 970 (w) , 932 (w) , 832 (s) cm^"1; *H NMR (500 MHZ, CDC1₃) d 3.41 (dd, J = 9.6, 3.7 Hz, 1 H) , 3.38 (dd, J^" = 6.3, 2.6 Hz, 1 H) , 3.10 (dd, J = 9.6, 7.5 Hz, 1 H) , 1.72-1.56 (m, 3 H) , 1.17 (ddd, J = 13.4, 8.3, 5.4 Hz, 1 H) , 1.09 (ddd, J = 13.3, 5.9, 2.1 Hz, I H), 0.99 (d, J = 6.8 Hz, 3 H) , 0.89 (s, 9 H) , 0.88 (d, J = 6.6 Hz , 3 H) , 0.84 (d, J= 6.6 Hz, 3 H), 0.81 (d, -7 = 6.8 Hz, 3 H), 0.09 (ε, 3 H) , 0.06 (ε, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 79.1, 43.7, 39.8, 33.8, 26.2, 25.3, 23.5, 22.0, 18.7, 18.5, 15.9, 14.4, -3.65, -3.71; high reεolution mass spectrum (CI, NH₃) m/z 399.1572 [(M+H)⁺; calcd for C₁₆H₃₆0ISi: 399.1580].

EXAMPLE 42

Wittig Reagent (+)-53.

A mixture of Iodide (+) -52 (195 mg, 0.489 mmol) and benzene (100 mL) waε treated with i-Pr₂NEt (85 μL, 0.488 mmol) and PPh₃ (1.28 g, 4.88 mmol), then heated at 70 °C for 24 h. The mixture was extracted with hexane (3 x 20 mL) . The residue was purified by flaεh chromatography (3% MeOH/CHCl₃) furniεhing ( +)-53 (303 mg, 94% yield) aε a white foam; [cx] ²² _D +3.3° (c 2.14, CHC1₃) ; IR (CHC1₃) 2950 (ε) , 2930 (s) , 2855 (m) , 1588 (w) , 1482 (w) , 1463 (m) , 1438 (s) , 1385 (m) , 1365 (w) , 1253 (m) , 1225 (m) , 1207 (m) , 1110 (s) , 1080 (m) , 1032 (m) , 1000 (m) , 832 (ε) , 804 (m) , 708 ( ) , 680 (m) , 653 (m) cm^"1; ^XE NMR (500 MHZ, CDC1₃) d 7.83-7.67 (m, 15 H) , 3.70 (ddd, J = 15.6, 11.0, 11.0 Hz, 1 H) , 3.52 (dd, J = 7.6, 1.7 Hz, 1 H) , 3.45 (apparent t, J = 15.4 Hz, 1 H) , 2.08-1.97 (m, 1 H) , 1.70-1.62 (m, 1 H) , 1.51 (9 lines, J = 6.5 Hz, 1 H) , 1.09-0.97 (m, 2 H) , 0.850 (ε, 9 H) , 0.79 (d, J = 6.7 Hz, 3 H) , 0.77 (d, J^" = 7.9 Hz , 3 H) , 0.74 (d, J = 6.5 Hz, 3 H) , 0.68 (d, J = 6.8 Hz, 3 H) , 0.12 (ε, 3 H) , 0.11 (S, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 135.2 (J_cp = 2.7 Hz) , 133.6 (-7_cp =9.9 Hz) , 130.6 (J_cp = 12.4 Hz) , 118.5 (-7 _op= 85.5 Hz) , 80.1 (-J_cp = 12.9 Hz) , 43.5, 33.6, 32.6 (J _cp= 3.7 Hz) , 26.2, 25.3 ( _cp = 51.1 Hz) , 25.0, 23.4, 21.7, 18.6, 18.5, 13.7, -2.7, -3.8; high resolution masε εpectrum (FAB, NBA) m/z 533.3369 [(M-I)⁺; calcd for C₃₄H₅₀OPSi: 533.3357] .

EXAMPLE 43 Olefin (-)-54. Phoεphonium εalt (-)-49 waε dried azeotropically with anhydrous benzene and heated at 50 °C under vacuum for 3 h before use. A solution of (-)-49 (97.7 mg, 0.0917 mmol) in THF (700 μL) was cooled to -78 °C and treated with NaHMDS (1.0 M in THF, 85.5 μL, 0.0855 mmol) . The mixture was stirred for 20 min at O'C, recooled to -78 °C and aldehyde C (28.0 mg, 0.0570 mmol) in THF (300 μL) was added. After 10 min at -78 °C and 2 h at room temperature, the mixture was quenched with εaturated aqueouε NH₄C1 (1.0 mL) and extracted with ether (30 L) . The ether εolution waε waεhed with water, brine (30 mL each) , dried over MgS0₄, filtered and concentrated. Flaεh chromatography (2% ethyl acetate/hexane) provided (-)-56 (50.0 mg, 76% yield) as a colorleεs oil: [ ] ²³ _D -44.9° (c 2.09, CHC1₃) ; IR (CHC1

2960 (ε), 2930 (ε) , 2855 (s) , 1615 (m) , 1587 (w) , 1517 (m) , 1463 (s) , 1380 (m) , 1360 (m) , 1320 (m) , 1300 (m) , 1250 (s), 1170 (m) , 1160 (m) , 1120-1000 (s, br) , 990 (m) , 965 (m) , 935 (m) , 900 (m) , 835 (ε), 807 (m) , 670 (m) cm^"1; ^XE NMR (500 MHZ, CDC1₃) d 7.35 (d, J = 8.7 Hz, 2 H) , 6.85 (d, J = 8.8 Hz, 2 H) , 5.37 (ε, 1 H) , 5.27 (dd, J = 11.2, 7.8 Hz , 1 H) , 5.19 (apparent t, J= 10.9 Hz, 1 H) , 5.08 (d, J^" = 10.1 Hz, 1 H) , 5.06 (d, J = 2.2 Hz, I H), 4.68 (apparent t, -7 = 9.1 Hz, I H), 4.08 (dd, J = 11.2, 4.7 Hz, 1 H) , 3.78 (ε, 3 H) , 3.68 (apparent t, J = 10.1 Hz, 1 H) , 3.61 (dd, -7 = 7.1, 1.7 Hz , 1 H) , 3.53 (apparent t, J = 2.6 Hz, 1 H) , 3.50 (dd, -7 = 9.9 , 1.6 Hz , 1 H) , 3.46 (apparent t, J = 11.1 Hz, 1 H) , 3.25 (apparent t, -7 = 5.3 Hz, 1 H) , 2.71-2.58 (m, 1 H) , 2.68 (dq, J = 12.8, 7.4 Hz , 1 H) , 2.62 (dq, J = 12.8, 7.4 Hz, 1 H) , 2.50 (m, 1 H) , 2.30 (apparent t, J = 12.2 Hz, 1 H) , 2.08-2.01 (m, 1 H) , 1.98-1.90 (m, 1 H) , 1.88 (dqd, ,7 = 7.1, 7.1, 1.7 Hz, I H), 1.82 (apparent qt , J^" = 7.1, 2.6 Hz, 1 H) , 1.65 (br d, J = 12.4 Hz, 1 H) , 1.62-1.57 (m, 2 H), 1.56 (d, J = 0.4 Hz, 3 H), 1.38 (ddd, J = 13.6, 10.7, 1.5 Hz, 1 H) , 1.29-1.22 (apparent t , J = 7.4 Hz, 3 H) , 1.00 (d, J = 7.1 Hz, 3 H) , 0.94 (d, J = 7.3 Hz, 3 H) , 0.930 (d, J = 6.9 Hz, 3 H) , 0.925 (d, J = 7.1 Hz , 3 H) , 0.90 (s, 18 H) , 0.89 (s, 9 H) , 0.86 (s, 9 H) , 0.74 (apparent d, J = 6.6 Hz, 6 H) , 0.73 (d, J = 6.1 Hz, 3 H) , 0.05 (ε, 3 H) , 0.04 (ε, 3 H) , 0.03 (s, 3 H) , 0.019 (ε, 3 H) , 0.017 (ε, 3 H) , 0.013 (s, 3 H) , 0.009 (s, 3 H) , 0.00 (S, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 159.8, 134.4, 131.9, 131.8, 131.5, 131.4, 127.3, 113.4, 101.0, 83.4, 80.9, 80.4, 78.5, 76.7, 76.5, 74.2, 73.3, 65.5, 55.2, 42.5, 41.9, 38.2, 37.5, 37.1, 35.4, 34.4, 33.8, 26.3, 26.2, 26.0, 25.9, 25.1, 23.2, 18.5, 18.4, 18.12, 18.08, 17.0, 16.6, 15.6, 14.4, 12.7, 12.1, 11.6, 10.9, -2.7, -3.5, -3.66, -3.69, -4.2, -4.5, -4.9, -5.0; high reεolution maεs spectrum (FAB, NBA) m/z 1171.7799 [(M+Na)⁺; calcd for C₆₃H₁₂₀O₈SSi₄Na : 1171.7781] .

EXAMPLE 44 Hydroxy Diene (-)-55.

A εolution of the olefin (-)-54 (49.8 mg, 0.0434 mmol) in CH₂C1₂ (4.4 mL) waε cooled to -78 °C and DIBAL (1.0 M in toluene, 430 μL, 0.430 mmol) waε added over 5 min. After 10 min at -78 °C and 30 min at 0 °C, the reaction waε quenched with εaturated aqueouε Rochelle'ε salt (500 μL) . The mixture was diluted with ether (60 mL) , washed with saturated aqueous Rochelle salt, brine (30 mL each) , dried over MgS0₄, filtered and concentrated. Flash chromatography (5% ethyl acetate/hexane) furnished (-)-57 (38.0 mg, 88% yield) as a colorleεε oil: [a] ²³ _D -32° (c 1.90, CHC1₃) ; IR (CHC1₃) 3500 (w, br) , 2960 (ε) , 2935 (ε), 2900 (m) , 2885 (m) , 2860 (ε) , 1610 (m) , 1585 (w) , 1510 (m) , 1470 (m) , 1460 (m) , 1400 (m) , 1375

(m) , 1360 (m) , 1300 (m) , 1250 (s), 1170 (m) , 1095 (m) , 1080

(m) , 1047 (s), 1000 (m) , 960 (m) , 950 (m) , 933 (m) , 835 (s),

805 (m) , 665 (m) cm^"1; *H NMR (500 MHZ, CDC1₃) d 7.24 (d, J = 8.6 Hz, 2 H) , 6.85 (d, J = 8.6 Hz, 2 H) , 5.27 (dd, J = 11.4,

7.8 Hz, 1 H) , 5.20 (apparent t, J = 10.3 Hz, 1 H) , 5.10 (d, J

= 10.0 Hz, 1 H) , 5.05 (d, J = 2.2 Hz, 1 H) , 4.68 (apparent t,

J = 9.2 Hz, 1 H) , 4.49 (ABq, -7_M = 10.4 Hz, Δδ_M = 23.4 Hz, 2

H) , 3.78 (S, 3 H) , 3.73 (ddd, J = 10.7, 4.0, 4.0 Hz, I H), 3.68 (apparent t, J = 10.4 Hz, 1 H) , 3.57 (ddd, -7 = 10.6, 5.1, 5.1

Hz, 1 H) , 3.53 (dd, -7 = 5.4, 3. Hz , 1 H) , 3.50 (apparent t, -7

= 5.2 Hz, 1 H) , 3.35 (apparent t, J = 5.5 Hz, 1 H) , 3.26

(apparent t, J = 5.2 Hz , 1 H) , 2.68 (dq, -J = 12.8, 7.4 Hz, 1

H) , 2.61 (dq, J = 12.8, 7.5 Hz, 1 H) , 2.71-2.58 (m, 2 H) , 2.51-2.44 (m, 1 H) , 2.22 (apparent t, J = 12.4 Hz, 1 H) , 1.99-1.86 (m, 3 H) , 1.81 (apparent qt, -7 = 7.1, 2.6 Hz, 1 H) , 1.72 (br d, J = 12.7 Hz, 1 H) , 1.62-1.57 (m, 1 H) , 1.61 (s, 3 H) , 1.56-1.48 (m, 1 H) , 1.38 (ddd, J = 13.5, 12.3, 1.4 Hz, 1 H) , 1.27 (apparent t, J = 7.4 Hz, 3 H), 1.03 (d, -7 = 6.9 Hz, 3 H) , 1.02 (d, J = 6.8 Hz, 3 H) , 0.95-0.92 (m, 9 H) , 0.93 (ε, 9 H) , 0.90 (S, 9 H) , 0.89 (s, 9 H) , 0.86 (s, 9 H) , 0.74 (d, J = 8.0 Hz, 3 H) , 0.73 (d, J = 7.0 Hz, 3 H) , 0.08 (s, 6 H) , 0.05 (ε, 3 H) , 0.024 (s, 3 H) , 0.020 (s, 3 H) , 0.012 (s, 3 H) , 0.009 (S, 3 H) , 0.006 (S, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 159.4, 134.4, 132.3, 131.7, 130.9, 130.4, 129.3, 114.0, 86.3, 80.9, 80.4, 77.6, 76.5, 75.3, 74.2, 65.6, 65.5, 55.3, 42.6, 41.9, 40.0, 37.6, 37.0, 36.8, 35.9, 35.2, 34.5, 26.30, 26.27, 25.9, 25.8, 25.1, 23.2, 18.53, 18.47, 18.13, 18.07, 17.1, 16.6, 15.7, 15.6, 14.4, 13.6, 11.6, 11.4, -2.8, -3.2, -3.4, -3.6, -4.2, -4.5, -4.9; high reεolution mass spectrum (FAB, NBA) m/z 1173.7859 [(M+Na)⁺; calcd for C₆₃H₁₂₂0₈SSi₄Na : 1173.7835] .

EXAMPLE 45 Aldehyde (-)-56.

A solution of alcohol (-)-55 (13.8 mg, 0.0120 mmol) and Et₃N (42 μL, 0.30 mmol) in CH₂C1₂ (200 μL) was cooled to 0

°C and treated with S0₃.pyridine (40 mg, 0.251 mmol) in DMSO (600 μL) . After 45 min at 0 ^°C, the mixture was diluted with ethyl acetate (30 mL) , washed with aqueous NaHS0₄ (1.0 M, 30 mL) , brine (2 x 30 mL) , dried over MgS0₄, filtered and concentrated. Pipette flash chromatography (3% ethyl acetate/hexane) afforded (-)-56 (13.2 mg, 96% yield) as a colorlesε oil: [ex] ²³ _D -32.1° (c 1.40, CHC1₃) ; IR (CHC1₃) 2960 (s) , 2935 (ε) , 2880 (m) , 1720 (m) , 1610 (m) , 1512 (m) , 1470 (m) , 1460 (m) , 1387 (m) , 1380 (m) , 1360 (m) , 1340 (m) , 1320 (m) , 1300 (m) , 1250 (s), 1110 (s), 1098 (s) , 1080 (s), 1048 (s) , 1002 (m) , 988 (m) , 965 (m) , 950 (m) , 935 (m) , 835 (s) cm^"1; ^XH NMR (500 MHZ, CDC1₃) d 9.78 (d, J = 2.5 Hz, 1 H) , 7.20 (d, J = 8.6 Hz, 2 H) , 6.85 (d, J = 8.7 Hz, 2 H) , 5.27 (dd, J = 11.1, 7.8 Hz, 1 H) , 5.19 (apparent t, -7 = 10.4 Hz, 1 H) , 5.10 (d, J = 10.0 Hz, 1 H) , 5.05 (d, J = 2.1 Hz, 1 H) , 4.67 (apparent t, J = 8.9 Hz, 1 H) , 4.45 (apparent s, 2 H) , 3.78 (ε, 3 H) , 3.68 (apparent t, J= 10.2 Hz, 1 H) , 3.58-3.56 (m, 2 H) , 3.51 (apparent t, J = 2 .6 Hz , 1 H) , 3.25 (apparent t, J = 5.2 Hz, 1 H) , 2.73 (dqd, J = 7.1, 6.0, 2.6 Hz, 1 H), 2.70 -2.57 ( , 3 H) , 2.51-2.44 ( , 1 H) , 2.23 (apparent t, J = 12.4 Hz, 1 H) , 1.98-1.85 (m, 2 H) , 1.81 (apparent qt, J = 7.1, 2.6 Hz, 1 H) , 1.67 (br d, J = 13.0 Hz, 1 H) , 1.60 (s, 3 H) , 1.62-1.50 (m, 2H) , 1.37 (ddd, J = 13.8, 10.4, 1.5 Hz, 1 H) , 1.26 (apparent t, -7 = 7.4 Hz, 3 H), 1.10 (d, J = 7.0 Hz, 3 H) , 1.02 (d, -7 = 7.0 Hz, 3 H) , 0.938 (d, J = 7.1 Hz, 3 H) , 0.932 (d, -7 = 7.8 Hz, 3 H) , 0.919 (s, 9 H) , 0.918 (d, J = 6.6 Hz, 3 H) , 0.90 (ε, 9 H) , 0.88 (ε, 9 H) , 0.86 (8, 9 H) , 0.732 (d, J = 6.7 Hz , 3 H) , 0.726 (d, J = 6.8 Hz, 3 H) , 0.07 (ε, 3 H) , 0.053 (s, 3 H) , 0.047 (s, 3 H) , 0.02 (S, 6 H) , 0.009 (8, 3 H) , 0.005 (s, 6 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 204.6, 159.3, 134.4, 132.3, 131.8, 130.8, 130.3, 129.1, 128.3, 113.8, 82.6, 80.9, 80.4, 76.5, 74.5, 74.2, 65.5, 55.3, 49.5, 42.5, 41.9, 40.3, 37.1, 36.8, 35.4, 34.9, 34.4, 26.3, 26.2, 25.9, 25.8, 25.1, 23.2, 18.49, 18.45, 18.12, 18.07, 17.0, 16.6, 15.6, 14.4, 13.3, 12.1, 11.6, 11.4, -2.8, -3.3, -3.4, -3.7, -4.2, -4.5, -4.9, -5.0; high resolution mass spectrum (FAB, NBA) m/z 1171.7670 [(M+Na)⁺; calcd for C₆₃H₁₂₀O₈SSiNa: 1171.7676]. EXAMPLE 46 Tetraene (-)-57.

A solution of Ph₂PCH₂CH=CH₂ (40 μL, 0.19 mmol) in THF (1.0 mL) was cooled to -78 °C and t-BuLi (1.7 M in pentane, 72.0 μL, 0.122 mmol) was added. The mixture was stirred at 0 °C for 30 min, recooled to -78 °C and treated with Ti(0iPr)₄ (45 μL, 0.15 mmol). After 30 min, a cold (-78 °C) solution of the aldehyde (-)-56 (30.2 mg, 0.0262 mmol) in THF (1.0 mL) was introduced via cannula, and the resultant mixture was εtirred for 10 min at -78 °C and 1 h at 0 °C. Mel (20 μL, 0.32 mmol) waε then added, and the reaction waε maintained at 0 °C for 30 min, warmed to room temperature, protected from light with aluminum foil, and εtirred overnight. The reaction mixture was diluted with ether (30 mL) , washed with aqueous NaHS0₄ (1.0 M) , brine (30 mL each) , dried over MgS0₄, filtered and concentrated. Flash chromatography (2% ethyl acetate/hexane) gave a 16:1 mixture of Z/E isomers (20.0 mg, 70% yield) as an oil. Pipette flash chromatography (20% benzene/hexane) furnished the Z-olefin (-)-57 as a colorless oil: [ex] ²³ _D -57.2° (c 2.56, CHC1₃) ; IR (CHC1₃) 3015 (m) , 2960 (ε), 2940 (s), 2900 (m) , 2885 (m) , 2860 (ε) , 1613 (w) , 1515 (m) , 1475 (m) , 1465 (m) , 1390 (w) , 1380 (w) , 1360 (w) , 1250 (ε) , 1110 (m) , 1100 (m) , 1080 ( ) , 1050 (ε) , 1003 (m) , 963 (w) , 950 (w) , 835 (s) , 800 (m) , 790 (m) , 770 (m) , 700 (w) , 690 (w) , 670 (w) , 655 (w) cm^"1,- ^XE NMR (500 MHZ, CDC1₃) d 7.25 (d, J - 8.2 Hz, 2 H) , 6.84 (d, J = 8.7 Hz, 2 H) , 6.57 (dddd, J = 16.8, 11.0, 11.0, 0.7 Hz , 1 H) , 6.00 (apparent t, J = 11.1 Hz, 1 H) , 5.55 (apparent t, J^" = 10.5 Hz, 1 H) , 5.26 (dd, J = 11.2, 7.8 Hz, 1 H) , 5.20-5.16 (m, 2 H) , 5.09 (d, J = 10.1 Hz, 1 H) , 5.05 (d, J = 2.2 Hz, 1 H) , 5.03 (d, J = 10.0 Hz, 1 H) , 4.67 (apparent t, -7 = 9.1 Hz,

1 H) , 4.49 (ABq, J_M = 10.6 Hz, Δδ_M = 41.3 Hz, 2 H) , 3.78 (s, 3 H) , 3.68 (apparent t, J = 10.2 Hz, 1 H) , 3.52 (apparent t, -7 = 2.6 Hz, 1 H) , 3.43 (dd, J = 4.8, 3.9 Hz , 1 H) , 3.24-3.21 (m,

2 H) , 3.01-2.94 (m, 1 H) , 2.67 (dq, J = 12.8, 7.4 Hz, 1 H) , 2.61 (dq, J = 12.8, 7.5 Hz, 1 H) , 2.71-2.57 (m, 1 H) , 2.46-2.39

(m, 1 H) , 2.00 (apparent t, J = 12.4 Hz, 1 H) , 1.83-1.73 (m, 3 H) , 1.64 (br d, J = 14.0 Hz, 1 H) , 1.62-1.52 (m, 2 H) , 1.55 (d, J = 0.5 Hz, 3 H) , 1.36 (ddd, J = 13.7, 10.8, 1.5 Hz , 1 H) , 1.26 (d, J = 7.4 Hz, 3 H) , 1.25 (d, J = 7.4 Hz, 3 H) , 1.08 (d, J = 6.8 Hz, 3 H) , 0.98 (d, J = 6.8 Hz, 3 H) , 0.94 (d, J = 7.1 Hz, 3 H) , 0.93 (ε, 9 H) , 0.90 (ε, 9 H) , 0.89 (ε, 9 H) , 0.89-0.86 (m, 3 H) , 0.86 (8, 9 H) , 0.73 (d, J = 6.8 Hz , 3 H) , 0.70 (d, J = 6.7 Hz, 3 H) , 0.08 (ε, 6 H) , 0.05 (ε, 3 H) , 0.02 (s, 3 H) , 0.013 (s, 3 H) , 0.010 (s, 6 H) , -0.02 (s, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 159.1, 134.5, 134.3, 132.2, 131.9, 131.8, 131.2, 129.13, 129.07, 117.6, 113.7, 84.6, 80.9, 80.5, 76.5, 75.0, 74.2, 65.5, 55.3, 42.5, 41.9, 40.2, 37.2, 36.1, 35.4, 35.3, 34.5, 29.7, 26.3, 26.0, 25.9, 25.1, 23.1, 18.7, 18.6, 18.5, 18.14, 18.09, 17.0, 16.8, 15.6, 14.8, 14.4, 11.6, 10.6, -2.8, -3.2, -3.3, -3.6, -4.2, -4.5, -4.90, -4.93; high resolution maεε εpectrum (FAB, NBA) m/z 1195.8001 [(M+Na)\- calcd for C₆₆H₁₂₄0₇SSi₄Na: 1195.8042] .

EXAMPLE 47 Lactone (-) -58.

A εolution of diene (-)-57 (7.0 mg, 0.00597 mmol) in THF/CH₃CN (2:1, 1.50 mL) waε treated with pH 7.0 phosphate buffer (500 μL) and HgCl₂ (215 mg) . The suεpenεion waε εtirred at room temperature for 40 min, diluted with ether (30 mL) , washed with brine (2 x 30 mL) , dried over MgS0₄, filtered and concentrated. Pipette flash chromatography (5% ethyl acetate/hexane) provided a mixture of lactolε as a colorlesε oil which waε further treated with DMSO (1.0 mL) and Ac₂0 (200 mL) at room temperature for 2 dayε . The mixture waε diluted with ether (30 mL) , washed with saturated NaHC0₃ (30 mL) , brine

(30 mL) , dried over MgS0₄, filtered and concentrated. Pipette flaεh chromatography (2% ethyl acetate/hexane) provided (-)-58 (5.5 mg, 82% yield from (-)-57) as a colorlesε oil: [ex] ²³ _D -31.6 (c 0.23, CHC1₃) ; IR (CHC1₃) 3015 (m) , 2960 (ε), 2930 (s), 2880 (m) , 2855 (m) , 1725 (m) , 1610 (w) , 1510 (w) , 1460 (m),1385 (m) , 1373 (m) , 1360 (m) , 1300 (w) , 1250 (s) , 1230 (m) , 1200 (m) , 1170 (m) , 1120 (m) , 1097 (m) , 1060 (m) , 1045 (ε), 1020 (m) , 1003 (m) , 980 (w) , 955 (w) , 930 (w) , 905 (w) , 867 (m) , 835 (ε), 800 (m) , 695 (m) , 670 (m) , 660 (m) cm^"1; ^XE NMR (500 MHZ, CDC1₃) d 7.25 (d, J = 9.0 Hz, 2 H) , 6.84 (d, J = 8.7 Hz, 2 H) , 6.57 (ddd, J = 16.7, 10.6, 10.6 Hz, 1 H) , 6.00 (apparent t, J = 11.0 Hz, 1 H) , 5.55 (apparent t, -7 = 10.5 Hz, 1 H) , 5.26 (dd, J = 11.1, 7.9 Hz, 1 H) , 5.19 (dd, -7 = 15.4, 1.4 Hz, 1 H) , 5.18 (apparent t J = 10.1 Hz, 1 H) , 5.10 (d, J = 10.2 Hz, 1 H) , 5.01 (d, -7 = 10.0 Hz, 1 H) , 4.75 (apparent t, -7 = 9.2 Hz, 1 H) , 4.50 (ddd, J = 10.5, 1.3, 1.3 Hz, 1 H) , 4.50 (ABq, -7_M = 10.6 Hz, Δδ_M = 42.6 Hz, 2 H) , 3.78 (ε, 3 H) , 3.60 (apparent t , -7 = 2.4 Hz, 1 H) , 3.42 (dd, J = 5.1, 3.7 Hz, 1 H) , 3.23 (dd, J = 7.5, 3.7 Hz, 1 H) , 3.20 (apparent t, J = 5.4 Hz, 1 H) , 3.01-2.94 (m, 1 H) , 2.60 (qd, J = 7.7, 2.6 Hz, 1 H) , 2.62-2.55 (m, 1 H) , 2.45-2.38 (m, 1 H) , 1.98 (apparent t , J = 12.3 Hz, 1 H) , 1.84-1.67 (m, 3 H) , 1.63 (br d, J = 13.2 Hz, IH) , 1.52 (s, 3 H) , 1.55-1.48 (m, 1 H) , 1.20 (d, J = 7.6 Hz, 3 H) , 1.09 (d, J = 6.8 Hz, 3 H) , 0.98 (d, J = 6.8 Hz, 3 H) , 0.93 (apparent d, J = 6.7 Hz, 6 H) , 0.93 (s, 9 H) , 0.89 (s, 9 H) , 0.86 (s, 9 H) , 0.85 (s, 9 H) , 0.84 (d, J = 6.8 Hz , 3 H) , 0.69 (d, J = 6.7 Hz , 3 H) , 0.085 (ε, 3 H) , 0.079 (s, 3 H) , 0.051 (s, 3 H) , 0.046 (s, 3 H) , 0.042 (s, 3 H) , 0.029 (s, 3 H) , 0.028 (s, 3 H) , -0.02 (ε, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 173.2, 159.1, 134.4, 133.4, 132.4, 132.2, 131.9., 131.3, 131.2, 129.11, 129.09, 117.6, 113.7, 84.6, 80.5, 76.9, 75.0, 74.9, 64.6, 55.3, 44.1, 42.7, 40.1, 37.5, 36.0, 35.44, 35.37, 35.2, 34.2, 26.31, 26.28, 25.9, 25.7, 23.0, 18.7, 18.6, 18.4, 18.1, 18.0, 17.1, 16.5, 16.4, 14.9, 14.1, 10.5, -3.0, -3.2, -3.3, -4.3, -4.4, -4.5, -4.8, -4.9; high reεolution mass spectrum (FAB, NBA) m/z 1149.7836 [(M+Na)⁺; Calcd for C₆₄H₁₁₈0₈Si₄Na: 1149.7802] .

EXAMPLE 48 Alcohol (-)-59. A solution of (-)-58 (4.0 mg, 0.00355 mmol) in CH₂C1₂

(500 μL) was treated with H₂0 (50 μL) and DDQ (3.0 mg, 0.0132 mmol) at 0 °C. After 1 h, the mixture was diluted with ethyl acetate (30 mL) , washed with brine (3 x 30 mL) , dried over

MgS0₄, filtered and concentrated. Pipette flash chromatography (2% ethyl acetate/hexane) provided (-)-59 (3.4 mg, 95% yield) as a colorleεs oil: [c.]²³ _D -20° (c 0.34, CHC1₃) ; IR (film, CHC1₃ on NaCl plate) 3500 (w, br) , 2960 (s) , 2930 (s) , 2890 (s) , 2855

(ε) , 1740 (m) , 1460 (m) , 1405 (m) , 1380 (m) , 1360 (ε), 1253

(m) , 1220 (m) , 1120 (ε) , 1093 (s), 1075 (s), 1045 (s), 1022

(s) , 1002 (m) , 980 (m) , 933 (m) , 902 (m) , 833 (ε) , 808 (m) , 770 (ε), 663 (m) cm^"1; ^XE NMR (500 MHZ, CDC1₃) d 6.61 (ddd, J =

16.8, 10.9, 10.9 Hz, 1 H) , 6.13 (apparent t, -7 = 11.0 Hz, 1 H) ,

5.32 (apparent t , J = 10.5 Hz, 1 H) , 5.28 (dd, J^" = 11.1, 7.9

Hz, 1 H) , 5.24-5.21 (m, 1 H) , 5.19 (apparent t, J = 10.3 Hz, 1

H) , 5.14 (d, J = 10.2 Hz, 1 H) , 5.06 (d, J = 10.0 Hz, 1 H) , 4:76 (apparent t, -7 = 9.3 Hz, I H), 4.50 (apparent t, J = 9.9 Hz, 1 H) , 3.62 (apparent t, J = 2.4 Hz, 1 H) , 3.60 (dd, J = 5.5, 3.4 Hz, 1 H) , 3.32 (br d, -7 = 5.3 Hz , 1 H) , 3.24 (apparent t, J = 5.1 Hz, 1 H) , 2.79 (ddq, J = 9.9, 6.7, 6.7 Hz, 1 H) , 2.60 (qd, -7 = 7.6, 2.7 Hz, I H), 2.63-2.57 (m, I H), 2.50-2.45 (m, 1 H) , 2.16 (apparent t, J^" = 12.3 Hz, 1 H) , 1.90-1.77 (m, 3

H) , 1.75-1.69 (m, 2 H) , 1.57 (ε, 3 H) , 1.60-1.50 (m, 1 H) , 1.20

'd, J = 7.6 Hz, 3 H) , 0.96 (d, J = 6.8 Hz, 3 H) , 0.95 (d, J =

5 Hz, 3 H) , 0.95-0.93 (m, 6 H) , 0.91 (s, 9 H) , 0.89 (s, 9 H) ,

0.89-0.84 (m, 3 H), 0.87 (s, 9 H), 0.85 (ε, 9 H), 0.73 (d, J = 6.8 Hz, 3 H) , 0.07 (apparent ε, 6 H) , 0.052 (ε, 3 H) , 0.051 (ε, 3 H) , 0.04 (apparent ε, 6 H) , 0.03 (s, 3 H) , -0.01 (ε, 3 H) _/ ¹³C NMR (125 MHZ, CDC1₃) d 173.3, 134.7, 133.5, 132.5, 132.1, 132.0, 131.5, 131.0, 118.4, 80.5, 78.8, 76.4, 74.9, 64.7, 44.1, 42.7, 38.0, 37.4, 36.3, 36.1, 35.2, 35.1, 34.2, 26.3, 26.2, 25.9, 25.7, 23.2, 18.5, 18.1, 18.0, 17.3, 17.2, 16.4, 16.1, 14.1, 13.7, 9.4, -3.0, -3.3, -3.6, -4.34, -4.36, -4.5, -4.8; high reεolution maεs εpectrum (FAB, NBA) m/z 1029.7273 [(M+Na)⁺; calcd for C₅₆H₁₁₀0₇Si₄Na : 1029.7226] .

EXAMPLE 49 Carbamate (-)-60.

A εolution of alcohol (-)-59 (2.2 mg, 0.00219 mmol) in CH₂C1₂ (500 μL) was treated with C1₃C0N=C=0 (20 μL, 0.168 mmol) at room temperature. After 30 min, the mixture was diluted with regular CH₂C1₂ (2.0 mL) and treated with neutral A1₂0₃ (500 mg) . The mixture was stirred at room temperature for 2 h, filtered through a short silica plug, and concentrated. Pipette flash chromatography (10% ethyl acetate/hexane) provided (-)-60 (1.9 mg, 83% yield) as a colorlesε oil: [ex] ²³ _D -37° (c 0.19, CHC1₃) ,- IR (film, CHC1₃ on NaCl plate) 3510 (m) , 3360 (m, br) , 3180 (m) , 2960 (s) , 2930 (s) , 2880 (s) , 2855 (s) , 1730 (s, br) , 1596 (m) , 1460 (s) , 1385 (s) , 1362 (s) , 1325 (m) , 1255 (s) , 1220 (m) , 1100 (ε) , 1043 (s) , 983 (m) , 937 (m) , 904 (m) , 832 (s) , 770 (s) , 663 (m) cm^"1; E NMR (500 MHZ, CDC1₃) d 6.58 (dddd, J = 16.8, 10.6, 10.6, 0.7 Hz, 1 H) , 6.01 (apparent t, J = 11.0 Hz, 1 H) , 5.36 (apparent t, J = 10.4 Hz, 1 H) , 5.27 (dd, J = 11.1, 7.9 Hz, 1 H) , 5.22-5.16 (m, 2 H) , 5.12 (d, J = 10.1 Hz, 1 H) , 5.03 (d, J = 10.0 Hz, 1 H) , 4.76 (apparent t, J = 9.2 Hz, 1 H) , 4.71 (apparent t, J = 6.1 Hz , 1 H) , 4.50 (ddd, J = 10.5, 10.5, 1.3 Hz, 1 H) , 4.44 (br s, 2 H) , 3.62 (apparent t, J = 2.4 Hz, 1 H) , 3.42 (apparent t, J = 4.5 Hz , 1 H) , 3.22 (apparent t , J = 5.3 Hz, 1 H) , 2.98 (ddq, J = 10.1, 6.6, 6.6 Hz, 1 H) , 2.60 (qd, J = 7.6, 2.7 Hz , 1 H) , 2.63-2.55 (m, 1 H) , 2.48-2.41 (m, 1 H) , 2.09 (apparent t, -7 = 12.4 Hz, 1 H) , 1.93-1.88 (m, 1 H) , 1.87-1.77 (m, 2 H) , 1.71 (ddd, J = 14.1, 10.8, 1.6 Hz, 1 H) , 1.67 (br d, J = 13.7 Hz, 1 H) , 1.56 (apparent s, 3 H) , 1.55-1.50 (m, 1 H) , 1.21 (d, J = 7.6 Hz, 3 H) , 0.98 (d, J = 6.8 Hz, 3 H) , 0.95 (d, J = 7.0 Hz, 3 H) , 0.94 (d, J = 7.5 Hz, 3 H) , 0.918 (d, J = 6.8 Hz, 3 H) , 0.915 (s, 9 H) , 0.89 (s, 9 H) , 0.86 (s, 9 H) , 0.853 (d, -7 = 6.4 Hz, 3 H) , 0.847 (s, 9 H) , 0.70 (d, J = 6.8 Hz, 3 H) , 0.09 (s, 3 H) , 0.07 (s, 3 H) , 0.053 (s, 3 H) , 0.051 (s, 3 H) , 0.040 (s, 3 H) , 0.037 (s, 3 H) , 0.03 (s, 3 H) , -0.02 (s, 3 H) ; ¹³C NMR (125 MHZ, CDCI₃) d 173.3, 156.9, 133.6, 133.5, 132.4, 132.1, 131.9, 131.4, 129.8,118.0, 80.5, 78.9, 74.9, 64.6, 44.2, 42.7, 37.8, 37.4, 36.0, 35.3, 35.2, 34.5, 34.2, 26.3, 26.2, 25.9, 25.7, 23.0, 18.5, 18.4, 18.1, 18.0, 17.5, 17.1, 16.44, 16.38, 14.1, 13.7, 10.1, -3.0, -3.4, -3.6, -4.4, -4.5, -4.8; high reεolution mass spectrum (FAB, NBA) m/z 1072.7264 [(M+Na)⁺; calcd for C₅₇H_lxlN0₈Si₄Na: 1072.7283 ] . EXAMPLE 50 Discodermolide [(-)-l].

A solution of olefin (-)-60 (5.8 mg, 5.5 mmol) in 48% HF-CH₃CN (1:9, 1.0 mL) was εtirred at room temperature for 12 h, then quenched with εaturated aqueouε NaHC0₃ (5.0 mL) . The mixture waε extracted with ethyl acetate (3 x 10 mL) . The combined organic extracts were washed with brine (5.0 mL) , dried over MgS0₄, filtered and concentrated. Pipette flaεh chromatography (gradient elution, 1:30 to 1:6 MeOH/CHCl₃) provided (-)-l (2.0 mg, 60% yield) as a white amorphous solid: [c-]²³ _D -16° (c 0.03, MeOH); IR (CHC1₃) 3690 (w) , 3620 (w) , 3540 (w) , 3430 (w) , 3020 (s) , 2975 (m) , 2935 (m) , 1740 (m) , 1590 (w) , 1540 (w) , 1520 (w) , 1467 (w) , 1430 (w) , 1385 (m) , 1330 (w) , 1233 (s) , 1210 (s) , 1100 (w) , 1045 (m) , 1033 (m) , 975 (w) , 930 (m) , 910 (w) , 793 (m) , 777 (m) , 765 (m) , 750 (m) , 705 (m) , 687 (m) , 670 (m) , 660 (m) , 625 (w) cm^"1; ^XE NMR (500 MHZ, CDC1₃) d 6.60 (dddd, .7 = 16.8, 8.4, 8.4, 0.8 Hz, I H), 6.02 (apparent t, -7 = 11.1 Hz, 1 H) , 5.51 (dd, J = 11.2, 7.9 Hz, 1 H) , 5.42 (ddd, J = 10.6, 10.6, 0.6 Hz, 1 H) , 5.34 (apparent t, J = 10.4 Hz, 1 H) , 5.20 (dd, J = 16.9, 1.9 Hz, 1 H) , 5.16 (d, J = 10.0 Hz, 1 H) , 5.11 (d, J = 10.1 Hz, 1 H) , 4.77-4.69 ( , 1 H) , 4.70 (dd, J = 7.3, 4.2 HZ, I H), 4.60 (ddd, J = 10.0, 10.0, 2.4 Hz, 1 H) , 4.56 (br ε, 2 H) , 3.73 (m, 1 H) , 3.28 (m, 1 H) , 3.18 (dd, .7 = 6.8, 4.8 Hz, I H), 2.98 (ddq, J^" = 10.1, 6.9, 6.9 Hz, I H), 2.78 (ddq, J = 9.8, 6.8, 6.8 Hz, 1 H) , 2.66 (qd, J^" = 7.3, 4.6 Hz, 1 H) , 2.60-2.55 (m, 1 H) , 2.10-1.80 (m, 10 H) , 1.69 (ddd, J = 14.4, 10.3, 3.1 Hz, 1 H) , 1.64 (d, J = 1.3 Hz, 3 H) , 1.30 (d, -7 = 7.4 Hz, 3 H), 1.06 (d, -7 = 6.9 Hz, 3 H), 1.00 (d, J = 6.8 Hz, 3 H), 0.99 (d, J = 6.7 Hz, 3 H), 0.97 (d, J = 6.8 Hz, 3 H) , 0.94 (d, J^" = 6.8 Hz, 3 H) , 0.82 (d, J = 6.3 Hz, 3 H) ; ¹³C NMR (125 MHZ, CDC1₃) d 173.6, 157.0, 134.4, 133.7, 133.4, 132.9, 132.2, 129.9, 129.8, 117.9, 79.1, 78.9, 77.9, 75.7, 73.2, 64.4, 43.1, 41.0, 37.4, 36.1, 36.0, 35.8, 35.3, 34.8, 33.1, 23.3, 18.4, 17.4, 15.6, 15.5, 13.7, 12.5, 9.0; high reεolution maεs spectrum (FAB, NBA) m/z 616.3840 [(M+Na)⁺; calcd for C₃₃H_ssN0₈Na : 616.3826]. EXAMPLE 51 (Figures 16 and 17)

A. Tosylate 101

A solution of diene 16 (see, Smith, et al . , J. Am . Chem . Soc . 1995, 117, 12011) (1.15 g, 1.0 mmol) in anhydrous pyridine (10 mL) at 0 °C is treated with p-toluenesulfonyl chloride (286 mg, 1.5 mmol) . The mixture is allowed to warm to room temperature for 4-6 h. The pyridine is removed in vacuo and the residue is purified by flaεh chromatography to afford tosylate 101. B. Arene 102

Phenyllithium (2.7 mL, 1.8 M in cyclohexane-ether

(70:30)) is added dropwise to a solution of copper (I) iodide

(460 mg, 2.4 mmol) in anhydrous diethyl ether (5 mL) at 0 °C.

To the resultant mixture is added a solution of tosylate 101 (780 mg, 0.6 mmol) in ether (5 mL) and the resultant mixture is warmed to room temperature with stirring. After 4 h, saturated aqueous ammonium chloride (20 mL) is added. The layers are separated and the aqueous layer is extracted with ethyl acetate. The combined organics are dried over magnesium sulfate and concentrated in vacuo . The residue is purified by flash chromatography to afford 102.

C. Lactol 103.

To a solution of 102 (120 mg, 0.1 mmol) in tetrahydrofuran-acetonitrile (15 mL, 2:1) is added phosphate buffer (pH 7, 5 mL) and mercury (II) chloride (272 mg, 1.0 mmol) . The resultant mixture is stirred 1 h at room temperature. The reaction mixture is diluted with ether (100 mL) and washed with saturated aqueous brine (2 x 50 mL) , dried over magnesium sulfate and concentrated in vacuo . The residue is purified by flaεh chromatography to afford 103 as a mixture of ex and β anomers .

D. Lactone 104.

To a εolution of 103 (84 mg, 0.070 mmol) in dimethyl εulfoxide (10 mL) iε added acetic anhydride (2 mL) . After 2 dayε at room temperature, the mixture iε diluted with ether

(100 mL) and waεhed with saturated aqueous sodium bicarbonate

(50 mL) , saturated aqueous brine (50 mL) , dried over magnesium sulfate and concentrated in vacuo . The residue is purif ied by f lash chromatography to af ford 104 .

E. Alcohol 105.

To a solution of 104 (56 mg, 0.050 mmol) in dichloromethane (3 mL) at 0 °C is added water (50 mL) and

2, 3-dichloro-5, 6-dicyano-l, 4-benzoquinone (52 mg, 0.018 mmol).

After 1 h, the reaction mixture is diluted with ethyl acetate

(50 mL) , waεhed with εaturated aqueouε brine (3 x 25 mL) , dried over magneεium sulfate and concentrated in vacuo . The residue is purified by flash chromatography to afford 105.

F. Carbamate 106.

To a solution of 105 (10 mg, 0.010 mmol) in dichloromethane (2 mL) is added trichloroacetyl isocyanate (0.12 mL, 1.00 mmol). After 30 min, the reaction mixture is diluted with dichloromethane (4 mL) and neutral alumina (1 g) is added. The resultant suspension is stirred an additional 4 h. The reaction mixture is filtered and the concentrated filtrate is chromatographed on εilica gel to afford 106.

G. Tetrol 107. A εolution of 106 (10 mg, 0.0096 mmol) in 48% hydrofluoric acid-acetonitrile (1:9, 2 mL) is stirred at ambient temperature. After 12 h, saturated aqueous εodium bicarbonate (25 mL) iε added and the mixture iε extracted with ethyl acetate (3 x 20 mL) . The combined organicε are dried over magneεium sulfate and concentrated in vacuo . The residue iε purified by flaεh chromatography to afford 107.

EXAMPLE 52 (Figureε 18-20) A. Alcohol 203. To a εlurry of powdered 4-A molecular sieves (2.0 g) in 100 mL of anhydrous toluene is added boronate 202 ( see, Rouεh, et al . , J. Am . Chem. Soc . 1990, 112 , 6348) (170 mL, 1.0 M in toluene) . The reεultant εolution iε stirred 10 min at room temperature and then cooled to - 78 °C. A solution of aldehyde 201 (see, Solladie, et al . , Tetrahedron Lett . 1987, 28 , 797) (113 mmol) in toluene (100 mL) is added over a 2 h period, after which the reaction is maintained at -78 °C for 10 h. Excess ethanolic sodium borohydride (ca. 0.75 g/10 mL) is added and the reaction mixture is warmed to 0 °C. Aqueous 1 N sodium hydroxide (300 mL) is added and the mixture is stirred vigorously for 2 h. The layerε are separated and the aqueous layer is extracted with ether (5 x 300 mL) . The combined organics are dried over potassium carbonate and concentrated in vacuo . The residue is purified by flaεh chromatography to afford 203.

B. Bis-silyl ether 204 A εolution of 203 (75 mmol) in dimethylformamide (150 mL) iε cooled to 0 °C and treated with imidazole (150 mmol) and tert-butyldimethylεilyl chloride (100 mmol) . The resultant solution iε warmed to room temperature. After 12 h, the reaction mixture iε poured into 1500 mL of water and extracted with ether (3 x 200 mL) . The ethereal extracts are washed with water (2 x 50 mL) and saturated aqueous brine (50 mL) , dried over magnesium εulfate and concentrated in vacuo . The residue is purified by flash chromatography to afford 204.

C. Alcohol 205. A solution of 204 (20 mmol) in 500 mL of methanol is cooled to -78 °C and treated with a stream of ozone and oxygen until the colorlesε solution is converted into a steel blue one. The crude reaction mixture is cautiously quenched with sodium borohydride (100 mmol) and the resultant solution iε warmed to room temperature. After 3 h, the excess sodium borohydride is destroyed by the cautious addition of water. The methanol is removed in vacuo and the residue is partitioned between εaturated aqueous ammonium chloride (200 mL) and ethyl acetate (200 mL) . The layers are separated and the aqueous layer iε further extracted with ethyl acetate (2 x 100 mL) . The combined organicε are dried over anhydrous magneεium εulfate and concentrated in vacuo . The residue is purified by flash chromatography to afford 205.

D. Triethylεilyl ether 206. A solution of 205 (15 mmol) in dimethylformamide (30 mL) is cooled to 0 °C and treated with imidazole (30 mmol) and triethylsilyl chloride (20 mmol) . The resultant solution is warmed to room temperature. After 12 h, the reaction mixture iε poured into 300 mL of water and extracted with ether (3 x 40 mL) . The ethereal extracts are washed with water (2 x 25 mL) and saturated aqueous brine (25 mL) , dried over magneεium εulfate and concentrated in vacuo . The reεidue iε purified by flash chromatography to afford 206.

E. Alcohol 207.

To a solution of 206 (6 mmol) in ethyl acetate-ethanol

(8:1, 90 mL) is added palladium on carbon (10% wet, 500 mg) . The mixture is stirred under hydrogen atmosphere for 3-6 h, then filtered and concentrated in vacuo . The reεidue iε purified by flaεh chromatography to afford 207.

F. Aldehyde 208.

To a -10 °C εolution of 207 (13 mmol) and triethylamine (50 mmol) in dichloromethane (26 mL) iε added a εolution of sulfur trioxide-pyridine (39 mmol) in dimethyl sulfoxide (50 mL) . The mixture iε stirred 1 h at room temperature and diluted with ether (150 mL) . The organic phase is waεhed with aqueous sodium bisulfate (1 M, 100 mL) , εaturated aqueous brine (4 x 100 mL) , dried over magneεium εulfate, and concentrated in vacuo . The residue is purified by flash chromatography to afford 208.

G. Wittig product 209.

Phoεphonium salt 15 ( see, Smith, et al . , J. Am . Chem . Soc . 1995, 111, 12011) (0.2 mmol) is diεεolved in anhydrouε tetrahydrofuran (2 mL) and chilled to 0 °C. A solution of sodium bis ( trimethylsilyl) amide (0.2 mmol, 1.0 M in tetrahydrofuran) is added and the reaction mixture is stirred 30 min at 0 °C. After cooling to -78 °C, a solution of aldehyde 208 (0.1 mmol) in tetrahydrofuran (2 mL) iε added and the mixture iε εtirred 10 min at -78 °C and 2 h at room temperature. Saturated aqueouε ammonium chloride (2 mL) iε added and the reεultant mixture is extracted with ether (3 x 20 L) . The ethereal layer is washed with water (2 x 25 mL) and saturated aqueouε brine (25 mL) , dried over magneεium sulfate and concentrated in vacuo . The residue is purified by flash chromatography to afford 209. H. Hydroxy diene 210.

A -78 °C solution of 209 (0.05 mmol) in CH₂C1₂ (5 mL) is treated with diisobutylaluminum hydride (0.5 mL, 1.0 M in toluene) . The reεultant solution is stirred 10 min at -78 °C and 30 min at 0 °C. The reaction iε quenched with a εaturated εolution of sodium potassium tartrate (50 mL) and the mixture iε diluted with ether (60 mL) . The organic layer iε εeparated, dried over magneεium sulfate, and concentrated in vacuo . The residue iε purified by flaεh chromatography to afford 210. I. Aldehyde 211.

To a -10 °C εolution of 207 (1.3 mmol) and triethylamine (5.0 mmol) in dichloromethane (3 mL) iε added a εolution of sulfur trioxide-pyridine (3.9 mmol) in dimethyl sulfoxide (5 mL) . The mixture is stirred 1 h at room temperature and diluted with ether (15 mL) . The organic phaεe is washed with aqueous sodium biεulfate (1 M, 10 mL) , saturated aqueous brine (4 x 10 mL) , dried over magnesium sulfate, and concentrated in vacuo . The residue is purified by flash chromatography to afford 211. J. Tetraene 212.

A solution of diphenylallylphosphine (0.08 mL, 0.38 mmol) in tetrahydrofuran (2 mL) is cooled to -78 °C and tert-butyllithium (0.14 mL, 1.7 M in pentane) is added. The mixture is warmed to 0 °C for 30 min, then recooled to -78 °C and treated with titanium (IV) isopropoxide (0.30 mmol) . After 30 min, aldehyde 211 (0.30 mmol) iε introduced aε a εolution in tetrahydrofuran (2 mL) . The reεultant εolution iε stirred at -78 °C for 15 min and at 0 °C for 1 h. Methyl iodide (0.64 mmol) is added, and the reaction is warmed to room temperature for 12 h. The reaction mixture is diluted with ether (60 mL) , waεhed with aqueouε εodium biεulfate (30 mL, 1.0 M) , εaturated aqueouε brine (30 mL) , and iε dried over magneεium εulfate and concentrated in vacuo . The reεidue iε purified by flaεh chromatography to afford 212. K. Aldehyde 213.

Oxalyl chloride (1.5 mmol) is added dropwise to a -78 °C solution of dimethyl sulfoxide (3 mmol) in dichloromethane (4 mL) . After 15 min, a -78 °C solution of 212 (1 mmol) in dichloromethane (2 mL) is added via canula . After an additional 15 min, diisopropylethylamme (4.5 mmol) is added and the reaction is gradually warmed to room temperature over 1 h and quenched with aqueous εodium biεulfate. The mixture iε diluted with ether (50 mL) and iε washed with water (2 x 30 mL) , saturated aqueous brine (2 x 30 mL) , is dried over magnesium sulfate and concentrated in vacuo . The reεidue is purified by flaεh chromatography to afford 213. L. Eεter 214.

To a -78 °C εolution of (F₃CCH₂0) ₂P0CH₂C0₂Et (2 mmol) and 18 -crown- 6 (2.4 mmol) in tetrahydrofuran (5 mL) is added potassium bis (trimethylεilyl) amide (2 mmol) in tetrahydrofuran (2 mL) . The reεultant εolution is stirred 10 min at -78 °C and then treated with aldehyde 213 (1.2 mmol) in 4 mL of tetrahydrofuran. The reaction mixture is warmed to 0 °C for 6-8 h and then quenched with saturated aqueous ammonium chloride (10 mL) . The aqueouε layer iε εeparated and extracted with hexane (2 x 25 mL) . The combined organics are dried over magnesium εulfate and concentrated in vacuo . The reεidue iε purified by flash chromatography to afford 214. M. Alcohol 215.

To a solution of 214 (0.050 mmol) in dichloromethane (3 mL) at 0 °C is added water (50 mL) and 2, 3-dichloro-5, 6-dicyano-l, 4-benzoquinone (0.018 mmol). After 1 h, the reaction mixture is diluted with ethyl acetate (50 mL) , washed with εaturated aqueous brine (3 x 25 mL) , dried over magnesium sulfate and concentrated in vacuo . The residue is purified by flaεh chromatography to afford 215. N. Carbamate 216.

To a solution of 215 (0.010 mmol) in dichloromethane

(2 mL) is added trichloroacety^'l isocyanate (1.00 mmol) . After

30 min, the reaction mixture iε diluted with dichloromethane (4 mL) and neutral alumina (1 g) iε added. The reεultant εuεpenεion is stirred an additional 4 h. The reaction mixture is filtered and the concentrated filtrate is chromatographed on silica gel to afford 216. 0. Triol 217. A εolution of 216 (0.010 mmol) in 48% hydrofluoric acid-acetonitrile (1:9, 2 mL) iε εtirred at ambient temperature. After 12 h, εaturated aqueouε εodium bicarbonate (25 mL) is added and the mixture is extracted with ethyl acetate (3 x 20 mL) . The combined organicε are dried over magneεium sulfate and concentrated in vacuo . The residue is purified by flash chromatography to afford 217.

EXAMPLE 53 (Figureε 21 and 22) A. Hydroxy-oxazole 302.

A εolution of oxazole (3 mmol) in tetrahydrofuran (15 mL) is cooled to -78 °C and treated with n-BuLi (3 mmol) in hexane. ( see, Hodges, et al . , J. Org. Chem . 1991, 56, 449). After 30 min at -78 °C, previously prepared (see, Smith, et al . , J. Am. Chem . Soc. 1995, 117, 12011) aldehyde 301 (2 mmol) is added in tetrahydrofuran (10 mL) and the reaction mixture is gradually allowed to warm to room temperature. After 18-24 h, the reaction iε quenched by addition of saturated aqueous ammonium chloride (25 mL) . The aqueous layer is separated and extracted with ether (3 x 25 mL) . The combined organics are dried over magneεium εulfate and concentrated in vacuo . The reεidue is purified by flash chromatography to afford 302.

B. Tosylate 303.

A εolution of 302 (1.0 mmol) in anhydrous pyridine (10 mL) at 0 °C is treated with p-toluenesulfonyl chloride (286 mg,

1.5 mmol) . The mixture iε allowed to warm to room temperature for 4-6 h. The pyridine iε removed in vacuo and the reεidue iε purified by flaεh chromatography to afford toεylate 303.

C. Reduction product 304. To a 0 °C solution of tosylate 303 (0.5 mmol) in tetrahydrofuran (2 mL) is added lithium triethylborohydride (2 mmol) as a solution in tetrahydrofuran (1.0 M) . The resultant εolution iε warmed to room temperature for 2-4 h and then quenched with water (1 mL) and diluted with ether (25 mL) . The ethereal layer is washed with saturated aqueous brine (2 x 10 mL) , dried over magnesium sulfate, and concentrated in vacuo . The residue is purified by flash chromatography to afford 304.

D. Lactol 305.

To a solution of 304 (0.1 mmol) in tetrahydrofuran-acetonitrile (15 mL, 2:1) is added phosphate buffer (pH 7, 5 mL) and mercury (II) chloride (1.0 mol). The reεultant mixture iε stirred 1 h at room temperature. The reaction mixture is diluted with ether (100 mL) and waεhed with εaturated aqueouε brine (2 x 50 mL) , dried over magneεium εulfate and concentrated in vacuo . The residue is purified by flash chromatography to afford 305 as a mixture of ex and β anomers .

E. Lactone 306.

To a εolution of 305 (0.070 mmol) in dimethyl εulfoxide (10 L) is added acetic anhydride (2 mL) . After 2 days at room temperature, the mixture is diluted with ether (100 mL) and waεhed with εaturated aqueous sodium bicarbonate (50 mL) , saturated aqueous brine (50 mL) , dried over magnesium εulfate and concentrated in vacuo . The reεidue iε purified by flash chromatography to afford 306.

F. Alcohol 307.

To a solution of 306 (0.050 mmol) in dichloromethane (3 mL) at 0 °C is added water (50 mL) and 2, 3-dichloro-5, 6-dicyano-l, 4-benzoquinone (0.018 mmol). After 1 h, the reaction mixture is diluted with ethyl acetate (50 mL) , washed with εaturated aqueous brine (3 x 25 mL) , dried over magneεium εulfate and concentrated in vacuo . The reεidue iε purified by flash chromatography to afford 307.

G. Carbamate 308. To a solution of 307 (0.010 mmol) in dichloromethane

(2 mL) iε added trichloroacetyl iεocyanate (1.00 mmol). After

30 min, the reaction mixture is diluted with dichloromethane (4 mL) and neutral alumina (1 g) is added. The resultant εuspension iε εtirred an additional 4 h. The reaction mixture is filtered and the concentrated filtrate is chromatographed on silica gel to afford 308. H. Tetrol 309. A solution of 308 (0.010 mmol) in 48% hydrofluoric acid-acetonitrile (1:9, 2 mL) iε εtirred at ambient temperature. After 12 h, εaturated aqueous sodium bicarbonate (25 mL) iε added and the mixture iε extracted with ethyl acetate (3 x 20 mL) . The combined organics are dried over magnesium sulfate and concentrated in vacuo . The residue is purified by flash chromatography to afford 309.

EXAMPLE 54 As εhown in Figure 23, a solution of 402 (10.5 mg,

10.4 mmol) in 48% HF-CH₃CN (1:9, 1.0 mL) is stirred at room temperature for 12 hr . The reaction is quenched by εaturated NaHC0₃ (5.0 mL) . The mixture iε extracted with ethyl acetate (3 x 10 mL) . The combined organic phase is then washed with brine (5.0 mL) , dried over MgS0₄, concentrated in vacuo . The residue is purified by flash chromatography to afford 401.

EXAMPLE 55 (Figure 24)

A. PMB-ether 503

ZnCl₂(1.32 g, 9.69 mmol) is dried at 160°C under vacuum overnight and then treated with a solution of iodide 502

(2.46 g, 9.59 mmol) in dry Et₂0 (50 mL) . The mixture is stirred at room temperature until most of the ZnCl₂ is dissolved and then cooled to -78°C. t-BuLi (1.7M in pentane,

17.0 mL) is added over 30 min, and the resultant εolution iε εtirred an additional 15 min, warmed to room temperature, and εtirred for lhr. The solution is added by cannula to a mixture of iodoolefin B ( see, Smith, et al . , J. Am . Chem . Soc . 1995, 117, 12011) (3.21 g, 6.19 mmol) and Pd(PPh₃)₄ (364.2 mg, 0.315 mmol) . The mixture is covered with aluminum foil, stirred overnight, and then diluted with ethyl acetate (100 mL) , waεhed with brine (2 X 100 mL) , dried over MgS0₄, filtered and concentrated in vacuo . The reεidue iε purified by flaεh chromatography to afford 503. B. Phosphonium salt 504

A solution of alcohol 503 (1.70 g, 3.26 mmol) in CH₂C1₂ (28 mL) iε cooled to 0 °C and treated with water (1.3 mL) and 2 , 3-dichloro-5, 6-dicyano-l, 4-benzoquinone (774 mg, 3.41 mmol) . The mixture iε εtirred at 0°C for 5 hr, diluted with CH₂C1₂ (20 mL) , dried over MgS0₄, and filtered through a column of εilica gel. Following concentration in vacuo, the residue is dissolved in ethanol (50 mL) at room temperature, and excess εodium borohydride iε added. After 30 min, the reaction is cooled to 0°C, quenched with εaturated aqueouε NH₄C1 (50 mL) , and concentrated. The reεidue iε then diεεolved in CH₂C1₂(90 mL) , and the εolution iε waεhed with water, dried over MgS0₄, filtered and concentrated in vacuo . The reεidue is purified by flash chromatography to afford an alcohol A solution of this alcohol (400 mg, 1.0 mmol) in dry benzene/ether (1:2, 50 mL) iε treated with triphenylphoεphine

(923 mg, 3.6 mmol) and imidazole (273 mg, 4.0 mmol) . After all of the imidazole diεεolved, iodine (761 mg, 3.0 mmol) iε added with vigorouε εtirring of the reaction mixture. The mixture iε εtirred 2 h further and then treated with triethylamine (4 mL) . The resultant solution is diluted with CH₂C1₂ (50 mL) and waεhed with εaturated aqueouε Na₂S₂O₃(100 mL) , saturated aqueous NaHCO₃(100 mL) , and brine (2 x 100 mL) . The organic phaεe iε dried over MgSO. , filtered and concentrated in vacuo . Filtration though εilica gel to remove triphenylphoεphine oxide, affordε an iodide. The iodide waε mixed with diiεopropylethylamine (0.6 mL, 3.44 mmol) and triphenylphosphine (4.94 g, 18.8 mmol). The mixture is heated at 80 °C for 24 hr, cooled to room temperature, and washed with hexane (2 x 50 mL) . The product is iεolated by flash chromatography to afford 504.

C. Coupled product 505.

Phosphonium salt 504 (386 mg, 0.5 mmol) iε dried azeotropically with dry benzene and heated at 50 °C under vacuum for 3 hr before uεe . It iε then dissolved in tetrahydrofuran

(3.0 mL) . Sodium bis (trimethylεilyl) amide (l.o M in tetrahydrofuran, 0.48 mL, 0.48 mmol) iε added at -78°C, and the mixture is stirred for 25 min and then recooled to -78°C. A solution of aldehyde C (see, Smith, et al . , J. Am . Chem . Soc . 1995, 117, 12011) (147 mg, 0.30 mmol) in tetrahydrofuran (1.5 mL) is added, and the mixture is stirred for 10 min at -78°C, and 2 hr at room temperature. The reaction is quenched with εaturated aqueouε NH₄C1(4.0 mL) , the resultant mixture is extracted with ether (120 mL) , and the ether layer is waεhed with water (100 mL) and brine (100 mL) , dried over MgS0₄, filtered and concentrated in vacuo . Flaεh chromatography provideε olefin 505.

D. Lactone 506.

To a εolution of 505 (200 mg, 0.23 mmol) in tetrahydrofuran-acetonitrile (10 mL, 2:1) is added a phosphate buffer solution (pH = 7.0, 3.3 mL) , and HgCl₂(1.3 g) . The suspension is εtirred at room temperature for 40 min, then diluted with ether (150 mL) , waεhed with brine (2 x 70 mL) , dried over MgS0₄, and concentrated in vacuo . Flash chromatography provides a mixture of lactols as ex/ β anomers . This material is used directly in the next oxidation: Under argon, to a solution of lactols in dimethylsulfoxide (5.0 mL) is added acetic anhydride (1.0 mL) . After 2 days at room temperature, the mixture is diluted with ether (150 mL) , washed with saturated NaHC0₃(150 mL) , brine (150 mL) , dried over MgS0₄, and concentrated in vacuo . Flash chromatography affords a lactone. A solution of the lactone (160 mg, 0.20 mmol) in methanol (4 mL) is treated with pyridinium p-tolueneεulfonate

(10 mg) and εtirred at 40°C for 30 min. The mixture iε diluted with ether (80 mL) and waεhed εucceεεively with εaturated aqueous NaHC0₃ solution (90 mL) and brine (40 mL) , and then dried over MgS0₄. The organic solution is concentrated in vacuo, and the residue is pasεed through a column of εilica gel to provide alcohol 506.

E. Acid 507.

To a εolution of alcohol 506 (140 mg, 0.19 mmol) in dimethyIformamide (5.0 mL) , is added pyridinium dichromate (210 mg, 0.55 mmol) . The reaction mixture is εtirred at room temperature for 5 hr, and diluted with water (120 mL) . The mixture is extracted with ether (3 x 15 L) . The organic solutions are combined and washed with brine (40 mL) , and dried over MgS0₄. Then it is concentrated in vacuo to give a residue, which is purified by flash chromatography to afford carboxylic acid 507.

F. Amino-amide 508.

To a solution of 507 (60.0 mg, 78.1 mmol) and D- leucine hydrochloride (26.0 mg, 0.16 mmol) in CH₂C1₂ (3 mL) is added 1- (3 -dimethylaminopropyl) -3 -ethylcarbodiimide hydrochloride (EDC, 23 mg, 0.12 mmol) and 1-hydroxybenzotriazole (21.0 mg, 0.14 mmol), followed by diisopropylamine (40 mL, 0.23 mmol) . The mixture iε stirred at room temperature overnight before addition of 5% KHS0₄ solution. The resulting mixture is extracted with ethyl acetate (30 mL) . The organic layer is washed with brine (20 mL) and dried over MgS0₄, and then concentrated in vacuo . The residue is purified by column chromatography to afford 508.

G. Analog 501.

A εolution of 508 (52 mg, 59 mmol) in 48% HF-acetonitrile (1:9, 1.0 mL) iε stirred at room temperature for

12 hr . The reaction is quenched by saturated NaHC0₃ (5. OmL) . The mixture iε extracted with ethyl acetate (3 x 10 mL) . The combined organic phaεe iε then washed with brine (5.0 mL) , dried over MgS0₄, and concentrated in vacuo . Flash chromatography provideε 501.

EXAMPLE 56 (Figure 25)

A. Diene 603.

Phosphonium salt 15 (98.0 mg, 0.092 mmol) is dried azeotropically with dry benzene and heated at 50°C under vacuum for 3 hr before use. It is then diεεolved in tetrahydrofuran

(0.7 mL) . Sodium bis (trimethylsilyl) amide (1.0 M in tetrahydrofuran, 86 mL, 0.0855 mmol) is added at -78°C, and the mixture is stirred for 20 min and then recooled to -78°C. A solution of aldehyde 602 (13 mg, 60 mmol) in tetrahydrofuran (300 mL) is added, and the mixture is stirred for 10 min at -78°C, and 2 hr at room temperature. The reaction is quenched with saturated aqueous NH.C1 (1.0 mL) . The resultant mixture is extracted with ether (30 mL) , and the ether layer is washed with water (30 mL) and brine (30 L) , dried over MgS0₄, filtered and concentrated in vacuo . Flash chromatography provides the coupled product .

A solution of the olefin (39 mg, 44 mmol) in CH₂C1₂ is cooled to -78°C, diisobutylaluminum hydride (1.0 M in toluene, 440 mL, 0.40 mmol) is added dropwise over 5 min, and the reεultant εolution iε εtirred for 10 min at -78°C and 30 min at 0°C. The reaction is quenched with a saturated solution of Rochelle's salt, and the mixture iε diluted with ether (60 mL) , waεhed with Rochelle solution, and brine (30 mL each), dried over MgS0₄, filtered and concentrated in vacuo . Flash chromatography provides alcohol 603. B. Alkane 604.

To a solution of alcohol 603 (82 mg, 0.93 mmol) in pyridine (1.5 mL) at 0°C is added p-tolueneεulfonyl chloride (26.6 mg, 0.14 mmol) with εtirring. After 3 hr, the reaction mixture iε concentrated in vacuo . The residue iε purified by column chromatography to give a toεylate . To a εolution of thiε toεylate (94 mg, 0.91 mmol) in ether (5 mL) iε added lithium diiεopropylcuprate (Pr₂CuLi) (ca. 0.5 M in ether, 10 mL, exceεs. The resultant εolution is stirred for 8 hr and then quenched with saturated aqueouε εolution of NH₄C1 (50 mL) . Stirring iε continued for an additional 2 h. The organic phase is εeparated and waεhed with NH₄C1 εolution (20 mL) , dried over MgS0₄, and concentrated in vacuo . Flaεh chromatography provides 604.

C. Enone 605. A solution of 604 (75 mg, 83 mmol) in methanol (2 mL) is treated with pyridinium p-tolueneεulfonate (ca.4 mg) and stirred at 40 °C for 30 min. The mixture is diluted with ether (20 mL) and washed εucceεεively with εaturated aqueouε NaHC0₃ εolution (25 mL) and brine (10 mL) , and then dried over MgS0₄. The organic solution is concentrated in vacuo, and the residue is pasεed through a column of εilica gel to provide an alcohol . To a εolution of the alcohol (62.0 mg, 68.2 mmol) in benzene (2.0 mL) is added manganese (IV) oxide (100 mg, 1.15 mmol).

After stirring for 8 h at room temperature, the reaction mixture is filtered through a pad of celite. The filtrate is concentrated in vacuo . Flash chromatography of the reεidue affordε ex , β-unsaturated ketone 605.

D. Triol 606.

A solution of the ex, β-unεaturated ketone 605 (45 mg, 56 mmol) in CH₂C1₂ (2 mL) is cooled to 0 °C and treated with water (0.1 mL) and 2, 3-dichloro-5 , 6-dicyano-l, 4-benzoquinone (15 mg, 66 mmol) . The mixture is stirred at 0 °C for 5 hr, diluted with CH₂C1₂ (15 mL) , dried over MgS0₄, and filtered through a column of silica gel. Following concentration in vacuo , the residue is used for next εtep without further purification. A εolution of the crude alcohol in 48% HF-acetonitrile (1:9, 1.0 mL) iε εtirred at room temperature for 12 hr. The reaction iε quenched by εaturated NaHC0₃ (5.0mL) . The mixture iε extracted with ethyl acetate (3 x 10 mL) . The combined organic phaεe iε then washed with brine (5.0 mL) , dried over MgS0₄, concentrated in vacuo . The residue is purified by flash chromatography to afford 601.

EXAMPLE 57 (Figure 26)

A. Alkane 702

To a solution of iodide A (300 mg, 0.54 mmol) in ether (5 mL) is added lithium dibutylcuprate (Bu₂CuLi) (ca. 0.5 M in ether, 5.4 mL, exceεε) at -25°C. The reεultant εolution iε εtirred for 8 hr and then quenched with saturated aqueous NH₄C1

(50 mL) . Stirring is continued for another 2 hr and the organic phaεe iε εeparated. The organic εolution iε waεhed with NH₄C1 εolution (20 mL) and dried over MgSO , and concentrated in vacuo . Flash chromatography provides 702.

B. Alcohol 703.

A solution of 702 ( 240 mg, 0 . 50 mmol ) in CH₂C1₂ ( 6 . 0 mL ) iε cooled to - 78 ° C . Diiεobutylaluminum hydride ( 1 . 0 M in toluene , 1 . 50 mL, 1 .50 mmol) is added dropwise over 5 min, and the reεultant solution iε stirred for 10 min at - 78 ° C and 30 min at 0 °C . The reaction is quenched with a saturated solution of Rochelle's salt, and the mixture is diluted with ether (60 mL) , waεhed with Rochelle εolution, and brine (30 mL each) , dried over MgS0₄, filtered and concentrated in vacuo . Flash chromatography provides alcohol 703. C. Iodide 704

A solution of alcohol 703 (210 mg, 0.44 mmol) in dry benzene/ether (1:2, 5 mL) is treated with triphenylphosphine

(420 mg, 1.6 mmol) and imidazole (123 mg, 1.8 mmol) . After all of the imidazole dissolved, iodine (335 mg, 1.32 mmol) is added with vigorous stirring. The mixture is εtirred for 2 h and then treated with triethylamine (1.8 mL) . The resultant solution is diluted with CH₂C1₂ (22 mL) and washed with saturated aqueous Na₂S₂0₃ (40 mL) , saturated aqueous NaHC0₃ (40 mL) , and brine (2 x 40 mL) . The organic phase is dried over MgS0₄, filtered and concentrated in vacuo . The residue is purified by flash chromatography to afford iodide 704.

D. Phoεphonium salt 705.

The iodide 704 is mixed with triphenylphoεphine (2.17 g, 8.27 mmol) and the mixture is heated at 80 °C for 24 hr, cooled to room temperature, and washed with hexane (2 x 20 mL) . Flash chromatography provideε phosphonium salt 705.

E. Alkene 707.

A solution of 705 (260 mg, 0.30 mmol) in tetrahydrofuran (6.0 mL) is cooled to -10°C and a εolution of n-butyl lithium (1.0 M in hexane, 0.29 mL, 0.29 mmol) is introduced dropwise over 5 min. The reεultant εolution iε εtirred for 50 min at room temperature and then the mixture is recooled to -78°C and aldehyde 706 (39 mg, 0.3 mmol) is added a solution in tetrahydrofuran (1.5 mL) . The mixture is stirred for 10 min at -78°C, and 1 hr at 0 °C. The reaction is quenched with saturated aqueous NH₄C1 (1.0 mL) and the resultant mixture is extracted with ether (30 mL) . The ether layer is washed with water (30 mL) and brine (30 mL) , dried over MgS0₄, filtered and concentrated in vacuo . The residue is purified by flaεh chromatography to afford olefin 707 (149 mg, 85% yield) . F . Diol 708 .

Acetonide 707 (147 mg, 0.25 mmol) is dissolved in 80% aqueous acetic acid (2.5 mL) at room temperature. The reaction mixture is stirred for 4 hr at room temperature and then diluted with water (20 mL) . The mixture iε extracted with ethyl acetate (2 x 5 mL) . The combined organic layerε are waεhed with εaturated NaHC0₃ εolution, and brine (10 mL each) , and then dried over MgS0₄. The organic solution is concentrated in vacuo, and the residue is flash chromatogaraphed over silica gel to afford diol 708.

G. Tosylate 709.

To a solution of diol 708 (134 mg, 0.25 mmol) in pyridine (2 mL) is added p- toluenesulfonyl chloride ( 52 mg, 0.27 mmol) . After 3 hr, the reaction mixture is diluted with ether (30 mL) , and washed with ice cold 1 M hydrochloric acid (60 mL) , saturated NaHC0₃ solution (20 mL) , and brine (20 mL) and then concentrated in vacuo . The residue is purified by column chromatography to give a monotosylate 709. H. Epoxide 710. A solution of tosylate 709 (145 mg, 0.21 mmol) in methanol (3.0 mL) is added potasεium carbonate (10 mg) at room temperature. The mixture is stirred for 20 min, and then diluted with water (60 mL) and extracted with ethyl acetate (2 x 20 mL) . The combined organic layers are washed with brine and concentrated in vacuo . Flash chromatography provides epoxide 710.

I. Alcohol 711.

To a solution of 710 (41 mg, 79 mmol) in CH₂C1₂ (3.0 mL) at 0°C is added water (0.15 mL) and 2, 3-dichloro-5, 6-dicyano-l, 4-benzoquinone (60 mg, 0.26 mmol). The mixture is stirred at 0°C for 5 hr, diluted with CH₂C1₂ (15 mL) , dried over MgS0₄, and filtered through a column of silica gel. Following concentration in vacuo, the crude 711 is used without further purification. J. Carbamate 712.

To a εolution of 711 (8.7 mg, 22 mmol) in CH₂C1₂ (1.0 mL) iε added trichloroacetyl iεocyanate (0.20 mL, 1.7 mmol) at room temperature. After 30 min, the mixture is diluted with CH₂C1₂(20 mL) , and some neutral Al O ₃ (500 mg) is added. The mixture is then stirred at room temperature for 2 hr, then filtered though a short column of silica gel, and concentrated in vacuo . The residue iε purified by flaεh chromatography to afford 712.

K. Hydroxy-urethane 701.

A solution of 712 (6.0 mg, 14 mmol) in 48% HF-acetonitrile (1:9, 1.0 mL) iε εtirred at room temperature for 12 hr. The reaction iε quenched by εaturated NaHC0₃ (5.0 mL) . The mixture iε extracted with ethyl acetate (3 x 10 mL) . The combined organic phase is then washed with brine (5.0 mL) , dried over MgS0₄, and concentrated in vacuo . The residue is purified by flash chromatography afford 701.

EXAMPLE 58 (Figures 27 and 28)

A. Iodide 802.

A solution of alcohol 16 (see, Smith, et al . , J. Am . Chem . Soc . 1995, 117, 12011) (410 mg, 0.360 mmol) in dry benzene/ether (1:2, 10 mL) is treated with triphenylphosphine (378 mg, 1.44 mmol) and imidazole (111 mg, 1.62 mmol) . After complete diεεolution of the imidazole, iodine (301 mg, 1.19 mmol) iε added with vigorouε stirring. The reaction mixture is stirred 2 h and then treated with triethylamine (1.7 mL) . The reεultant εolution iε diluted with CH₂C1₂ (30 mL) and waεhed with εaturated aqueouε Na₂S₂0₃ (40 mL) , saturated aqueous NaHC0₃ (40 mL) , and brine (2 x 40 mL) . The organic phase iε dried over MgS0₄, filtered and concentrated in vacuo . Purification of the reεidue by flash chromatography affords iodide 802.

B. Phosphonium εalt 803. To a εolution of iodide 802 (410 mg, 0.325 mmol) in benzene (20 mL) iε added triphenylphosphine (1.00 g, 3.81 mmol). The mixture iε heated at 80°C for 24 hr, cooled to room temperature, and concentrated in vacuo . The reεidue iε waεhed with hexane (2 x 20 mL) . Flash chromatography affords phosphonium εalt 803. C . Alkene 805

A εolution of 803 (460 mg, 0.30 mmol) in tetrahydrofuran (9.0 mL) iε cooled to -10°C. A solution of n-butyl lithium (1.0 M in hexane, 0.29 mL, 0.29 mmol) is added dropwise over 5 min, and the resultant solution is stirred for 50 min at room temperature. Then the mixture is recooled to -78°C and a solution of aldehyde 804 (39 mg, 0.3 mmol) in tetrahydrofuran (1.5 mL) is added. The mixture is stirred for 10 min at -78°C, and 1 hr at 0 °C. The reaction is quenched with saturated aqueous NH₄C1 (20 mL) , the resultant mixture is extracted with ether (40 mL) , and the ether layer is washed with water (30 mL) and brine (30 mL) , dried over MgS0₄, filtered and concentrated in vacuo . Flash chromatography of the residue affords 805. D. Diol 806

Acetonide 805 (280 mg, 0.22 mmol) iε diεεolved in 80% aqueous acetic acid (3.5 mL) at room temperature. The reaction mixture is stirred for 4 hr at room temperature and then diluted with water (40 mL) . The mixture is extracted with ethyl acetate (2 x 10 mL) . The combined organic layers are washed with saturated NaHC0₃ solution, and brine (10 mL each) , and then dried over MgS0₄. The organic solution is concentrated in vacuo, and the reεidue is flash chromatogaraphed over silica gel to afford diol 806. E. Tosylate 807.

To a solution of diol 806 (235 mg, 0.19 mmol) in pyridine (2 mL) at 0 °C is added p-tolueneεulfonyl chloride (45 mg, 0.23 mmol) . After 3 hr, the reaction mixture iε diluted with ether (30 mL) , and washed with ice cold 1 M hydrochloric acid (30 mL) , saturated NaHC0₃ solution (20 mL) , and brine (20 mL) and then concentrated in vacuo . The residue is purified by column chromatography to give a monotosylate 807. F. Epoxide 808. To a solution of tosylate 807 (187 mg, 0.21 mmol) in methanol (3.0 mL) iε added potassium carbonate (10 mg) at room temperature. The mixture is stirred for 20 min, and then diluted with water (60 mL) and extracted with ethyl acetate (2 x 20 mL) . The combined organic layers were washed with brine and concentrated in vacuo . Flash chromatography provides epoxide 808.

G. Lactone 809. To a εolution of 808 (110 mg, 93 mmol) in tetrahydrofuran-acetonitrile (10 mL, 2:1) is added a phosphate buffer εolution (pH = 7.0, 3.5 mL) , and HgCl₂ (2.3 g) . The suspension is εtirred at room temperature for 40 min, then diluted with ether (30 mL) , washed with brine (2 x 30 mL) , dried over MgS0₄, and concentrated in vacuo . Flash chromatography affords the lactol as an ex/β anomeric mixture. This material is used directly in the next oxidation: Under argon atmosphere, a solution of the lactols in dimethylsulfoxide (3.0 mL) is treated with acetic anhydride (0.60 mL) . After 2 days at room temperature, the mixture is diluted with ether (50 mL) , waεhed with εaturated NaHC0₃ (30 mL) , brine (30 mL) , dried over MgS0₄, and concentrated in vacuo . Flash chromatography provides 809.

H. Alcohol 810. To a εolution of 809 (90 mg, 79 mmol) in CH₂C1₂ (3.0 mL) at 0°C iε added water (0.15 mL) and 2, 3-dichloro-5 , 6-dicyano-l, 4-benzoquinone (60 mg, 0.26 mmol) . The mixture iε stirred at 0°C for 5 hr, diluted with CH₂C1₂ (15 mL) , dried over MgS0₄, and filtered through a column of silica gel. Following concentration in vacuo, the crude 810 is used in the next reaction without further purification. I. Carbamate 811

To a solution of 810 (22 mg, 22 mmol) in CH₂C1₂ (1.0 mL) is added trichloroacetyl isocyanate (0.20 mL, 1.7 mmol) at room temperature. After 30 min, the mixture iε diluted with CH₂C1₂(20 mL) , and εome neutral A1₂0₃ (500 mg) iε added. The mixture iε then εtirred at room temperature for 2hr, then filtered though a short column of silica gel, and concentrated in vacuo . Flash chromatography affords 811. J. Epoxide analog 812.

A solution of 811 (15 mg, 14 mmol) in tetrahydrofuran (1.0 mL) iε cooled to 0°C, and treated with a 1.0 M solution of tetrabutylammonium fluoride in tetrahydrofuran (0.14 mL, 0.14 mmol) . The reaction mixture iε stirred for 2 hr, and diluted with water (20 mL) . The mixture is extracted with ethyl acetate (3 x 10 mL) . The combined organic phase is then washed with brine (10 mL) , dried over MgS0₄, concentrated in vacuo . Flaεh chromatography affordε 801.

EXAMPLE 59 (Figure 29)

A. Alcohol 903. Phoεphonium salt 15 (98.0 mg, 0.092 mmol) is dried azeotropically with dry benzene and heated at 50 °C under vacuum for 3 hr before use. It is then diεεolved in tetrahydrofuran (0.7 mL) . Sodium bis (trimethylsilyl) amide (1.0 M in tetrahydrofuran, 86 mL, 0.0855 mmol) is added at -78°C, and the mixture is stirred for 20 min and then recooled to -78°C. A solution of aldehyde 902 (60 mmol) in tetrahydrofuran (300 mL) is added, and the mixture is stirred for 10 min at -78°C, and

2 hr at room temperature. The reaction is quenched with saturated aqueous NH₄C1 (1.0 mL) . The resultant mixture is extracted with ether (30 mL) , and the ether layer iε washed with water (30 mL) and brine (30 mL) , dried over MgS0₄, filtered and concentrated in vacuo . Flash chromatography provides an olefin. A solution of the olefin (44 mmol) in CH₂C1₂ is cooled to -78°C. Diisobutylaluminum hydride (1.0 M in toluene, 440 mL, 0.40 mmol) is added dropwise over 5 min, and the resultant solution is εtirred for 10 min at -78 °C and

30 min at 0 °C. The reaction is quenched with a saturated solution of Rochelle's εalt, and the mixture is diluted with ether (60 mL) , washed with Rochelle solution, and brine (30 mL each) , dried over MgS0₄, filtered and concentrated in vacuo . Flaεh chromatography provideε alcohol 903.

B. Diene 905.

A solution of 903 (0.012 mmol) and Et₃N (42 mL, 0.30 mmol) in CH₂C1₂ (2.0 mL) is cooled to 0°C and a solution of S0₃ -pyridine complex (40 mg, 0.251 mmol) in dimethylεulfoxide

(0.6 mL) iε added. The mixture iε εtirred at 0°C for 45 min and then diluted with ethyl acetate (30 mL) , waεhed with aqueous NaHS0₄ (1.0 M, 30 mL) and brine (2 x 30 mL) , dried over MgS0₄, and concentrated in vacuo . Flash chromatography affords an aldehyde. A solution of allyldiphenylphosphine 904 (0.19 mmol) in tetrahydrofuran (1.0 mL) iε cooled to -78°C and t-butyl lithium (1.7 M in pentane, 0.122 mmol) iε added. The mixture is stirred at 0°C for 30 min, recooled to -78°C and treated titanium tetra-i-propoxide (0.15 mmol) . After 30 min, a cold (-78°C) solution of the aldehyde (0.26 mmol) in tetrahydrofuran (1.0 mL) is introduced via cannula, and the mixture is stirred 10 min further at -78°C and at 0°C for 1 hr . Iodomethane (0.32 mmol) is added, and the reaction is maintained at 0°C for 30 min, warmed to room temperature, protected from light, and stirred overnight. The reaction mixture iε diluted with ether (30 mL) , waεhed with 1.0 M aqueouε NaHS0₄ and brine (30 mL each) , dried over MgSO ,₄ concentrated in vacuo . Flaεh chromatography affordε diene 905. C. Glycoεide 908. A εolution of 905 (83 mmol) in methanol (2 mL) is treated with pyridinium p-tolueneεulfonate (ca.4 mg) and stirred at 40°C for 30 min. The mixture is diluted with ether (20 mL) and waεhed εucceεεively with saturated aqueous NaHC0₃ solution (25 mL) and brine (10 mL) , and then dried over MgS0₄. The organic solution is concentrated in vacuo, and the residue is pasεed through a column of silica gel to give an alcohol. To a solution of glycosyl bromide 906 (75 mmol) in CH₂C1₂(2.0 mL) is added HgBr₂ (7 mmol) and powdered molecular εieveε (4A, 50 mg) and εtirred for 60 min at room temperature. The mixture iε then cooled to 0°C, and the alcohol (74 mmol) prepared above iε added in CH₂C1₂ (0.7 mL) . The reεultant mixture is stirred 6 hr at 0°C and then warmed to room temperature and diluted with CH₂C1₂ (10 mL) , and filtered through a pad of celite. The filtrate is washed with aqueous Kl solution, and dried over MgS0₄. The organic solution is concentrated in vacuo, and the residue is pasεed through a column of εilica gel to give an anomeric mixture of glycoεideε 908. D . Triol 901 .

To a solution of 908 (79 mmol) in CH₂C1₂ (3.0 mL) at 0°C is added water (0.15 mL) and 2, 3-dichloro-5 , 6-dicyano-l, 4-benzoquinone (60 mg, 0.26 mmol) . The mixture is stirred at 0°C for 5 hr, diluted with CH₂C1₂ (15 mL) , dried over MgS0₄, and filtered through a column of silica gel. Following concentration in vacuo, the crude alcohol is used for next step without further purification. To a solution of the alcohol (22 mmol) in CH₂C1₂ (1.0 mL) is added trichloroacetyl isocyanate (0.20 mL, 1.7 mmol) at room temperature. After 30 min, the mixture iε diluted with CH₂C1₂(20 mL) , and some neutral A1₂0₃

(500 mg) is added. The mixture iε then stirred at room temperature for 2 hr, then filtered though a short column of silica gel, and concentrated in vacuo . Flash chromatography affords a carbamate. A εolution of the carbamate (14 mmol) in

48% HF-acetonitrile (1:9, 1.0 mL) iε εtirred at room temperature for 12 hr . The reaction iε quenched by saturated

NaHC0₃ (5.0 mL) . The mixture is extracted with ethyl acetate

(3 x 10 mL) . The combined organic phase is then washed with brine(5.0 mL) , dried over MgS0₄, concentrated in vacuo . Flash chromatography affords 901.

EXAMPLE 60 (Figure 30)

A. Olefin 1001

A solution of model phosphonium salt (0.0917 mmol) in THF (700 mL) iε cooled to -78 °C and treated with NaHMDS (1.0 M in THF, 85.5 mL, 0.0855 mmol) . The mixture iε εtirred for 20 min at 0 °C, recooled to -78 °C and aldehyde C (0.0570 mmol) in THF (300 mL) iε added. After 10 min at -78 °C and 2 h at room temperature, the mixture is quenched with saturated aqueouε NH₄C1 (1.0 mL) and extracted with ether (30 mL) . The ether εolution iε waεhed with water, brine (30 mL each) , dried over MgS0₄, filtered and concentrated. Flaεh chromatography provideε olefin 1001.

B. Lactone 1002 A εolution of olefin 1001 (0.00597 mmol) in THF/CH₃CN

(2:1, 1.50 mL) iε treated with pH 7.0 phoεphate buffer (500 mL) and HgCl₂ (215 mg) . The suspenεion iε stirred at room temperature for 40 min, diluted with ether (30 mL) , washed with brine (2 x 30 mL) , dried over MgS0₄, filtered and concentrated. Pipette flash chromatography (5% ethyl acetate/hexane) provides a mixture of lactols as a colorleεε oil which iε further treated with DMSO (1.0 mL) and Ac₂0 (200 mL) at room temperature for 2 days. The mixture is diluted with ether (30 mL) , washed with εaturated NaHC0₃ (30 mL) , brine (30 L) , dried over MgS0₄, filtered and concentrated. Flaεh chromatography provides lactone 1002.

C. Model Compound 1003

A solution of olefin 1002 (5.5 mmol) in 48% HF-CH₃CN (1:9, 1.0 mL) is εtirred at room temperature for 12 h, then quenched with εaturated aqueous NaHC0₃ (5.0 mL) . The mixture is extracted with ethyl acetate (3 x 10 mL) . The combined organic extracts are washed with brine (5.0 mL) , dried over MgS0₄, filtered and concentrated. Pipette flaεh chromatography (gradient elution, 1:30 to 1:6 Me0H/CHC13) provideε 1003.

EXAMPLE 61 (Figureε 31 and 32) I. General procedure for synthesis of hydroxy aldehydes

1104.

A. TBS ether 1102a

A solution of bromide 1101a ( see, Jacquesy, et al . , Tetrahedron 1981, 37, 747) (20 mmol) in ether (40 mL) is added slowly to a -78 °C solution of tert-butyllitium (40 mmol, 1.7 M in pentane) . After 1 h at -78 °C, the cold solution is transferred to a suεpenεion of copper (I) iodide (10 mmol) in ether at 0 °C. After an additional 30 min at 0 °C, a εolution of benzyl (S) - (+) -glycidyl ether (9 mmol) in ether (20 mL) is added and the reaction is allowed to warm to room temperature.

After 18-24 h, the reaction is quenched by the addition of tert-butyldimethylsilyl triflate (10 mmol) . The reaction mixture is poured into saturated aqueous sodium bicarbonate (100 mL) . The aqueous layer is εeparated and extracted with ether (2 x 50 mL) . The combined organicε are waεhed with saturated aqueous brine (50 mL) , dried over magneεium sulfate and concentrated in vacuo . The residue is purified by flash chromatography to afford 1102a.

B. Alcohol 1103a.

To a solution of 1102a (6 mmol) in ethyl acetate-ethanol (8:1, 90 mL) iε added palladium on carbon (10% wet, 500 mg) . The mixture iε εtirred under hydrogen atmoεphere for 3-6 h, then filtered and concentrated in vacuo . The residue is purified by flash chromatography to afford 1103a.

C. Aldehyde 1104a. Oxalyl chloride (1.5 mmol) is added dropwise to a -78

°C solution of dimethyl sulfoxide (3 mmol) in dichloromethane

(4 mL) . After 15 min, a -78 °C εolution of 1103a (1 mmol) in dichloromethane (2 L) is added via canula . After an additional 15 min, diisopropylethylamme (4.5 mmol) is added and the reaction is gradually warmed to room temperature over 1 h and quenched with aqueous εodium bisulfate. The mixture is diluted with ether (50 mL) and is waεhed with water (2 x 30 mL) , εaturated aqueouε brine (2 x 30 mL) , iε dried over magneεium εulfate and concentrated in vacuo . The reεidue iε purified by flaεh chromatography to afford 1104a.

II. General procedure for the conversion of 1104 to arene analog 1111: A. Diene 1105. Phosphonium salt 15 (see, Smith, et al . , J. Am . Chem . Soc . 1995, 117, 12011) (0.2 mmol) is dissolved in anhydrous tetrahydrofuran (2 mL) and chilled to 0 °C. A solution of εodium biε (trimethylsilyl) amide (0.2 mmol, 1.0 M in tetrahydrofuran) is added and the reaction mixture is stirred 30 min at 0 °C. After cooling to -78 °C, a solution of aldehyde 1104 (0.1 mmol) in tetrahydrofuran (2 mL) is added and the mixture is stirred 10 min at -78 °C and 2 h at room temperature. Saturated aqueouε ammonium chloride (2 L) is added and the resultant mixture iε extracted with ether (3 x 20 mL) . The ethereal layer iε waεhed with water (2 x 25 mL) and εaturated aqueouε brine (25 mL) , dried over magnesium sulfate and concentrated in vacuo . The residue iε purified by flaεh chromatography to afford 1105. B. Hydroxy diene 1106.

A -78 °C solution of 1105 (0.05 mmol) in CH₂C1₂ (5 mL) is treated with diiεobutylaluminum hydride (0.5 mL, 1.0 M in toluene) . The reεultant solution is εtirred 10 min at -78 °C and 30 min at 0 °C. The reaction is quenched with a saturated solution of εodium potaεsium tartrate (50 mL) and the mixture is diluted with ether (60 mL) . The organic layer is separated, dried over magnesium sulfate, and concentrated in vacuo . The residue is purified by flash chromatography to afford 1106. C. Aldehyde 1107.

Oxalyl chloride (1.5 mmol) is added dropwise to a -78

°C solution of dimethyl sulfoxide (3 mmol) in dichloromethane

(4 mL) . After 15 min, a -78 °C solution of 1106 (1 mmol) in dichloromethane (2 mL) is added via canula. After an additional 15 min, diisopropylethylamme (4.5 mmol) is added and the reaction iε gradually warmed to room temperature over 1 h and quenched with aqueous sodium bisulfate. The mixture is diluted with ether (50 mL) and is waεhed with water (2 x 30 mL) , saturated aqueouε brine (2 x 30 mL) , iε dried over magneεium εulfate and concentrated in vacuo . The residue is purified by flash chromatography to afford 1107. D. Tetraene 1108.

A solution of diphenylallylphosphine (0.08 mL, 0.38 mmol) in tetrahydrofuran (2 mL) iε cooled to -78 °C and tert-butyllithium (0.14 mL, 1.7 M in pentane) iε added. The mixture iε warmed to 0 °C for 30 min, then recooled to -78 °C and treated with titanium (IV) iεopropoxide (0.30 mmol) . After 30 min, aldehyde 1107 (0.30 mmol) iε introduced as a solution in tetrahydrofuran (2 mL) . The resultant solution is stirred at -78 °C for 15 min and at 0 °C for 1 h. Methyl iodide (0.64 mmol) is added, and the reaction is warmed to room temperature for 12 h. The reaction mixture is diluted with ether (60 mL) , washed with aqueous sodium bisulfate (30 mL, 1.0 M) , εaturated aqueouε brine (30 mL) , and is dried over magnesium sulfate and concentrated in vacuo . The residue iε purified by flash chromatography to afford 1108. E. Alcohol 1109.

To a solution of 1108 (0.050 mmol) in dichloromethane (3 mL) at 0 °C is added water (50 mL) and 2, 3-dichloro-5, 6-dicyano-l, 4-benzoquinone (0.018 mmol). After 1 h, the reaction mixture is diluted with ethyl acetate (50 mL) , washed with saturated aqueous brine (3 x 25 mL) , dried over magnesium sulfate and concentrated in vacuo . The residue is purified by flash chromatography to afford 1109.

F. Carbamate 1110. To a εolution of 1109 (0.010 mmol) in dichloromethane

(2 mL) is added trichloroacetyl isocyanate (1.00 mmol) . After

30 min, the reaction mixture is diluted with dichloromethane (4 mL) and neutral alumina (1 g) is added. The resultant suspenεion is stirred an additional 4 h. The reaction mixture is filtered and the concentrated filtrate is chromatographed on silica gel to afford 1110.

G. Arene analog 1111.

A solution of 1110 (0.010 mmol) in 48% hydrofluoric acid-acetonitrile (1:9, 2 mL) is εtirred at ambient temperature. After 12 h, εaturated aqueous sodium bicarbonate

(25 mL) iε added and the mixture iε extracted with ethyl acetate (3 x 20 mL) . The combined organicε are dried over magneεium εulfate and concentrated in vacuo . The reεidue iε purified by flash chromatography to afford 1111.

Those εkilled in the art will appreciate that numerous changes and modifications may be made to the preferred embodiments of the invention and that εuch changeε and modifications may be made without departing from the spirit of the invention. It is therefore intended that the appended claims cover all equivalent variations as fall within the true spirit and εcope of the invention.

Claims

WHAT IS CLAIMED IS

1. A process of producing a diene of the formula

comprising contacting a phosphonium εalt of the formula

with base and an alkylthiol of the formula:

SR 13

wherein: R₁, R₂ , R₃ , R_s, R₇, R₈ , R_lι; R₁₂ and R₁₃ are, independently, C^C^ alkyl;

X iε a halogen;

Z_x and Z₂ are, independently, 0, S or NR' ;

R₄, R₉, R₁₄, and R₁₅ are, independently, acid labile hydroxyl protecting groups ;

R₅ is C₆-C₁₄ aryl;

Y iε 0, S or NR' ;

R' and R₁₆ are, independently, hydrogen or C^C_g alkyl; and

R₁₈ iε C₆-C₁₄ aryl.

2. The proceεs of claim 1 wherein:

R_ι; R₂, R₃, R₆, R₇, R₈, R_1X and R₁₂ are methyl;

R₄, R₉, R₁₄ are t-butyldimethylsilyl ,-

R₅ iε p- methoxyphenyl ,-

R₁₃ is ethyl;

R_1S is hydrogen,- and

Y, Z_λ and Z₂ are 0.

3. The process of claim 1 wherein εaid baεe iε εodium hexamethyldisilazide or n-butyllithium with hexamethylphosphoramide .

4. A process for producing an alkene of the formula :

comprising:

[a) contacting an organometallic reagent of the formula :

with a vinyl halide of the formula:

or

(b) contacting a vinyl halide of formula

with an organometallic compound of formula:

wherein:

R_1; R₂, R₃, R₆, R₇ and R₈ are, independently, C _rC ₁₀ alkyl ;

M iε Li, Cu, Mg, or Zn; X iε a halogen;

Z-_L and Z₂ are, independently, 0, S or NR' ,- R₄ and R₉ are, independently, acid labile hydroxyl protecting groupε;

R₅ iε C₆-C₁₄ aryl;

R' is hydrogen or

alkyl; and

R₁₀ is an acid stable hydroxyl protecting group.

5. The process of claim 4 wherein R_1# R₂ , R₃ , R₆, R₇ and R_a are, independently, C₁-C₄ alkyl.

6. The process of claim 4 wherein: R_1; R₂, R₃, R₆, R₇ and R₈ are methyl; X is iodide;

Z_x and Z₂ are 0;

R₄ and R₉ are t-butyldimethylsilyl ;

R₅ iε p-methoxyphenyl ,- and

R₁₀ is p-methoxybenzyl .

7 . The proceεε of claim 4 wherein M iε Li .

8 . A proceεε of producing a lactone of the formula :

compriεing :

(a) contacting a diene of the formula - I l l -

with an organometallic compound of the formula:

or contacting an organometallic compound having formula:

with a vinyl halide having formula:

wherein:

R_1; R₂, R₃, R₆, R₇, R₈, R₁₁₍ R₁₂ and R₁₃ are, independently, C^C^ alkyl;

M iε Li, Cu, Mg, or Zn;

X iε a halogen;

Z, Z_x and Z₂ are, independently, 0, S or NR' ;

R₄, R₉, R₁₄, and R₁₅ are, independently, acid labile hydroxyl protecting groups;

R₅ iε C₆-C₁₄ aryl;

R' and R₁₆ are, independently, hydrogen or C-^C_g alkyl; and

R₂₄ is hydrogen; and R₂₅ iε hydrogen or an acid stable hydroxyl protecting group

9. A process of producing a diene of the formula:

compriεing contacting a phoεphonium salt of the formula:

with base and an alkylthiol of the formula :

wherein:

R_s, R₇, R₈, R_X1, R₁₂ and R₁₃ are, independently, C^C^ alkyl ;

X iε a halogen;

Z iε 0, S or NR' ;

R₉, R₁₄, and R_1S are, independently, acid labile hydroxyl protecting groups ;

Y is 0, S or NR' ;

R' and R₁₆ are, independently, hydrogen or C_j-C₈ alkyl; and

R₁₈ iε C₆-C₁₄ aryl.

10. A compound of the formula:

wherein R_x, R₂ and R₃ are, independently, C_j-C^ alkyl;

M iε Li, Cu, Mg, or Zn;

X iε a halogen;

Z_x and Z₂ are, independently, 0, S or NR' ,-

R₄ iε an acid labile hydroxyl protecting group;

R₅ iε C₆-C₁₄ aryl; and

R' iε hydrogen or

alkyl .

11 . The compound of claim 10 wherein R_{1 7} R₂ and R₃ are , independently, C₁-C₄ alkyl .

12 . The compound of claim 11 wherein R_{1 (} R₂ and R₃ are methyl

13. The compound of claim 10 wherein X iε iodide.

14. The compound of claim 10 wherein Z_x and Z₂ are 0.

15. The compound of claim 10 wherein R₄ is t- butyldimethylεilyl .

16. The compound of claim 10 wherein R_s iε p- methoxyphenyl .

17. The compound of claim 10 wherein: R_x, R₂ and R₃ are methyl;

X iε iodide; -_L and Z₂ are 0;

R₄ iε t-butyldimethylεilyl; and

R₅ iε p-methoxyphenyl .

18. A compound of the formula:

wherein

R₆, R₇ and R₈, are, independently, C^C^ alkyl;

M iε Li, Cu, Mg, or Zn;

X iε a halogen;

Rg iε an acid labile hydroxyl protecting group; and

R₁₀ is an acid stable hydroxyl protecting group.

19. The compound of claim 18 wherein R₇ and R₈ are, independently, C^ alkyl.

20. The compound of claim 19 wherein R₇ and R₈ are methyl .

21. The compound of claim 18 wherein X is iodide.

22. The compound of claim 18 wherein R₂ is t- butyldimethylsilyl .

23. The compound of claim 18 wherein R₅ is p- methoxybenzyl .

24. The compound of claim 18 wherein: R₇ and R₈ are methyl;

X iε iodide,-

R₂ is t-butyldimethylsilyl ; and

R₅ is p-methoxybenzyl .

25 . A compound of the formula :

wherein

Rii, R₁₂ and R₁₃ are, independently, C^C_K, alkyl;

R₁₄ and R₁₅ are, independently, acid labile hydroxyl protecting groups;

Y is 0, S or NR' ,- and

R' and Rig are , independently, hydrogen or C_ι-C₆ alkyl .

26 . The compound of claim 25 wherein R_n , R₁₂ and R₁₃ are , independently, C_ι ~C₄ alkyl .

27. The compound of claim 26 wherein R_lλ and R₁₂ are methyl .

28. The compound of claim 26 wherein R₁₃ is ethyl.

29. The compound of claim 25 wherein R₁₄ and R₁₅ are t-butyldimethylsilyl .

30. The compound of claim 25 wherein Y iε 0 and R₁₆ iε hydrogen.

31. The compound of claim 25 wherein: Rii and R₁₂ are methyl;

R₁₃ is ethyl;

R₁₄ and R₁₅ are t-butyldimethylsilyl ;

Y is 0 ; and

R₁₆ is hydrogen.

32. A compound of the formula:

wherein

R₁₉, R₂₀, R₂₁ and R₂₂ are, independently, C_ι-C₁₀ alkyl; and

R₂₃ iε C₇-C₁₅ aralkyl.

33. The compound of claim 32 wherein R_19; R₂₀, R₂₁ and R₂₂ are, independently, C₁-C₄ alkyl.

34. The compound of claim 33 wherein R₁₉, R₂₀, R₂₁ and R₂₂ are methyl .

35. The compound of claim 32 wherein R₂₃ iε p- methoxybenzyl .

36. The compound of claim 32 wherein: Ri_g, R₂₀, R₂₁ and R₂₂ are methyl; and

R_s is p-methoxybenzyl .

37. A compound of the formula:

wherein

R₆, R₇, and R₈ are, independently, C_ι-C₁₀ alkyl; X iε halogen,- Rg is an acid labile hydroxyl protecting groups,- and R_lβ is C₆-C_ι4 aryl.

38. A compound of the formula:

39.

wherein:

R₆, R₇, R₈, Rii, R₁₂ and R₁₃ are, independently, C_x-C_ι0 alkyl ;

X iε a halogen;

M iε Li, Cu, Mg, or Zn;

Z iε 0, S or NR' ;

R₉, R₁₄, and R_1S are, independently, acid labile hydroxyl protecting groupε; and

R' and R₁₆ are, independently, hydrogen or C_ι-C₆ alkyl.

40. A compound of the formula:

wherein

Ri, R ^R3 ^R6/ ^R7 ^Rβ- Rn, ^Ri2 and R₁₃ are, independently, Cι-C₁₀ alkyl;

Z iε 0, S or NR' ;

R₄, R₉, R_i4, and R₁₅ are, independently, acid labile hydroxyl protecting groups;

R' and R_ι6 are, independently, hydrogen or C_ι-C₆ alkyl; and

R₂₄ is hydrogen; and

R_2S is an acid εtable hydroxyl protecting group.

41. A compound of the formula

where R₃₀ is subεtituted or unsubstituted C^C._Q alkyl or a moiety of one of the formulas:

where A is C_ι-C₂₀ alkyl, -CH₂NH(T) or a moiety of the formula

wherein

T is peptide having 1 to about 10 amino acids;

R₃₂, R₄₀, R₄₂, R₄₃, R₄₆, R₄₇, and R₄₈ are, independently, hydrogen or C_ι-C₆ alkyl;

R_4i iε a εide chain of an amino acid; i and ₂ are, independently, -0R₄₉ or -NHPi,-

Pi iε hydrogen or an amine protecting group,-

R₃₃ and R₃₆ are, independently, hydrogen, C_ι-C₁₀ alkyl, -OR_S0, =0 or together form -CH₂-CH₂-;

R₃₄ and R₃₅ are, independently, hydrogen or together form -C(H)=C(H)-C(H)=C(H) -;

R₃₉ iε -0R_S1 or -CH₂-R₅₁;

R₃₁ and R₄₄ are, independently, C^C^ alkyl;

Q_x and Q₂ are, independently, hydrogen, -0R_Q, -NHR₅₂, -0C(=0)NH₂ or together form -0-C(0)-NH-;

R_Q iε hydrogen or a hydroxyl protecting group,-

R_5ι iε substituted or unsubstituted Cg-C₁₄ aryl, tetrahydropyranyl, furanosyl, pyranosyl, C₃-C_ι0 lactonyl or 2- pyranonyl ;

R₄₅ iε C_x-Cg alkenyl, C_ι-C₆ alkyl, C₃-C₁₄ aryl, C₂-C_ι0 heterocycloalkyl, C₃-C_ι0 cycloalkyl, or C₇-C_ι5 aralkyl; and R₄₉, R_so, and R₅₂ are, independently, hydrogen or C-^C_g alkyl

42. The compound of claim 40 wherein R₃₀ iε εubεtituted or unεubεtituted C^-Cu, alkyl.

43. The compound of claim 41 wherein εaid alkyl iε ethyl

44. The compound of claim 40 wherein R₃₀ iε a moiety of the formula:

45. The compound of claim 43 wherein: R₄₀ and R₄₂ are hydrogen;

R₄₃ iε C_x-C₆ alkyl; and

Wi and W₂ are, independently, -NHPi.

46. The compound of claim 44 wherein R₄₃ is methyl

47. The compound of claim 40 wherein R₃₀ is of the formula:

48. The compound of claim 46 wherein A is Ci- alkyl

49. The compound of claim 47 wherein said alkyl is methyl .

50. The compound of claim 46 wherein A is -CH₂NH(T) .

51. The compound of claim 46 wherein A is of the formula :

52. The compound of claim 50 wherein R₄₆ , R₄₇, and R₄₈ are hydrogen.

53. The compound of claim 50 wherein at least one of R₄₆, R₄₇, and R₄₈ is methyl.

54. The compound of claim 50 wherein Qi is 0R_Q and Q₂ is hydrogen.

55. The compound of claim 50 wherein Q_x is hydrogen and Q₂ is OR_Q.

56. The compound of claim 50 wherein Q₁ is -0C(=0)NH₂.

57. The compound of claim 50 wherein Q_λ and Q₂ together form -0-C(0)-NH-.

58. The compound of claim 50 wherein R₄₅ is C^C_g alkenyl .

59. The compound of claim 57 wherein εaid alkenyl iε 1, 3 -butadienyl .

60. The compound of claim 57 wherein εaid alkenyl iε 3, 4-epoxy-l-butenyl.

61. The compound of claim 50 wherein R₄₅ is C_ι-C₆ alkyl .

62. The compound of claim 60 wherein said alkyl is butyl .

63. The compound of claim 50 wherein R₄₅ is C₆-C_ι4 aryl .

64. The compound of claim 62 wherein said aryl is phenyl .

65. The compound of claim 50 wherein R₄₅ is C₇-C₁₅ arylalkyl .

66. The compound of claim 64 wherein εaid arylakyl is benzyl.

67. The compound of claim 50 wherein R_4S is C₂-C_ι0 heterocycloalkyl .

68. The compound of claim 66 wherein εaid heterocycloalkyl iε oxazol-2-ylmethyl .

69. The compound of claim 66 wherein εaid heterocycloalkyl iε thiazol-2-ylmethyl .

70. The compound of claim 50 wherein R₄₅ is C₃- C__o cycloalkyl .

71. The compound of claim 69 wherein said cycloalkyl is 2- (cyclopropyl) cyclopropyl .

72. The compound of claim 40 wherein R₃₉ is -0R_S1 where R_S1 iε substituted or unsubstituted C₃-C_ι4 aryl, tetrahydropyranyl, furanosyl, pyranosyl, C₃-C_ι0 lactonyl or 2- pyranonyl .

73. The compound of claim 40 wherein R₃₉ is -CH₂-R₅₁ where R_1S iε εubstituted or unεubεtituted C₈-C₁₄ aryl, tetrahydropyranyl, furanosyl, pyranoεyl, C₃-C₁₀ lactonyl or 2 - pyranonyl .

74. The compound of claim 40 wherein R₅₁ iε εubεtituted or unεubstituted C₆-C₁₄ aryl.

75. The compound of claim 73 wherein εaid aryl is selected from the group consisting of pyridin-2-yl, pyridin- 3-yl, pyridin-4-yl, naphthal-1-yl , naphthal-2-yl, phenyl, (3- hydroxy-5-methoxy-2, 4-dimethyl) phenyl, (3-methoxy-2 , 4- dimethyl) phenyl, (3-hydroxy-2 , 4-dimethyl) phenyl, (5-methoxy- 2, 4 -dimethyl) phenyl, (5 -methoxy- 2 -methyl) phenyl, (2,4- dimethyl) phenyl, (4-methyl) phenyl , (2 -methyl) phenyl and (5- methoxy-4 -methyl) phenyl .

76. The compound of claim 40 wherein R₅₁ is substituted or unsubstituted tetrahydropyranyl .

77. The compound of claim 75 wherein said tetrahydropyranyl is (4-hydroxy-3 , 5 -dimethyl) tetra- hydropyran-2 -yl .

78. The compound of claim 40 wherein R_S1 is a εubεtituted or unsubstituted furanosyl or pyranosyl.

79. The compound of claim 77 wherein said pyranosyl iε selected from the group consiεting of tetramethylfucoεyl , tetramethylmannoεyl , tetramethylgaractoεyl and tetramethylglucoεyl .

80. The compound of claim 40 wherein R₅₁ is subεtituted or unεubεtituted C₃-C₁₀ lactonyl.

81. The compound of claim 79 wherein εaid lactonyl is substituted or unsubεtituted δ-valerolactonyl.

82. The compound of claim 81 wherein said δ- valerolactonyl is of the formula:

wherein

R₆₀ and R₆₂ are, independently, C_ι-C_ι0 alkyl; and R_Sι iε hydrogen or C_ι-C₆ alkyl.

83. The compound of claim 81 wherein R₆₀ and R₆₂ are methyl and R_6ι iε hydrogen.

84. The compound of claim 40 wherein R_5i iε substituted or unεubεtituted 2 -pyranonyl.

85. The compound of claim 83 wherein εaid 2- pyranonyl iε εelected from the group conεisting of moieties of the formula:

wherein

Qi is hydrogen or ZR₆₅;

Z iε 0, NH or S; and

R-63 R₆₄ and R_S5 are , independently, hydrogen or C_x-

C₆ alkyl

86. The compound of claim 84 wherein εaid 2 pyranonyl iε of the formula:

87. The compound of claim 85 wherein Q_x iε hydrogen .

88. The compound of claim 85 wherein Q_x iε ZR₆₅ where Z iε 0 and R₆₅ iε hydrogen

89. The compound of claim 85 wherein at leaεt one of R₆₃ and R₆₄ iε methyl.

90. The compound of claim 84 wherein εaid 2- pyranonyl iε of the formula:

91. The compound of claim 89 wherein Q_x is hydrogen .

92. The compound of claim 89 wherein Q_x is ZR_S5 where Z is 0 and R₆₅ is hydrogen

93. The compound of claim 89 wherein at least one of R₆₃ and R_S4 is methyl .

94. The compound of claim 40 wherein R₄₄ are methyl .

95. The compound of claim 40 wherein R₄₂ is hydrogen .

96. The compound of claim 40 wherein R₃₄ and R_3S are hydrogen .

97. The compound of claim 40 wherein R₃₄ and R₃₅ together form -C (H) =C (H) -C (H) =C (H) - .

98. The compound of claim 40 wherein R₄₁ is methyl.

99. The compound of claim 40 wherein R₃₆ is hydrogen .

100. The compound of claim 40 wherein R₃₆ is methyl .

101. The compound of claim 40 wherein R₃₆ is - OR₅₀ where R_so is hydrogen or C_ι-C₆ alkyl.

102. The compound of claim 40 wherein R_3S is =0.

103. The compound of claim 40 wherein R₃₃ and R₃₆ together form -CH₂-CH₂-.

104. A compound of the formula:

wherein

R₇₀ and R₇₂ are, independently, C^C^ alkyl;

R₇₁ iε hydrogen or an acid labile hydroxyl protecting group;

R₇₄ iε hydrogen or an acid labile hydroxyl protecting group;

R₇₅ is C₂-C_ι0 alkenyl;

Y iε 0, S or NR' ;

Z is 0, S or NR' ; each R' is independently, hydrogen or C_ι-C₆ alkyl;

105 A compound of the formula

wherein

R₈₀ is C₂ -C₁₀ alkenyl ;

R₈₁ , R₈₃ and R_β5 are , independently, C_ι -C₁₀ alkyl ;

R₈₂ is hydrogen or an acid stable hydroxyl protecting group;

R₈₄ is hydrogen or an acid labile hydroxyl protecting group ;

R₈₆ is C₂-C₁₀ alkenyl or C₆-C₁₄ aryl .

106. A method for inhibiting mammalian cell proliferation, compriεing contacting mammalian cells with a compound according to claim 40.

107. A method for treating a mammal suffering from undesired cell proliferation, comprising administering to εaid mammal the compoεition of claim 40.

108. A method for inhibiting rejection of a tranεplanted organ in a mammal, compriεing adminiεtering to a compound according to claim 40 to a mammalian organ recipient .

109. A method for treating a mammal εuffering from rejection of tranεplanted organ, compriεing adminiεtering a compound according to claim 40 to εaid mammal .

110. A composition compriεing a compound according to claim 40 in admixture with and a pharmaceutically-acceptable carrier or excipient.

AMENDED CLAIMS

[received by the International Bureau on 1 May 1998 (01.05.98); original claims 10-24,32-36,39 and 40 cancelled; original claims 4 and 38 amended; remaining claims unchanged

(22 pages)]

A process of producing a diene of the formula:

comprising contacting a phosphonium salt of the formula

with base and an alkylthiol of the formula:

wherein :

^Rι / ^R2 / ^R3 ' ^R6 ^R7 / ^Rβ ' ^Rn ' ^Ri2 and R₁₃ are , independently, C^C^ alkyl;

X is a halogen;

Z_x and Z₂ are, independently, 0, S or NR' ;

R₅ is C₆-C₁₄ aryl;

Y is 0, S or NR' ;

R' and R₁₆ are, independently, hydrogen or

alkyl; and R₁₈ is C₆-C₁₄ aryl.

2. The process of claim 1 wherein:

R_x, R₂, R₃, R₆, R₇, R₈, R_1± and R₁₂ are methyl;

R₄, R₉, R₁₄ are t-butyldimethylsilyl;

R₅ is p-methoxyphenyl ;

R₁₃ is ethyl;

R₁₆ is hydrogen; and

Y, Z and Z₂ are 0.

3. The process of claim 1 wherein said base is sodium hexamethyldisilazide or n-butyllithium with hexamethylphosphoramide .

4. A process for producing an alkene of the formula

comprising :

contacting a vinyl halide of formula:

with an organometallic compound of formula:

wherein :

R_x, R₂, R₃, R₆, R₇ and R₈ are, independently, C₁-C₁₀ alkyl ;

M is Li, Cu, Mg, or Zn;

X is a halogen,-

Z_τ and Z₂ are, independently, 0, S or NR' ;

R₄ and R₉ are, independently, acid labile hydroxyl protecting groups; R₅ is C₆-C₁₄ aryl;

R' is hydrogen or C_ι-C₆ alkyl; and

R₁₀ is an acid stable hydroxyl protecting group.

5. The process of claim 4 wherein R₁₍ R₂, R_3/ R₆, R₇ and R₈ are, independently, C_x-C₄ alkyl.

6. The process of claim 4 wherein:

R_x, R₂, R₃, R₆, R₇ and R₈ are methyl;

X is iodide;

Z and Z₂ are 0;

R₄ and R₉ are t-butyldimethylsilyl;

R_B is p-methoxyphenyl ; and

R₁₀ is p-methoxybenzyl .

7. The process of claim 4 wherein M is Li.

8. A process of producing a lactone of the formula:

comprising :

(a) contacting a diene of the formula

with an organometallic compound of the formula:

or

(b) contacting an organometallic compound having formula :

with a vinyl halide having formula:

wherein :

R_x , R₂, R₃ , R₆ , R₇, R₈, Rii, R₁₂ and R₁₃ are, independently, C₁-C₁₀ alkyl;

M is Li, Cu, Mg, or Zn;

X is a halogen;

Z, Z_x and Z₂ are, independently, O, S or NR' ;

R₄, R₉, R ₁₄ and R ₁₅are , independently, acid labile hydroxyl protecting groups;

R₅ is C₆-C₁₄ aryl;

R' and R₁₆ are, independently, hydrogen or C-_L-C₈ alkyl; and

R₂₄ is hydrogen; and R₂₅ is hydrogen or an acid stable hydroxyl protecting group

9. A process of producing a diene of the formula:

comprising contacting a phosphonium salt of the formula :

with base and an alkylthiol of the formula

Amemde sheet Article 19

wherein :

R₆, R₇, R₈, R_X1, R₁₂ and R₁₃ are, independently, C₁-C₁₀ alkyl ;

X is a halogen;

Z is O, S or NR' ;

R₉, R₁₄, and R ₁₅ are, independently, acid labile hydroxyl protecting groups;

Y is 0, S or NR' ;

R' and R₁₆ are, independently, hydrogen or Ci-Cg alkyl; and

R₁₈ is C₆-C₁₄ aryl.

10. Deleted

11. Deleted

12. Deleted

13. Deleted

14 Deleted

15 Deleted

16 Deleted

17. Deleted Deleted

19. Deleted

20 Deleted

21 Deleted

22 Deleted

23. Deleted

24. Deleted

25. A compound of the formula:

wherein

R_11# R₁₂ and R₁₃ are, independently, C_ι-C₁₀ alkyl;

R₁₄ and R₁₅ are, independently, acid labile hydroxyl protecting groups;

Y is O, S or NR' ; and

R' and R₁₆ are, independently, hydrogen or Ci-C₈ alkyl.

26. The compound of claim 25 wherein R_n, R₁₂ and R_x3 are, independently, Ci-C₄ alkyl.

27. The compound of claim 26 wherein R_n and R₁₂ are methyl .

28. The compound of claim 26 wherein R₁₃ is ethyl. 29 The compound of claim 25 wherein R₁₄ and R₁₅ are t- butyldimethylsilyl .

30. The compound of claim 25 wherein Y is O and R₁₆ is hydrogen .

31. The compound of claim 25 wherein: Rii and R₁₂ are methyl ;

R₁₃ is ethyl;

R₁₄ and R₁₅ are t-butyldimethylsilyl ;

Y is 0 ; and

R₁₆ is hydrogen .

32. Deleted

33. Deleted

34. Deleted

35. Deleted

36. Deleted

wherein

R₆, R₇, and R₈ are, independently, C_ι-C₁₀ alkyl;

X is halogen;

R₉ is an acid labile hydroxyl protecting groups; and ^R18 is C₆-C_ι4 aryl .

38. A compound of the formula:

wherein :

R₆ , R₇ , R₈ , Rii , R₁₂ and R₁₃ are , independently, Ci-C_ι0 alkyl;

X is a halogen;

M is Li, Cu, Mg, or Zn;

Z is 0, S or NR' ;

R₉, R₁₄, and R₁₅ are, independently, acid labile hydroxyl protecting groups; and

R' and R₁₆ are , independently, hydrogen or Ci-C₆ alkyl

39 Deleted

40 Deleted

41. A compound of the formula

where

R₃₀ is substituted or unsubstituted C^C^ alkyl or a moiety of one of the formulas :

where A is C_ι-C₂₀ alkyl, -CH₂NH(T) or a moiety of the formula

wherein

T is peptide having 1 to about 10 amino acids; R₃₂, R₄₀, R₄₂, R₄₃, R₄₆, R₄₇, and R₄₈ are, independently, hydrogen or

alkyl; R₄₁ is a side chain of an amino acid; W_x and ₂ are, independently, -0R₄₉ or -NHP_1#- P_x is hydrogen or an amine protecting group; R, and R₃₆ are, independently, hydrogen, C _TC _1C alkyl, -OR₅₀, =0 or together form -CH₂-CH₂-;

R₃g is -0R₅₁ or -CH₂-R₅₁;

R₃₁ and R₄₄ are, independently, Ci-C₁₀ alkyl;

Qi and Q₂ are, independently, hydrogen, -0R_Q, -NHR₅₂,

-0C(=0)NH₂ or together form -0-C (0) -NH- ;

R_Q is hydrogen or a hydroxyl protecting group;

R₅₁ is substituted or unsubstituted C₆-C_ι4 aryl, tetrahydropyranyl, furanosyl, pyranosyl, C₃-C_ι0 lactonyl or 2 -pyranonyl;

R₄₅ is Ci-Cg alkenyl ,

alkyl , C_s - C_ι4 aryl , C₂- C_ι0 heterocycloalkyl , C₃ - C_ι0 cycloalkyl , or C₇- C_ιB aralkyl ; and

R₄₉, R₅₀, and R₅₂ are , independently, hydrogen or Ci-C₈ alkyl .

42. The compound of claim 41 wherein R₃₀ is substituted or unsubstituted C_ι-C_ι0 alkyl.

43. The compound of claim 42 wherein said alkyl is ethyl .

44. The compound of claim 41 wherein R₃₀ is a moiety of the formula:

45 . The compound of claim 44 wherein : R₄₀ and R₄₂ are hydrogen; R₄₃ is Ci- Cg alkyl ; and

19 Wi and W₂ are, independently, -NHPi.

46. The compound of claim 45 wherein R₄₃ is methyl .

47. The compound of claim 41 wherein R₃₀ is of the formula :

48. The compound of claim 47 wherein A is Ci-C₁₀ alkyl .

49. The compound of claim 48 wherein said alkyl is methyl.

50. The compound of claim 47 wherein A is -CH₂NH(T) .

51. The compound of claim 47 wherein A is of the formula :

52. The compound of claim 51 wherein R₄₆, R₄₇, and R₄₈ are hydrogen .

53. The compound of claim 51 wherein at least one of R₄₆, R₄₇, and R₄₈ is methyl.

icle 19

54. The compound of claim 51 wherein Q is 0R_Q and Q₂ is hydrogen.

55. The compound of claim 51 wherein Q_x is hydrogen and Q₂ is 0R_Q.

56. The compound of claim 51 wherein Q is -OC(=0)NH₂.

57. The compound of claim 51 wherein Q_x and Q₂ together form -0-C(0)-NH-.

58. The compound of claim 51 wherein R₄₅ is Ci-C₆ alkenyl .

59. The compound of claim 58 wherein said alkenyl is 1, 3-butadienyl .

60. The compound of claim 58 wherein said alkenyl is 3 , 4-epoxy-l-butenyl .

61. The compound of claim 51 wherein R₄₅ is C_ι-C₆ alkyl .

62. The compound of claim 61 wherein said alkyl is butyl.

63. The compound of claim 51 wherein R₄₅ is C₆-C_ι4 aryl .

64. The compound of claim 63 wherein said aryl is phenyl.

65. The compound of claim 51 wherein R₄₅ is C₇-C_ι5 arylalkyl .

66. The compound of claim 65 wherein said arylakyl is benzyl .

67. The compound of claim 51 wherein R₄₅ is C₂-C₁₀ heterocycloalkyl .

68. The compound of claim 67 wherein said heterocycloalkyl is oxazol-2-ylmethyl .

69. The compound of claim 67 wherein said heterocycloalkyl is thiazol-2-ylmethyl .

70. The compound of claim 51 wherein R₄₅ is C₃-C_ι0 cycloalkyl .

71. The compound of claim 70 wherein said cycloalkyl is 2 - (cyclopropyl) cyclopropyl .

72. The compound of claim 41 wherein R_3g is -OR₅₁ where R₅₁ is substituted or unsubstituted C₆- C_i4 aryl, tetrahydropyranyl, furanosyl, pyranosyl, C₃-C_ι0 lactonyl or 2-pyranonyl.

73. The compound of claim 41 wherein R₃₉ is -CH₂- R₅₁ where R_i5 is substituted or unsubstituted C₆-C_ι4 aryl, tetrahydropyranyl, furanosyl, pyranosyl, C₃-C_ι0 lactonyl or 2 -pyranonyl.

74. The compound of claim 41 wherein R_5i is substituted or unsubstituted C₅~C₁₄ aryl.

75. The compound of claim 74 wherein said aryl is selected from the group consisting of pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, naphthal-1-yl, naphthal-2-yl, phenyl, (3- hydroxy-5-methoxy-2 , 4-dimethyl) phenyl, (3- methoxy-2, 4 -dimethyl) phenyl, (3-hydroxy-2 , 4- dimethyl) phenyl, (5-methoxy-2 , 4- dimethyl) phenyl , (5-methoxy-2-methyl) phenyl , (2 , 4 -dimethyl) phenyl, (4 -methyl) phenyl, (2- methyl) phenyl and (5-methoxy-4- methyl) phenyl .

76. The compound of claim 41 wherein R₅₁ is substituted or unsubstituted tetrahydropyranyl .

77. The compound of claim 76 wherein said tetrahydropyranyl is (4-hydroxy-3 , 5- dimethyl) tetra-hydropyran-2-yl .

78. The compound of claim 41 wherein R₅₁ is a substituted or unsubstituted furanosyl or pyranosyl .

79. The compound of claim 78 wherein said pyranosyl is selected from the group consisting of tetramethylfucosyl, tetramethylmannosyl , tetramethylgaractosyl and tetramethylglucosyl .

80. The compound of claim 41 wherein R₅₁ is substituted or unsubstituted C₃-C₁₀ lactonyl.

81. The compound of claim 80 wherein said lactonyl is substituted or unsubstituted δ- valerolactonyl .

82. The compound of claim 81 wherein said δ- valerolactonyl is of the formula:

wherein

R₆₀ and R₆₂ are, independently, Ci-C₁₀ alkyl; and

Rgi is hydrogen or C_ι-C₆ alkyl.

83. The compound of claim 82 wherein R₆₀ and R₆₂ are methyl and R₆₁ is hydrogen.

84. The compound of claim 41 wherein R₅₁ is substituted or unsubstituted 2 -pyranonyl.

85. The compound of claim 84 wherein said 2- pyranonyl is selected from the group consisting of moieties of the formula:

wherein

Qi is hydrogen or ZR₆₅;

Z is 0, NH or S; and

R₆₃ , R₆₄ , and R₆₅ are , independently, hydrogen or

Ci- Cg alkyl .

86. The compound of claim 84 wherein said 2- pyranonyl is of the formula:

19

87. The compound of claim 85 wherein Q_x is hydrogen .

88. The compound of claim 85 wherein Q_x is ZR₆₅ where Z is 0 and R₆₅ is hydrogen

89. The compound of claim 85 wherein at least one of R₆₃ and R₆₄ is methyl.

90. The compound of claim 84 wherein said 2- pyranonyl is of the formula:

91. The compound of claim 89 wherein Q is hydrogen.

92. The compound of claim 89 wherein Q_x is ZR₆₅ where Z is 0 and R₆₅ is hydrogen

93. The compound of claim 89 wherein at least one of R₆₃ and R₆₄ is methyl .

94. The compound of claim 41 wherein R₄₄ are methyl .

95. The compound of claim 41 wherein R₄₂ is hydrogen .

96. The compound of claim 41 wherein R₃₄ and R₃₅ are hydrogen .

97. The compound of claim 41 wherein R₃₄ and R₃₅ together form -C(H) =C(H) -C (H) =C(H) - .

98. The compound of claim 41 wherein R₄₁ is methyl .

99. The compound of claim 41 wherein R₃₆ is hydrogen .

100. The compound of claim 41 wherein R₃₆ is methyl .

101. The compound of claim 41 wherein R₃₆ is -OR₅₀ where R₅₀ is hydrogen or

alkyl.

102. The compound of claim 41 wherein R₃₆ is =0.

103. The compound of claim 41 wherein R₃₃ and R₃₆ together form -CH₂-CH₂-.

104. A compound of the formula:

wherein

R₇₀ and R₇₂ are, independently, Ci-C₁₀ alkyl;

R₇₁ is hydrogen or an acid labile hydroxyl protecting group;

R₇₄ is hydrogen or an acid labile hydroxyl protecting group;

R₇₅ is C₂-C_ι0 alkenyl;

Y is 0, S or NR' ;

Z is 0, S or NR' ; each R' is independently, hydrogen or Ci-C₆ alkyl;

105. A compound of the formula:

wherein

R₈₀ is C₂-C_ι0 alkenyl ;

R_8ι , R₈₃ and R₈₅ are , independently, C_ι-C_ι0 alkyl ;

R₈₂ is hydrogen or an acid stable hydroxyl protecting group;

R₈₄ is hydrogen or an acid labile hydroxyl protecting group ;

R₈₆ is C₂-C₁₀ alkenyl or C₆-Cι₄ aryl.

106. A method for inhibiting mammalian cell proliferation, comprising contacting mammalian cells with a compound according to claim 41.

107. A method for treating a mammal suffering from undesired cell proliferation, comprising administering to said mammal the composition of claim 41.

108. A method for inhibiting rejection of a transplanted organ in a mammal, comprising administering to a compound according to claim 41 to a mammalian organ recipient.

109. A method for treating a mammal suffering from rejection of transplanted organ, comprising administering a compound according to claim 41 to said mammal.

110. A composition comprising a compound according to claim 41 in admixture with and a pharmaceutically-acceptable carrier or excipient .

Article 19